

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
17 January 2019 (17.01.2019)



(10) International Publication Number
WO 2019/012001 A1

(51) International Patent Classification:

C07D 413/14 (2006.01) C07D 413/10 (2006.01)
A01N 43/82 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2018/068822

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

(22) International Filing Date:

11 July 2018 (11.07.2018)

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

17181043.5 12 July 2017 (12.07.2017) EP

(71) Applicant: SYNGENTA PARTICIPATIONS AG
[CH/CH]; Schwarzwaldallee 215, 4058 Basel (CH).


(72) Inventors: HOFFMAN, Thomas, James; Syngenta
Crop Protection AG Schaffhauserstrasse, 4332 Stein
(CH). STIERLI, Daniel; Syngenta Crop Protection
AG Schaffhauserstrasse, 4332 Stein (CH). PITTERNA,
Thomas; Syngenta Crop Protection AG Schaffhauser-
strasse, 4332 Stein (CH).

(74) Agent: SYNGENTA INTERNATIONAL AG; Sch-
warzwaldallee 215 (CHBS-B4.8), 4058 Basel (CH).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: MICROBIOCIDAL OXADIAZOLE DERIVATIVES



(I)

(57) Abstract: Compounds of the formula (I): (I) wherein the substituents are as defined in claim 1, useful as pesticides, especially as fungicides.




WO 2019/012001 A1

Microbiocidal Oxadiazole Derivatives

The present invention relates to microbiocidal oxadiazole derivatives, e.g., as active ingredients, which have microbiocidal activity, in particular, fungicidal activity. The invention also relates to agrochemical compositions which comprise at least one of the oxadiazole derivatives, to processes of preparation of these compounds and to uses of the oxadiazole derivatives or compositions in agriculture or horticulture for controlling or preventing infestation of plants, harvested food crops, seeds or non-living materials by phytopathogenic microorganisms, preferably fungi.

According to the present invention, there is provided a compound of formula (I):



wherein R^1, R^2, R^3, R^4 are independently selected from hydrogen or fluoro and wherein 0, 1 or 2 of R^1, R^2, R^3 and R^4 are fluoro;

R^5 and R^6 are independently selected from hydrogen, methyl or fluoro;

Z is selected from Z^1 or Z^2 ; wherein

Z^1 represents a heterocycyl linked to $C(R^5)(R^6)$ via a C-C bond, wherein the heterocycyl moiety is a 6-membered non-aromatic ring which contains 1 or 2 groups independently selected from N or NR^7 , wherein Z^1 is optionally substituted by 1, 2 or 3 substituents, which may be the same or different, selected from R^8 ;

R^7 is hydrogen, C_{1-4} alkyl, C_{1-4} alkoxy, formyl, C_{1-4} alkylcarbonyl, C_{1-4} alkoxycarbonyl, N- C_{1-4} alkylaminocarbonyl, N,N-di- C_{1-4} alkylaminocarbonyl, C_{1-4} alkylsulfonyl, N- C_{1-2} alkylaminosulfonyl or N,N-di- C_{1-2} alkylaminosulfonyl;

R^8 is methyl, C_{2-4} alkyl, methoxy, C_{2-4} alkoxy, formyl, C_{1-4} alkylcarbonyl, C_{1-4} alkoxycarbonyl, N- C_{1-4} alkylaminocarbonyl, N,N-di- C_{1-4} alkylaminocarbonyl, C_{1-4} alkylsulfonyl, N- C_{1-2} alkylaminosulfonyl, N,N-di- C_{1-2} alkylaminosulfonyl, oxo (=O) or thio (=S);

Z^2 represents a heteroaryl linked to $C(R^5)(R^6)$ via a C-C bond, wherein the heteroaryl moiety is a 6-membered aromatic ring which contains 1, 2 or 3 nitrogen atoms in the ring system, wherein Z^2 is optionally substituted by 1, 2 or 3 substituents, which may be the same or different, selected from R^9 ;

R⁹ represents cyano, amino, hydroxyl, hydrosulfido (-SH), halogen, methyl, C₂₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, C₁₋₄haloalkyl, C₂₋₄haloalkenyl, methoxy, C₂₋₄alkoxy, C₁₋₄haloalkoxy, C₃₋₄alkenyloxy, C₃₋₄alkynyloxy, C₁₋₂alkoxyC₁₋₂alkyl C₁₋₄alkylthio, C₁₋₄haloalkylthio, C₃₋₄alkenylthio, C₃₋₄alkynylthio, N-C₁₋₄alkylamino, N,N-diC₁₋₄alkylamino, C₁₋₄alkylcarbonyl, hydroxycarbonyl, C₁₋₄alkoxycarbonyl, C₁₋₄alkylcarbonylamino, N-C₁₋₄alkylaminocarbonyl, N-(cyclopropyl)aminocarbonyl, N,N-diC₁₋₄alkylaminocarbonyl, C₁₋₄alkoxycarbonylamino, N-C₁₋₄alkoxyaminocarbonyl or N-C₁₋₄alkyl(N-C₁₋₄alkoxy)aminocarbonyl;

5 or

a salt or an N-oxide thereof,

15 with the proviso that the compound of Formula (I) is not 3-[4-[1-(6-methoxy-3-pyridyl)ethyl]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole or 3-[4-[(6-methoxy-3-pyridyl)methyl]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole.

20 Surprisingly, it has been found that the novel compounds of Formula (I) have, for practical purposes, a very advantageous level of biological activity for protecting plants against diseases that are caused by fungi.

25 According to a second aspect of the invention, there is provided an agrochemical composition comprising a fungicidally effective amount of a compound of Formula (I). Such an agricultural composition may further comprise at least one additional active ingredient and/or an agrochemically-acceptable diluent or carrier.

30 According to a third aspect of the invention, there is provided a method of controlling or preventing infestation of useful plants by phytopathogenic microorganisms, wherein a fungicidally effective amount of a compound of Formula (I), or a composition comprising this compound as active ingredient, is applied to the plants, to parts thereof or the locus thereof.

35 According to a fourth aspect of the invention, there is provided the use of a compound of Formula (I) as a fungicide. According to this particular aspect of the invention, the use may exclude methods for the treatment of the human or animal body by surgery or therapy.

As used herein, the term "halogen" or "halo" refers to fluorine (fluoro), chlorine (chloro), bromine (bromo) or iodine (iodo), preferably fluorine, chlorine or bromine.

As used herein, acyl means a -C(O)CH₃ group.

As used herein, formyl means a -C(O)H group.

As used herein, the term "C₁₋₄alkyl" refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to four carbon atoms, and which is attached to the rest of the molecule by a single bond. C₁₋₃alkyl and C₁₋₂alkyl are to be construed accordingly. Examples of C₁₋₄alkyl include, but are not limited to, methyl, ethyl, *n*-propyl, 1-methylethyl (isopropyl), *n*-butyl, and 1-dimethylethyl (*t*-butyl). A "C₁₋₄alkylene" group refers to the corresponding definition of C₁₋₄alkyl, except that such radical is attached to the rest of the molecule by two single bonds. Examples of C₁₋₄alkylene, are -CH₂- and -CH₂CH₂-.

As used herein, the term "C₁₋₄alkoxy" refers to a radical of the formula -OR_a where R_a is a C₁₋₄alkyl radical as generally defined above. The terms C₁₋₃alkoxy and C₁₋₂alkoxy are to be construed accordingly. Examples of C₁₋₄alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, and *t*-butoxy.

As used herein, the term "C₁₋₄haloalkyl" refers to a C₁₋₃alkyl radical as generally defined above substituted by one or more of the same or different halogen atoms. Examples of C₁₋₄haloalkyl include, but are not limited to fluoromethyl, fluoroethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, and 3,3,3-trifluoropropyl.

As used herein, the term "C₃₋₅alkenyl" refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one double bond that can be of either the (*E*)- or (*Z*)-configuration, having from three to five carbon atoms, which is attached to the rest of the molecule by a single bond. Examples of C₃₋₅alkenyl include, but are not limited to, prop-1-enyl, allyl (prop-2-enyl), and but-1-enyl.

As used herein, the term "C₃₋₅alkenoxy" refers to a radical of the formula -OR_a where R_a is a C₃₋₅alkenyl radical as generally defined above.

As used herein, the term "C₃₋₄alkynyl" refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one triple bond, having three or four carbon atoms, and which is attached to the rest of the molecule by a single bond. Examples of C₂₋₆alkynyl include, but are not limited to, prop-1-ynyl, propargyl (prop-2-ynyl).

As used herein, the term "C₃₋₄alkynoxy" refers to a radical of the formula -OR_a where R_a is a C₃₋₄alkynyl radical as generally defined above.

As used herein, the term "C₁₋₄alkoxyC₁₋₄alkyl" refers to radical of the formula R_b-O-R_a- where R_b is a C₁₋₄alkyl radical as generally defined above, and R_a is a C₁₋₄alkylene radical as generally defined above.

As used herein, the term "C₃₋₆cycloalkyl" refers to a stable, monocyclic ring radical which is saturated or partially unsaturated and contains 3 to 6 carbon atoms. C₃₋₅cycloalkyl and C₃cycloalkyl are to be construed accordingly. Examples of C₃₋₆cycloalkyl include, but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclopenten-1-yl, cyclopenten-3-yl, and cyclohexen-3-yl.

As used herein, the term "C₃₋₆cycloalkylC₁₋₄alkyl" refers to a C₃₋₆cycloalkyl ring as defined above attached to the rest of the molecule by a C₁₋₄alkylene radical as defined above. Examples of C₃₋₆cycloalkylC₁₋₃alkyl include, but are not limited to cyclopropyl-methyl and cyclobutyl-ethyl.


The presence of one or more possible asymmetric carbon atoms in a compound of Formula (I) means that the compounds may occur in chiral isomeric forms, i.e., enantiomeric or diastereomeric forms. Also, atropisomers may occur as a result of restricted rotation about a single bond. Formula (I) is intended to include all those possible isomeric forms and mixtures thereof. The present invention includes all those possible isomeric forms and mixtures thereof for a compound of Formula (I). Likewise, Formula (I) is intended to include all possible tautomers (including lactam-lactim tautomerism and keto-enol tautomerism) where present. The present invention includes all possible tautomeric forms for a compound of Formula (I).

In each case, the compounds of Formula (I) according to the invention are in free form, in oxidized form as an N-oxide, in covalently hydrated form, or in salt form, e.g., an agronomically usable or agrochemically acceptable salt form.


N-oxides are oxidized forms of tertiary amines or oxidized forms of nitrogen containing heteroaromatic compounds. They are described for instance in the book "Heterocyclic N-oxides" by A. Albini and S. Pietra, CRC Press, Boca Raton 1991.

15

According to the invention, the compound of Formula (I) is not:



3-[4-[1-(6-methoxy-3-pyridyl)ethyl]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole, or



20

3-[4-[(6-methoxy-3-pyridyl)methyl]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole.

The following list provides definitions, including preferred definitions, for substituents Z (Z¹ and Z²), R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸ and R⁹ with reference to the compounds of Formula (I) according to the invention. For any one of these substituents, any of the definitions given below may be combined with any definition of any other substituent given below or elsewhere in this document.

R¹, R², R³, R⁴ are independently selected from hydrogen or fluoro, wherein 0, 1 or 2 of R¹, R², R³ and R⁴ are fluoro.

30

In certain embodiments of the invention, R^1 , R^2 , R^3 and R^4 are hydrogen; R^2 , R^3 and R^4 are hydrogen and R^1 is fluoro; R^1 , R^2 and R^4 are hydrogen and R^3 is fluoro; R^1 and R^2 are fluoro and R^3 and R^4 are hydrogen; R^1 and R^3 are fluoro and R^2 and R^4 are hydrogen, or R^1 and R^2 are hydrogen and R^3 and R^4 are fluoro. Preferably, R^1 to R^4 are hydrogen.

5

R^5 and R^6 are independently selected from hydrogen, methyl or fluoro. Preferably, R^5 and R^6 are both hydrogen, or R^5 is hydrogen and R^6 is methyl. More preferably, R^5 and R^6 are both hydrogen.

Z is selected from Z^1 or Z^2 .

10

Z^1 represents a heterocycyl linked to $C(R^5)(R^6)$ via a C-C bond, wherein the heterocycyl moiety is a 6-membered non-aromatic ring which contains 1 or 2 groups independently selected from N or NR^7 , wherein Z^1 is optionally substituted by 1, 2 or 3 substituents (or optionally substituted by 1 or 2 substituents, or optionally substituted by 1 substituent), which may be the same or different, selected from R^8 .

15

Z^2 represents a heteroaryl linked to $C(R^5)(R^6)$ via a C-C bond, wherein the heteroaryl moiety is a 6-membered aromatic ring which contains 1, 2 or 3 nitrogen atoms in the ring system, wherein Z^3 is optionally substituted by 1, 2 or 3 substituents (or optionally substituted by 1 or 2 substituents, or optionally substituted by 1 substituent), which may be the same or different, selected from R^9 .


20

In certain embodiments of the invention, Z is Z^1 .


In certain embodiments of the invention, Z is Z^2 .

25

Preferably, Z^1 is



Preferably, Z^2 is



30

R^7 is hydrogen, C_{1-4} alkyl, C_{1-4} alkoxy, formyl, C_{1-4} alkylcarbonyl, C_{1-4} alkoxycarbonyl, N- C_{1-4} alkylaminocarbonyl, N,N-di- C_{1-4} alkylaminocarbonyl, C_{1-4} alkylsulfonyl, N- C_{1-2} alkylaminosulfonyl or N,N-

diC₁₋₂alkylaminosulfonyl. Preferably, R⁷ is selected from hydrogen, C₁₋₄alkyl, C₁₋₄alkoxy, formyl, C₁₋₄alkylcarbonyl, C₁₋₄alkoxycarbonyl. More preferably, R⁷ is selected from hydrogen, methyl, methoxy, formyl, methylcarbonyl or methoxycarbonyl. Still more preferably, R⁷ is selected from hydrogen or methyl.

5

R⁸ is methyl, C₂₋₄alkyl, methoxy, C₂₋₄alkoxy, formyl, C₁₋₄alkylcarbonyl, C₁₋₄alkoxycarbonyl, N-C₁₋₄alkylaminocarbonyl, N,N-diC₁₋₄alkylaminocarbonyl, C₁₋₄alkylsulfonyl, N-C₁₋₂alkylaminosulfonyl, N,N-diC₁₋₂alkylaminosulfonyl, oxo (=O) or thio (=S). Preferably, R⁸ is methyl, C₂₋₄alkyl, methoxy, C₂₋₄alkoxy, formyl, C₁₋₂alkylcarbonyl, C₁₋₂alkoxycarbonyl, N-C₁₋₂alkylaminocarbonyl, N,N-diC₁₋₂alkylaminocarbonyl, C₁₋₂alkylsulfonyl, N-C₁₋₂alkylaminosulfonyl, N,N-diC₁₋₂alkylaminosulfonyl, oxo (=O) or thio (=S). More preferably, R⁸ is methyl, C₂₋₄alkyl, methoxy, C₂₋₄alkoxy, formyl, C₁₋₂alkylcarbonyl, C₁₋₂alkoxycarbonyl, N-C₁₋₂alkylaminocarbonyl, N,N-diC₁₋₂alkylaminocarbonyl or oxo (=O).

10

R⁹ represents cyano, amino, hydroxyl, hydrosulfido (-SH), halogen, methyl, C₂₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, C₁₋₄haloalkyl, C₂₋₄haloalkenyl, methoxy, C₂₋₄alkoxy, C₁₋₄haloalkoxy, C₃₋₄alkenyloxy, C₃₋₄alkynyloxy, C₁₋₂alkoxyC₁₋₂alkyl C₁₋₄alkylthio, C₁₋₄haloalkylthio, C₃₋₄alkenylthio, C₃₋₄alkynylthio, N-C₁₋₄alkylamino, N,N-diC₁₋₄alkylamino, C₁₋₄alkylcarbonyl, hydroxycarbonyl, C₁₋₄alkoxycarbonyl, C₁₋₄alkylcarbonylamino, N-C₁₋₄alkylaminocarbonyl, N-(cyclopropyl)aminocarbonyl, N,N-diC₁₋₄alkylaminocarbonyl, C₁₋₄alkoxycarbonylamino, N-C₁₋₄alkoxyaminocarbonyl or N-C₁₋₄alkyl(N-C₁₋₄alkoxy)aminocarbonyl

15

20


Preferably, R⁹ is cyano, amino, hydroxyl, hydrosulfido (-SH), halogen, methyl, C₂₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, C₁₋₄haloalkyl, C₂₋₄haloalkenyl, methoxy, C₂₋₄alkoxy, C₁₋₂fluoroalkoxy, C₃₋₄alkenyloxy, C₃₋₄alkynyloxy, C₁₋₂alkoxyC₁₋₂alkyl, C₁₋₂alkylthio, C₁₋₂haloalkylthio, C₃₋₄alkenylthio, C₃₋₄alkynylthio, N-C₁₋₂alkylamino, N,N-diC₁₋₂alkylamino, C₁₋₂alkylcarbonyl, hydroxycarbonyl, C₁₋₂alkoxycarbonyl, C₁₋₂alkylcarbonylamino, N-C₁₋₂alkylaminocarbonyl, N-(cyclopropyl)aminocarbonyl, N,N-diC₁₋₂alkylaminocarbonyl, C₁₋₂alkoxycarbonylamino, N-C₁₋₂alkoxyaminocarbonyl or N-C₁₋₂alkyl(N-C₁₋₂alkoxy)aminocarbonyl. More preferably, R⁹ is cyano, amino, hydroxyl, hydrosulfido (-SH), halogen, methyl, C₂₋₄alkyl, C₁₋₂fluoroalkyl, C₂₋₄haloalkenyl, methoxy, C₂₋₄alkoxy, C₁₋₂fluoroalkoxy, C₃₋₄alkenyloxy, C₃₋₄alkynyloxy, C₁₋₂alkoxyC₁₋₂alkyl, C₁₋₂alkylcarbonyl, hydroxycarbonyl, C₁₋₂alkoxycarbonyl, C₁₋₂alkylcarbonylamino or N-C₁₋₂alkylaminocarbonyl. Even more preferably, R⁹ is hydroxyl, hydrosulfido (-SH), halogen, methyl, C₂₋₄alkyl, C₁₋₂fluoroalkyl, methoxy, C₂₋₄alkoxy, C₁₋₂alkoxyC₁₋₂alkyl, C₁₋₂alkylcarbonyl, hydroxycarbonyl, C₁₋₂alkoxycarbonyl, C₁₋₂alkylcarbonylamino or N-C₁₋₂alkylaminocarbonyl.

25

30

35

In some embodiments, Z is:




wherein R^7 is selected from hydrogen, C_{1-4} alkyl, C_{1-4} alkoxy, formyl, C_{1-4} alkylcarbonyl, C_{1-4} alkoxycarbonyl.

5 Preferably, the compound according to Formula (I) is selected from a compound A.1 to A.35 described in Table A (below).


The compounds of the present invention may be enantiomers of the compound of Formula (I) as represented by a Formula (Ia) or a Formula (Ib), wherein R^5 and R^6 are different substituents.

10



20


It is understood that when in aqueous media, the compounds of formula (I) according to the invention may be present in a reversible equilibrium with the corresponding covalently hydrated forms (ie, the compounds of formula (I-Ia) and formula (I-IIa) as shown below, which may exist in tautomeric form as the compounds of formula (I-Ib) and formula (I-IIb)) at the CF_3 -oxadiazole motif). This dynamic equilibrium may be important for the biological activity of the compounds of Formula (I). The designations Z (Z^1 and Z^2), R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^8 and R^9 with reference to the compounds of formula (I) of the present invention, apply generally to the compounds of Formula (I-Ia), Formula (I-IIa), Formula (I-Ib), and Formula (I-IIb), as do the specific disclosures of combinations of Z (Z^1 and Z^2), R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^8 and R^9 as represented for compounds T-2.01 to T-2.08 to T-47.01 to T-47.08 shown in Tables 2 to 47 (below) and compounds A.1 to A.35 described in Table A (below).



Compounds of the present invention can be made as shown in the following schemes 1 to 20, in which, unless otherwise stated, the definition of each variable is as defined above for a compound of formula (I).

Compounds of formula (I) can be prepared from compounds of formula (II), wherein X is a halogen, preferably Cl, Br, I, SO₂CF₃, or SO₂C₄F₉, and compounds of formula (III) wherein Met is a metalloid [eg, B(OH)₂, BF₃K, B(pinacol), B(9-BBN)₂, or B-methyl MIDA-boronate], via cross-coupling reaction using a metal (eg, Cu and Pd) in the presence of base (eg, KO-*t*-Bu, K₂CO₃, or Cs₂CO₃) and in a suitable solvent (eg, toluene, dimethylformamide, sulfolane, dimethylsulfoxide, or dioxane) at a temperature of between 60°C and 150°C. For related examples, see Kuriyama, Masami *et al J. Org.*


Chem., (2014) 79, 5921. The compounds of formula (III) are commercially available. This is shown in Scheme 1 below.



5

Compounds of formula (I) can be prepared from compounds of formula (II) via treatment with an organometallic of formula (IV), wherein Z-[M] represents a organomagnesium or organolithium species (eg, Z-MgBr or Z-Li), in a suitable solvent (eg, tetrahydrofuran) at a temperature between -78°C and 25°C. Compounds of formula (III) are commercially available or can be prepared *in situ* from the corresponding organo halide via metal-halogen exchange with a suitable organometallic species (eg, *i*PrMgCl-LiCl, *n*-BuLi, or *t*-BuLi). For related examples, see: *The Preparation of Organolithium Reagents and Intermediates* Leroux, F., Schlosser, M., Zohar, E., Marek, I., Wiley, New York, 2004. This is shown in Scheme 2 below.


10



15


Compounds of formula (I-A), wherein R⁶ represents H or methyl, can be prepared from compounds of formula (V) via treatment with compounds of formula (III), wherein Met is a metalloid [eg, B(OH)₂, BF₃K, B(pinacol), B(9-BBN)₂, or B-methyl MIDA-boronate], in the presence of a base (eg, K₂CO₃, CsCO₃, CsF, or K₃PO₄) in a suitable solvent (eg, dioxane) at a temperature between 50°C and 110°C. For related examples, see: *Metal-free carbon-carbon bond-forming reductive coupling between boronic acids and tosylhydrazones* Barluenga J., *Nature Chemistry*, (2009), Vol.1, 494-499. This is shown in Scheme 3 below.

20



Scheme 3


5 Compounds of formula (V), wherein R^6 represents H or methyl, can be prepared from compounds of formula (VI) via condensation with tosylhydrazine of formula (VII). Barluenga J., *Nature Chemistry*, (2009), Vol.1, 494-499, This is shown in Scheme 4 below.



Scheme 4


10 Compounds of formula (I-A), wherein R^6 represents H or methyl, can be prepared from compounds of formula (VIII) by stoichiometric reduction conditions (eg, Et_3SiH in the presence of an acid such as methanesulfonic acid) or catalytic hydrogenation conditions (eg, Pd/C under H_2 atmosphere), in a suitable solvent such as MeOH or EtOH, at a temperature between 0°C and 65°C , are optionally applied. For related examples, see: WO 2013170072 and WO 2005054201. This is shown in Scheme 5.

15



Scheme 5


20 Compounds of formula (I-A1), wherein R^6 represents H or methyl, can be prepared by treating compounds of formula (VIII) with diethylaminosulfur trifluoride (DAST), in a suitable solvent such as dichloromethane, or trichloroethane, at a temperature between -20°C and 40°C . For related example, see: *Tetrahedron Lett.* (1984), Vol. 25, 5227-5230. This is shown in Scheme 6.



Scheme 6

5 Compounds of formula (VIII), wherein R^6 represents H or methyl, can be prepared from compounds of formula (VI) via treatment with an organometallic of formula (IV), wherein Z-[M] represents a organomagnesium or organolithium species (eg, Z-MgBr or Z-Li), in a suitable solvent (e.g. tetrahydrofuran) at a temperature between -78°C and 25°C . Compounds of formula (IV) are commercially available or can be prepared *in situ* from the corresponding organo halide via metal-


10 halogen exchange with a suitable organometallic species (eg, *i*PrMgCl-LiCl, *n*-BuLi, or *t*-BuLi). For related examples, see: 'The Preparation of Organolithium Reagents and Intermediates' Leroux, F., Schlosser, M., Zohar, E., Marek, I., Wiley, New York, **2004**. This is shown in Scheme 7 below.



Scheme 7

15 Compounds of formula (X), wherein R^{6a} represents methyl, ethyl, O-methyl or O-ethyl, can be prepared from compounds of formula (VI) via condensation reaction with an β -di-carbonyl-derivative of formula (IX), wherein R^5 represents H or methyl, in the presence of base (eg, piperidine) in a suitable solvent (eg, benzene, toluene, acetic acid) at a temperature between 50°C and 110°C . Compounds of


20 formula (XI) can be prepared from compounds of Formula (X) by hydrogenation (eg, Pd/C under H_2 atmosphere), in a suitable solvent such as MeOH or EtOH. For general examples examples, see: US2007/0060644. The compounds of formula (IX) are commercially available or prepared using known methods. This is shown in Scheme 8.



Scheme 8


- 5 Alternatively compounds of formula (XI), wherein R^{8a} represents methyl, ethyl, O-methyl or O-ethyl, can be prepared from compounds of formula (II) by treatment with an β-di-carbonyl-derivative of formula (IX), in the presence of base (eg, K₂CO₃, CsCO₃, or Na₂CO₃) in a suitable solvent (eg, dimethylformamide, acetone, or acetonitrile) at a temperature between 20°C and 130°C. For general alkylation examples, see: *J. Org. Chem.* (1965) 30, 3321. This is shown in Scheme 9.

10




Scheme 9

- 15 Compounds of formula (I-B) can be prepared from compounds of formula (XI) via condensation reaction with a compound of Formula (XII), wherein R^{8a} represents methyl, ethyl, O-methyl or O-ethyl and R⁹ represents OH, SH, NH₂, hydrogen, methyl, ethyl or propyl, in the presence of an acid (eg, HCl or acetic acid) in a suitable solvent (eg, methanol, ethanol, propanol) at a reflux temperature. For general examples examples, see: *J. Org. Chem.* (1953), 18, 588, The compounds of formula (XII) are commercially available or prepared using known methods. This is shown in Scheme 10.




Scheme 10

Compounds of formula (I-C) can be prepared from compounds of formula (XIV) via condensation reaction with a compound of Formula (IXb), wherein R^{8a} represents methyl, ethyl, O-methyl or O-ethyl and R¹⁰ represents hydrogen, methyl, ethyl or propyl, in the presence of an acid (eg, HCl, acetic acid) in a suitable solvent (eg, methanol, ethanol, propanol) at a reflux temperature. The compounds of formula (IXb) are commercially available or prepared using known methods. This is shown in Scheme 11.




Scheme 11

Compounds of formula (XIV) can be prepared from compounds of formula (II) via compounds of formula (XIII). For a specific example, see the preparation of Compound A.1 of Table A. This is shown in Scheme 12.




Scheme 12

Additionally, compounds of formula (I), can be prepared from compounds of formula (XV) by treatment with trifluoroacetic anhydride, trifluoroacetyl chloride, or trifluoroacetyl fluoride in the presence of a base (eg, pyridine or 4-dimethylaminopyridine) in a suitable solvent, such as tetrahydrofuran or ethanol, at a temperature between 25°C and 75°C. For related examples, see WO 2003/028729 and WO 2010/045251. This reaction is shown in Scheme 13.



Scheme 13


Compounds of formula (XV) can be prepared from compounds of formula (XVI) by treatment with a hydroxylamine hydrochloride salt in the presence of a base, such as triethylamine, in a suitable solvent, such as methanol, at a temperature between 0°C and 100°C. For related examples, see Kitamura, S. *et al Chem. Pharm. Bull.* (2001), 49, 268 and WO 2013/066838. This reaction is shown in Scheme 14.



Scheme 14

10

Compounds of formula (XVI) can be prepared from compounds of formula (XVII), wherein Y is Br or I, via metal-promoted reaction with a suitable cyanide reagent, such as Pd(0)/Zn(CN)₂ or CuCN, in a suitable solvent (eg, dimethylformamide or N-methylpyrrolidone) at elevated temperature between 100°C and 120°C. For related examples, see US 2007/0155739 and WO 2009/022746. This reaction is shown in Scheme 15.




Scheme 15

20


Compounds of formula (II), wherein X is Cl or Br, can be prepared from compounds of formula (XVIII) by treatment with a halogen source (eg, N-bromosuccinimide (NBS) or N-chlorosuccinimide

(NCS)) and a radical initiator (eg, $(\text{PhCO}_2)_2$ or azobisisobutyronitrile (AIBN)) in a suitable solvent, such as tetrachloromethane, at temperatures between 55° and 100°C in the presence of ultraviolet light. For related examples, see Liu, S. *et al Synthesis* (**2001**), 14, 2078 and Kompella, A. *et al Org. Proc. Res. Dev.* (**2012**), 16, 1794. This reaction is shown in Scheme 16.




Scheme 16

10 Alternatively, compounds of formula (II) can be prepared from compounds of formula (XIX) by treatment with trifluoroacetic anhydride, trifluoroacetyl chloride, or trifluoroacetyl fluoride in the presence of a base (eg, pyridine or 4-dimethylaminopyridine) in a suitable solvent, such as tetrahydrofuran or ethanol, at a temperature between 25°C and 75°C . For related examples, see WO 2003/028729 and WO 2010/045251. This reaction is shown in Scheme 17.




Scheme 17

20 Compounds of formula (XIX) can be prepared from compounds of formula (XX) by treatment with a hydroxylamine hydrochloride salt in the presence of a base, such as triethylamine, in a suitable solvent, such as methanol, at a temperature between 0°C and 100°C . For related examples, see Kitamura, S. *et al Chem. Pharm. Bull.* (**2001**), 49, 268 and WO 2013/066838. This reaction is shown in Scheme 18.



Scheme 18


Compounds of formula (XXI), wherein Y is Br, I or CN and X is Cl, Br or I, are either commercially available or can be prepared from compounds of formula (XXII), by treatment with a halogen source, (eg, *N*-bromosuccinimide (NBS) or *N*-chlorosuccinimide (NCS)) and a radical initiator, such as (PhCO₂)₂ or azobisisobutyronitrile (AIBN), in the presence of ultraviolet light, in a suitable solvent, such as tetrachloromethane, at temperatures between 55°C and 100°C. For related examples, see Liu, S. *et al Synthesis* (2001), 14, 2078 and Kompella, A. *et al Org. Proc. Res. Dev.* (2012), 16, 1794. This reaction is shown in Scheme 19.



10

Scheme 19

Alternatively, compounds of formula (XXI), wherein X is Cl, Br, I or OSO₂Me and Y is Br, I or CN, are either commercially available or can be prepared from compounds of formula (XXIII), by treatment with a halogen source (eg, CCl₃Br, CCl₄ or I₂) in the presence of triphenylphosphine, or with methanesulfonyl chloride (ClSO₂Me), in a suitable solvent, (eg, dichloromethane) at a temperature between 0°C and 100°C. For related examples, see Liu, H. *et al Bioorg. Med. Chem.* (2008), 16, 10013, WO 2014/020350 and Kompella, A. *et al Bioorg. Med. Chem. Lett.* (2001), 1, 3161. Compounds of formula (XII) are commercially available. This reaction is shown in Scheme 20.



20

Scheme 20

As already indicated, surprisingly, it has now been found that the compounds of Formula (I) of the present invention have, for practical purposes, a very advantageous level of biological activity for protecting plants against diseases that are caused by fungi.

25

The compounds of Formula (I) can be used in the agricultural sector and related fields of use, e.g., as active ingredients for controlling plant pests or on non-living materials for the control of spoilage

microorganisms or organisms potentially harmful to man. The novel compounds are distinguished by excellent activity at low rates of application, by being well tolerated by plants and by being environmentally safe. They have very useful curative, preventive and systemic properties and can be used for protecting numerous cultivated plants. The compounds of Formula (I) can be used to inhibit or
5 destroy the pests that occur on plants or parts of plants (fruit, blossoms, leaves, stems, tubers, roots) of different crops of useful plants, while at the same time protecting also those parts of the plants that grow later, e.g., from phytopathogenic microorganisms.

The present invention further relates to a method for controlling or preventing infestation of
10 plants or plant propagation material and/or harvested food crops susceptible to microbial attack by treating plants or plant propagation material and/or harvested food crops wherein an effective amount a compound of Formula (I) is applied to the plants, to parts thereof or the locus thereof.

It is also possible to use compounds of Formula (I) as a fungicide. The term "fungicide" as used
15 herein means a compound that controls, modifies, or prevents the growth of fungi. The term "fungicidally effective amount" where used means the quantity of such a compound or combination of such compounds that is capable of producing an effect on the growth of fungi. Controlling or modifying effects include all deviation from natural development, such as killing, retardation and the like, and prevention includes barrier or other defensive formation in or on a plant to prevent fungal infection.
20

It may also be possible to use compounds of Formula (I) as dressing agents for the treatment of plant propagation material, e.g., seed, such as fruits, tubers or grains, or plant cuttings, for the protection against fungal infections as well as against phytopathogenic fungi occurring in the soil. The propagation material can be treated with a composition comprising a compound of Formula (I) before
25 planting: seed, for example, can be dressed before being sown. The active compounds of Formula (I) can also be applied to grains (coating), either by impregnating the seeds in a liquid formulation or by coating them with a solid formulation. The composition can also be applied to the planting site when the propagation material is being planted, for example, to the seed furrow during sowing. The invention relates also to such methods of treating plant propagation material and to the plant propagation material
30 so treated.

Furthermore, the compounds of Formula (I) can be used for controlling fungi in related areas, for example in the protection of technical materials, including wood and wood related technical products, in food storage, in hygiene management.
35

In addition, the invention could be used to protect non-living materials from fungal attack, e.g. lumber, wall boards and paint.

The compounds of Formula (I) are for example, effective against fungi and fungal vectors of disease as well as phytopathogenic bacteria and viruses. These fungi and fungal vectors of disease as well as phytopathogenic bacteria and viruses are for example:

Absidia corymbifera, Alternaria spp, Aphanomyces spp, Ascochyta spp, Aspergillus spp.
 5 including A. flavus, A. fumigatus, A. nidulans, A. niger, A. terrus, Aureobasidium spp. including A. pullulans, Blastomyces dermatitidis, Blumeria graminis, Bremia lactucae, Botryosphaeria spp. including B. dothidea, B. obtusa, Botrytis spp. including B. cinerea, Candida spp. including C. albicans, C. glabrata, C. krusei, C. lusitaniae, C. parapsilosis, C. tropicalis, Cephaloascus fragrans, Ceratocystis spp, Cercospora spp. including C. arachidicola, Cercosporidium personatum, Cladosporium spp,
 10 Claviceps purpurea, Coccidioides immitis, Cochliobolus spp, Colletotrichum spp. including C. musae, Cryptococcus neoformans, Diaporthe spp, Didymella spp, Drechslera spp, Elsinoe spp, Epidermophyton spp, Erwinia amylovora, Erysiphe spp. including E. cichoracearum, Eutypa lata, Fusarium spp. including F. culmorum, F. graminearum, F. langsethiae, F. moniliforme, F. oxysporum, F. proliferatum, F. subglutinans, F. solani, Gaeumannomyces graminis, Gibberella fujikuroi, Gloeodes pomigena, Gloeosporium musarum, Glomerella cingulate, Guignardia bidwellii, Gymnosporangium juniperi-virginianae, Helminthosporium spp, Hemileia spp, Histoplasma spp. including H. capsulatum, Laetisaria fuciformis, Leptographium lindbergi, Leveillula taurica, Lophodermium seditiosum, Microdochium nivale, Microsporium spp, Monilinia spp, Mucor spp, Mycosphaerella spp. including M. graminicola, M. pomi, Oncobasidium theobromaeon, Ophiostoma piceae, Paracoccidioides spp,
 20 Penicillium spp. including P. digitatum, P. italicum, Petriellidium spp, Peronosclerospora spp. Including P. maydis, P. philippinensis and P. sorghi, Peronospora spp, Phaeosphaeria nodorum, Phakopsora pachyrhizi, Phellinus igniarius, Phialophora spp, Phoma spp, Phomopsis viticola, Phytophthora spp. including P. infestans, Plasmopara spp. including P. halstedii, P. viticola, Pleospora spp., Podosphaera spp. including P. leucotricha, Polymyxa graminis, Polymyxa betae, Pseudocercospora herpotrichoides, Pseudomonas spp, Pseudoperonospora spp. including P. cubensis, P. humuli, Pseudopeziza tracheiphila, Puccinia Spp. including P. hordei, P. recondita, P. striiformis, P. triticina, Pyrenopeziza spp, Pyrenophora spp, Pyricularia spp. including P. oryzae, Pythium spp. including P. ultimum, Ramularia spp, Rhizoctonia spp, Rhizomucor pusillus, Rhizopus arrhizus, Rhynchosporium spp, Scedosporium spp. including S. apiospermum and S. prolificans, Schizothyrium pomi, Sclerotinia spp, Sclerotium spp, Septoria spp, including S. nodorum, S. tritici, Sphaerotheca macularis, Sphaerotheca fusca (Sphaerotheca fuliginea), Sporothrix spp, Stagonospora nodorum, Stemphylium spp, Stereum hirsutum, Thanatephorus cucumeris, Thielaviopsis basicola, Tilletia spp, Trichoderma spp. including T. harzianum, T. pseudokoningii, T. viride, Trichophyton spp, Typhula spp, Uncinula necator, Urocystis spp, Ustilago spp, Venturia spp. including V. inaequalis, Verticillium spp, and
 35 Xanthomonas spp.

The compounds of Formula (I) may be used for example on turf, ornamentals, such as flowers, shrubs, broad-leaved trees or evergreens, for example conifers, as well as for tree injection, pest management and the like.

Within the scope of present invention, target crops and/or useful plants to be protected typically comprise perennial and annual crops, such as berry plants for example blackberries, blueberries, cranberries, raspberries and strawberries; cereals for example barley, maize (corn), millet, oats, rice, rye, sorghum triticales and wheat; fibre plants for example cotton, flax, hemp, jute and sisal; field crops for example sugar and fodder beet, coffee, hops, mustard, oilseed rape (canola), poppy, sugar cane, sunflower, tea and tobacco; fruit trees for example apple, apricot, avocado, banana, cherry, citrus, nectarine, peach, pear and plum; grasses for example Bermuda grass, bluegrass, bentgrass, centipede grass, fescue, ryegrass, St. Augustine grass and Zoysia grass; herbs such as basil, borage, chives, coriander, lavender, lovage, mint, oregano, parsley, rosemary, sage and thyme; legumes for example beans, lentils, peas and soya beans; nuts for example almond, cashew, ground nut, hazelnut, peanut, pecan, pistachio and walnut; palms for example oil palm; ornamentals for example flowers, shrubs and trees; other trees, for example cacao, coconut, olive and rubber; vegetables for example asparagus, aubergine, broccoli, cabbage, carrot, cucumber, garlic, lettuce, marrow, melon, okra, onion, pepper, potato, pumpkin, rhubarb, spinach and tomato; and vines for example grapes.

The term "useful plants" is to be understood as also including useful plants that have been rendered tolerant to herbicides like bromoxynil or classes of herbicides (such as, for example, HPPD inhibitors, ALS inhibitors, for example primisulfuron, prosulfuron and trifloxysulfuron, EPSPS (5-enol-pyrovyl-shikimate-3-phosphate-synthase) inhibitors, GS (glutamine synthetase) inhibitors or PPO (protoporphyrinogen-oxidase) inhibitors) as a result of conventional methods of breeding or genetic engineering. An example of a crop that has been rendered tolerant to imidazolinones, e.g. imazamox, by conventional methods of breeding (mutagenesis) is Clearfield® summer rape (Canola). Examples of crops that have been rendered tolerant to herbicides or classes of herbicides by genetic engineering methods include glyphosate- and glufosinate-resistant maize varieties commercially available under the trade names RoundupReady®, Herculex I® and LibertyLink®.

The term "useful plants" is to be understood as also including useful plants which have been so transformed by the use of recombinant DNA techniques that they are capable of synthesising one or more selectively acting toxins, such as are known, for example, from toxin-producing bacteria, especially those of the genus *Bacillus*.

Examples of such plants are: YieldGard® (maize variety that expresses a CryIA(b) toxin); YieldGard Rootworm® (maize variety that expresses a CryIIIB(b1) toxin); YieldGard Plus® (maize variety that expresses a CryIA(b) and a CryIIIB(b1) toxin); Starlink® (maize variety that expresses a Cry9(c) toxin); Herculex I® (maize variety that expresses a CryIF(a2) toxin and the enzyme phosphinothricine N-acetyltransferase (PAT) to achieve tolerance to the herbicide glufosinate ammonium); NuCOTN 33B® (cotton variety that expresses a CryIA(c) toxin); Bollgard I® (cotton variety that expresses a CryIA(c) toxin); Bollgard II® (cotton variety that expresses a CryIA(c) and a CryIIA(b) toxin); VIPCOT® (cotton variety that expresses a VIP toxin); NewLeaf® (potato variety that expresses a CryIIIA toxin); NatureGard® Agrisure® GT Advantage (GA21 glyphosate-tolerant trait), Agrisure® CB Advantage (Bt11 corn borer (CB) trait), Agrisure® RW (corn rootworm trait) and Protecta®.

The term "crops" is to be understood as including also crop plants which have been so transformed by the use of recombinant DNA techniques that they are capable of synthesising one or more selectively acting toxins, such as are known, for example, from toxin-producing bacteria, especially those of the genus *Bacillus*.

5 Toxins that can be expressed by such transgenic plants include, for example, insecticidal proteins from *Bacillus cereus* or *Bacillus popilliae*; or insecticidal proteins from *Bacillus thuringiensis*, such as δ -endotoxins, e.g. Cry1Ab, Cry1Ac, Cry1F, Cry1Fa2, Cry2Ab, Cry3A, Cry3Bb1 or Cry9C, or vegetative insecticidal proteins (Vip), e.g. Vip1, Vip2, Vip3 or Vip3A; or insecticidal proteins of bacteria colonising nematodes, for example *Photorhabdus* spp. or *Xenorhabdus* spp., such as *Photorhabdus*
10 *luminescens*, *Xenorhabdus nematophilus*; toxins produced by animals, such as scorpion toxins, arachnid toxins, wasp toxins and other insect-specific neurotoxins; toxins produced by fungi, such as *Streptomyces* toxins, plant lectins, such as pea lectins, barley lectins or snowdrop lectins; agglutinins; proteinase inhibitors, such as trypsin inhibitors, serine protease inhibitors, patatin, cystatin, papain inhibitors; ribosome-inactivating proteins (RIP), such as ricin, maize-RIP, abrin, luffin, saporin or
15 bryodin; steroid metabolism enzymes, such as 3-hydroxysteroidoxidase, ecdysteroid-UDP-glycosyl-transferase, cholesterol oxidases, ecdysone inhibitors, HMG-COA-reductase, ion channel blockers, such as blockers of sodium or calcium channels, juvenile hormone esterase, diuretic hormone receptors, stilbene synthase, bibenzyl synthase, chitinases and glucanases.

Further, in the context of the present invention there are to be understood by δ -endotoxins, for
20 example Cry1Ab, Cry1Ac, Cry1F, Cry1Fa2, Cry2Ab, Cry3A, Cry3Bb1 or Cry9C, or vegetative insecticidal proteins (Vip), for example Vip1, Vip2, Vip3 or Vip3A, expressly also hybrid toxins, truncated toxins and modified toxins. Hybrid toxins are produced recombinantly by a new combination of different domains of those proteins (see, for example, WO 02/15701). Truncated toxins, for example a truncated Cry1Ab, are known. In the case of modified toxins, one or more amino acids of the naturally occurring
25 toxin are replaced. In such amino acid replacements, preferably non-naturally present protease recognition sequences are inserted into the toxin, such as, for example, in the case of Cry3A055, a cathepsin-G-recognition sequence is inserted into a Cry3A toxin (see WO 03/018810).

Examples of such toxins or transgenic plants capable of synthesising such toxins are disclosed, for example, in EP-A-0 374 753, WO93/07278, WO95/34656, EP-A-0 427 529, EP-A-451 878 and WO
30 03/052073.

The processes for the preparation of such transgenic plants are generally known to the person skilled in the art and are described, for example, in the publications mentioned above. CryI-type deoxyribonucleic acids and their preparation are known, for example, from WO 95/34656, EP-A-0 367
474, EP-A-0 401 979 and WO 90/13651.

35 The toxin contained in the transgenic plants imparts to the plants tolerance to harmful insects. Such insects can occur in any taxonomic group of insects, but are especially commonly found in the beetles (Coleoptera), two-winged insects (Diptera) and butterflies (Lepidoptera).

Transgenic plants containing one or more genes that code for an insecticidal resistance and
40 express one or more toxins are known and some of them are commercially available. Examples of such

plants are: YieldGard® (maize variety that expresses a Cry1Ab toxin); YieldGard Rootworm® (maize variety that expresses a Cry3Bb1 toxin); YieldGard Plus® (maize variety that expresses a Cry1Ab and a Cry3Bb1 toxin); Starlink® (maize variety that expresses a Cry9C toxin); Herculex I® (maize variety that expresses a Cry1Fa2 toxin and the enzyme phosphinothricine N-acetyltransferase (PAT) to achieve tolerance to the herbicide glufosinate ammonium); NuCOTN 33B® (cotton variety that expresses a Cry1Ac toxin); Bollgard I® (cotton variety that expresses a Cry1Ac toxin); Bollgard II® (cotton variety that expresses a Cry1Ac and a Cry2Ab toxin); VipCot® (cotton variety that expresses a Vip3A and a Cry1Ab toxin); NewLeaf® (potato variety that expresses a Cry3A toxin); NatureGard®, Agrisure® GT Advantage (GA21 glyphosate-tolerant trait), Agrisure® CB Advantage (Bt11 corn borer (CB) trait) and Protecta®.

Further examples of such transgenic crops are:

1. **Bt11 Maize** from Syngenta Seeds SAS, Chemin de l'Hobit 27, F-31 790 St. Sauveur, France, registration number C/FR/96/05/10. Genetically modified *Zea mays* which has been rendered resistant to attack by the European corn borer (*Ostrinia nubilalis* and *Sesamia nonagrioides*) by transgenic expression of a truncated Cry1Ab toxin. Bt11 maize also transgenically expresses the enzyme PAT to achieve tolerance to the herbicide glufosinate ammonium.
2. **Bt176 Maize** from Syngenta Seeds SAS, Chemin de l'Hobit 27, F-31 790 St. Sauveur, France, registration number C/FR/96/05/10. Genetically modified *Zea mays* which has been rendered resistant to attack by the European corn borer (*Ostrinia nubilalis* and *Sesamia nonagrioides*) by transgenic expression of a Cry1Ab toxin. Bt176 maize also transgenically expresses the enzyme PAT to achieve tolerance to the herbicide glufosinate ammonium.
3. **MIR604 Maize** from Syngenta Seeds SAS, Chemin de l'Hobit 27, F-31 790 St. Sauveur, France, registration number C/FR/96/05/10. Maize which has been rendered insect-resistant by transgenic expression of a modified Cry3A toxin. This toxin is Cry3A055 modified by insertion of a cathepsin-G-protease recognition sequence. The preparation of such transgenic maize plants is described in WO 03/018810.
4. **MON 863 Maize** from Monsanto Europe S.A. 270-272 Avenue de Tervuren, B-1150 Brussels, Belgium, registration number C/DE/02/9. MON 863 expresses a Cry3Bb1 toxin and has resistance to certain Coleoptera insects.
5. **IPC 531 Cotton** from Monsanto Europe S.A. 270-272 Avenue de Tervuren, B-1150 Brussels, Belgium, registration number C/ES/96/02.

6. **1507 Maize** from Pioneer Overseas Corporation, Avenue Tedesco, 7 B-1160 Brussels, Belgium, registration number C/NL/00/10. Genetically modified maize for the expression of the protein Cry1F for achieving resistance to certain Lepidoptera insects and of the PAT protein for achieving tolerance to the herbicide glufosinate ammonium.

5

7. **NK603 × MON 810 Maize** from Monsanto Europe S.A. 270-272 Avenue de Tervuren, B-1150 Brussels, Belgium, registration number C/GB/02/M3/03. Consists of conventionally bred hybrid maize varieties by crossing the genetically modified varieties NK603 and MON 810. NK603 × MON 810 Maize transgenically expresses the protein CP4 EPSPS, obtained from *Agrobacterium sp.* strain CP4, which imparts tolerance to the herbicide Roundup® (contains glyphosate), and also a Cry1Ab toxin obtained from *Bacillus thuringiensis subsp. kurstaki* which brings about tolerance to certain Lepidoptera, include the European corn borer.

10

The compounds of Formula (I) (including any one of compounds A.1 to A.35 described in Table A (below)) according to the present invention may be used in controlling or preventing phytopathogenic diseases, especially phytopathogenic fungi (such as *Phakopsora pachyrhizi*) on soy bean plants.

15

In particular, transgenic soybean plants expressing toxins, for example insecticidal proteins such as delta-endotoxins, e.g. Cry1Ac (Cry1Ac Bt protein). Accordingly, this may include transgenic soybean plants comprising event MON87701 (see U.S. Patent No. 8,049,071 and related applications and patents, as well as WO 2014/170327 A1 (eg, see paragraph [008] reference to Intacta RR2 PRO™ soybean)), event MON87751 (US. Patent Application Publication No. 2014/0373191) or event DAS-81419 (U.S. Patent No. 8632978 and related applications and patents).

20

Other transgenic soybean plants may comprise event SYHT0H2 - HPPD tolerance (U.S. Patent Application Publication No. 2014/0201860 and related applications and patents), event MON89788 - glyphosate tolerance (U.S. Pat. No. 7,632,985 and related applications and patents), event MON87708 - dicamba tolerance (U.S. Patent Application Publication No. US 2011/0067134 and related applications and patents), event DP-356043-5 - glyphosate and ALS tolerance (U.S. Patent Application Publication No. US 2010/0184079 and related applications and patents), event A2704-12 - glufosinate tolerance (U.S. Patent Application Publication No. US 2008/0320616 and related applications and patents), event DP-305423-1 - ALS tolerance (U.S. Patent Application Publication No. US 2008/0312082 and related applications and patents), event A5547-127 - glufosinate tolerance (U.S. Patent Application Publication No. US 2008/0196127 and related applications and patents), event DAS-40278-9 - tolerance to 2,4-dichlorophenoxyacetic acid and aryloxyphenoxypropionate (see WO 2011/022469, WO 2011/022470, WO 2011/022471, and related applications and patents), event 127 - ALS tolerance (WO 2010/080829 and related applications and patents), event GTS 40-3-2 - glyphosate tolerance, event DAS-68416-4-2,4-dichlorophenoxyacetic acid and glufosinate tolerance, event FG72 - glyphosate and isoxaflutole tolerance, event BPS-CV127-9 - ALS tolerance and GU262 - glufosinate tolerance or event SYHT04R - HPPD tolerance.

25

30

35

Under certain circumstances, compounds of Formula (I) according to the present invention when used in controlling or preventing phytopathogenic diseases, especially phytopathogenic fungi (such as

40

Phakopsora pachyrhizi) on soy bean plants (in particular any of the transgenic soybean plants as described above), may display a synergistic interaction between the active ingredients.

5 Additionally, to date, no cross-resistance has been observed between the compounds of Formula (I) (including any one of compounds A.1 to A.35 described in Table A (below)) and the current fungicidal solutions used to control *Phakopsora pachyrhizi*.

10 Indeed, fungicidal-resistant strains of *Phakopsora pachyrhizi* have been reported in the scientific literature, with strains resistant to one or more fungicides from at least each of the following fungicidal mode of action classes being observed: sterol demethylation-inhibitors (DMI), quinone-outside-inhibitors (QoI) and succinate dehydrogenase inhibitors (SDHI). See for example: "Sensitivity of *Phakopsora pachyrhizi* towards quinone-outside-inhibitors and demethylation-inhibitors, and corresponding resistance mechanisms." Schmitz HK *et al*, *Pest Manag Sci* (2014) 70: 378-388; "First detection of a SDH variant with reduced SDHI sensitivity in *Phakopsora pachyrhizi*" Simões K *et al*, *J Plant Dis Prot* (2018) 125: 21-2; "Competitive fitness of *Phakopsora pachyrhizi* isolates with mutations in the CYP51 and CYTB genes." Klosowski AC *et al*, *Phytopathology* (2016) 106: 1278-1284; "Detection of the F129L mutation in the cytochrome b gene in *Phakopsora pachyrhizi*." Klosowski AC *et al*, *Pest Manag Sci* (2016) 72: 1211-1215.

15 Thus, in a preferred embodiment, the compounds of Formula (I) (including any one of compounds A.1 to A.35 described in Table A (below)), or fungicidal compositions according to the present invention comprising a compound of Formula (I), are used to control *Phakopsora pachyrhizi* which are resistant to one or more fungicides from any of the following fungicidal MoA classes: sterol demethylation-inhibitors (DMI), quinone-outside-inhibitors (QoI) and succinate dehydrogenase inhibitors (SDHI).

20 The compounds of Formula (I) (including any one of compounds A.1 to A.35 described in Table A (below)) or fungicidal compositions according to the present invention comprising a compound of Formula (I) may be used in controlling or preventing phytopathogenic diseases, especially phytopathogenic fungi (such as *Phakopsora pachyrhizi*) on soy bean plants. In particular, there are known in the scientific literature certain Elite soybean plant varieties where R-gene stacks, conferring a degree of immunity or resistance to specific *Phakopsora pachyrhizi*, have been been introgressed in the plant genome, see for example: "*Fighting Asian Soybean Rust*", Langenbach C, *et al*, *Front Plant Science* 7(797) 2016).

25 An elite plant is any plant from an elite line, such that an elite plant is a representative plant from an elite variety. Non-limiting examples of elite soybean varieties that are commercially available to farmers or soybean breeders include: AG00802, A0868, AG0902, A1923, AG2403, A2824, A3704, A4324, A5404, AG5903, AG6202 AG0934; AG1435; AG2031; AG2035; AG2433; AG2733; AG2933; AG3334; AG3832; AG4135; AG4632; AG4934; AG5831; AG6534; and AG7231 (Asgrow Seeds, Des Moines, Iowa, USA); BPR0144RR, BPR 4077NRR and BPR 4390NRR (Bio Plant Research, Camp Point, Ill., USA); DKB17-51 and DKB37-51 (DeKalb Genetics, DeKalb, Ill., USA); DP 4546 RR, and DP 7870 RR (Delta & Pine Land Company, Lubbock, Tex., USA); JG 03R501, JG 32R606C ADD and JG 55R503C (JGL Inc., Greencastle, Ind., USA); NKS 13-K2 (NK Division of Syngenta Seeds, Golden

Valley, Minnesota, USA); 90M01, 91M30, 92M33, 93M11, 94M30, 95M30, 97B52, P008T22R2; P16T17R2; P22T69R; P25T51R; P34T07R2; P35T58R; P39T67R; P47T36R; P46T21R; and P56T03R2 (Pioneer Hi-Bred International, Johnston, Iowa, USA); SG4771NRR and SG5161NRR/STS (Soygenetics, LLC, Lafayette, Ind., USA); S00-K5, S11-L2, S28-Y2, S43-B1, S53-A1, S76-L9, S78-G6, S0009-M2; S007-Y4; S04-D3; S14-A6; S20-T6; S21-M7; S26-P3; S28-N6; S30-V6; S35-C3; S36-Y6; S39-C4; S47-K5; S48-D9; S52-Y2; S58-Z4; S67-R6; S73-S8; and S78-G6 (Syngenta Seeds, Henderson, Ky., USA); Richer (Northstar Seed Ltd. Alberta, CA); 14RD62 (Stine Seed Co. Ia., USA); or Armor 4744 (Armor Seed, LLC, Ar., USA).

Thus, in a further preferred embodiment, the compounds of Formula (I) (including any one of compounds A.1 to A.35 described in Table A (below)), or fungicidal compositions according to the present invention comprising a compound of Formula (I), are used to control *Phakopsora pachyrhizi*, (including fungicidally-resistant strains thereof, as outlined above) on Elite soybean plant varieties where R-gene stacks, conferring a degree of immunity or resistance to specific *Phakopsora pachyrhizi*, have been introgressed in the plant genome. Numerous benefits may be expected to ensue from said use, e.g. improved biological activity, an advantageous or broader spectrum of activity (inc. sensitive and resistant strains of *Phakopsora pachyrhizi*), an increased safety profile, improved crop tolerance, synergistic interactions or potentiating properties, improved onset of action or a longer lasting residual activity, a reduction in the number of applications and/or a reduction in the application rate of the compounds and compositions required for effective control of the phytopathogen (*Phakopsora pachyrhizi*), thereby enabling beneficial resistance-management practices, reduced environmental impact and reduced operator exposure.

The term "locus" as used herein means fields in or on which plants are growing, or where seeds of cultivated plants are sown, or where seed will be placed into the soil. It includes soil, seeds, and seedlings, as well as established vegetation.

The term "plants" refers to all physical parts of a plant, including seeds, seedlings, saplings, roots, tubers, stems, stalks, foliage, and fruits.

The term "plant propagation material" is understood to denote generative parts of the plant, such as seeds, which can be used for the multiplication of the latter, and vegetative material, such as cuttings or tubers, for example potatoes. There can be mentioned for example seeds (in the strict sense), roots, fruits, tubers, bulbs, rhizomes and parts of plants. Germinated plants and young plants which are to be transplanted after germination or after emergence from the soil, may also be mentioned. These young plants can be protected before transplantation by a total or partial treatment by immersion. Preferably "plant propagation material" is understood to denote seeds.

The compounds of Formula (I) may be used in unmodified form or, preferably, together with the adjuvants conventionally employed in the art of formulation. To this end they may be conveniently Formulated in known manner to emulsifiable concentrates, coatable pastes, directly sprayable or dilutable solutions or suspensions, dilute emulsions, wettable powders, soluble powders, dusts, granulates, and also encapsulations e.g. in polymeric substances. As with the type of the compositions, the methods of application, such as spraying, atomising, dusting, scattering, coating or pouring, are

chosen in accordance with the intended objectives and the prevailing circumstances. The compositions may also contain further adjuvants such as stabilizers, antifoams, viscosity regulators, binders or tackifiers as well as fertilizers, micronutrient donors or other formulations for obtaining special effects.

5 Suitable carriers and adjuvants, e.g. for agricultural use, can be solid or liquid and are substances useful in formulation technology, e.g. natural or regenerated mineral substances, solvents, dispersants, wetting agents, tackifiers, thickeners, binders or fertilizers. Such carriers are for example described in WO 97/33890.

10 Suspension concentrates are aqueous formulations in which finely divided solid particles of the active compound are suspended. Such formulations include anti-settling agents and dispersing agents and may further include a wetting agent to enhance activity as well an anti-foam and a crystal growth inhibitor. In use, these concentrates are diluted in water and normally applied as a spray to the area to be treated. The amount of active ingredient may range from 0.5% to 95% of the concentrate.

15 Wettable powders are in the form of finely divided particles which disperse readily in water or other liquid carriers. The particles contain the active ingredient retained in a solid matrix. Typical solid matrices include fuller's earth, kaolin clays, silicas and other readily wet organic or inorganic solids. Wettable powders normally contain from 5% to 95% of the active ingredient plus a small amount of wetting, dispersing or emulsifying agent.

20 Emulsifiable concentrates are homogeneous liquid compositions dispersible in water or other liquid and may consist entirely of the active compound with a liquid or solid emulsifying agent, or may also contain a liquid carrier, such as xylene, heavy aromatic naphthas, isophorone and other non-volatile organic solvents. In use, these concentrates are dispersed in water or other liquid and normally applied as a spray to the area to be treated. The amount of active ingredient may range from 0.5% to 95% of the concentrate.

25 Granular formulations include both extrudates and relatively coarse particles and are usually applied without dilution to the area in which treatment is required. Typical carriers for granular Formulations include sand, fuller's earth, attapulgit clay, bentonite clays, montmorillonite clay, vermiculite, perlite, calcium carbonate, brick, pumice, pyrophyllite, kaolin, dolomite, plaster, wood flour, ground corn cobs, ground peanut hulls, sugars, sodium chloride, sodium sulphate, sodium silicate, sodium borate, magnesia, mica, iron oxide, zinc oxide, titanium oxide, antimony oxide, cryolite, gypsum, 30 diatomaceous earth, calcium sulphate and other organic or inorganic materials which absorb or which can be coated with the active compound. Granular Formulations normally contain 5% to 25% of active ingredients which may include surface-active agents such as heavy aromatic naphthas, kerosene and other petroleum fractions, or vegetable oils; and/or stickers such as dextrans, glue or synthetic resins.

35 Dusts are free-flowing admixtures of the active ingredient with finely divided solids such as talc, clays, flours and other organic and inorganic solids which act as dispersants and carriers.

40 Microcapsules are typically droplets or granules of the active ingredient enclosed in an inert porous shell which allows escape of the enclosed material to the surroundings at controlled rates. Encapsulated droplets are typically 1 to 50 microns in diameter. The enclosed liquid typically constitutes 50 to 95% of the weight of the capsule and may include solvent in addition to the active compound. Encapsulated granules are generally porous granules with porous membranes sealing the granule pore

openings, retaining the active species in liquid form inside the granule pores. Granules typically range from 1 millimetre to 1 centimetre and preferably 1 to 2 millimetres in diameter. Granules are formed by extrusion, agglomeration or prilling, or are naturally occurring. Examples of such materials are vermiculite, sintered clay, kaolin, attapulgite clay, sawdust and granular carbon. Shell or membrane materials include natural and synthetic rubbers, cellulosic materials, styrene-butadiene copolymers, polyacrylonitriles, polyacrylates, polyesters, polyamides, polyureas, polyurethanes and starch xanthates.

Other useful formulations for agrochemical applications include simple solutions of the active ingredient in a solvent in which it is completely soluble at the desired concentration, such as acetone, alkylated naphthalenes, xylene and other organic solvents. Pressurised sprayers, wherein the active ingredient is dispersed in finely-divided form as a result of vaporisation of a low boiling dispersant solvent carrier, may also be used.

Suitable agricultural adjuvants and carriers that are useful in formulating the compositions of the invention in the formulation types described above are well known to those skilled in the art.

Liquid carriers that can be employed include, for example, water, toluene, xylene, petroleum naphtha, crop oil, acetone, methyl ethyl ketone, cyclohexanone, acetic anhydride, acetonitrile, acetophenone, amyl acetate, 2-butanone, chlorobenzene, cyclohexane, cyclohexanol, alkyl acetates, diacetonalcohol, 1,2-dichloropropane, diethanolamine, p-diethylbenzene, diethylene glycol, diethylene glycol abietate, diethylene glycol butyl ether, diethylene glycol ethyl ether, diethylene glycol methyl ether, N,N-dimethyl formamide, dimethyl sulfoxide, 1,4-dioxane, dipropylene glycol, dipropylene glycol methyl ether, dipropylene glycol dibenzoate, diproxitol, alkyl pyrrolidinone, ethyl acetate, 2-ethyl hexanol, ethylene carbonate, 1,1,1-trichloroethane, 2-heptanone, alpha pinene, d-limonene, ethylene glycol, ethylene glycol butyl ether, ethylene glycol methyl ether, gamma-butyrolactone, glycerol, glycerol diacetate, glycerol monoacetate, glycerol triacetate, hexadecane, hexylene glycol, isoamyl acetate, isobornyl acetate, isooctane, isophorone, isopropyl benzene, isopropyl myristate, lactic acid, laurylamine, mesityl oxide, methoxy-propanol, methyl isoamyl ketone, methyl isobutyl ketone, methyl laurate, methyl octanoate, methyl oleate, methylene chloride, m-xylene, n-hexane, n-octylamine, octadecanoic acid, octyl amine acetate, oleic acid, oleylamine, o-xylene, phenol, polyethylene glycol (PEG400), propionic acid, propylene glycol, propylene glycol monomethyl ether, p-xylene, toluene, triethyl phosphate, triethylene glycol, xylene sulfonic acid, paraffin, mineral oil, trichloroethylene, perchloroethylene, ethyl acetate, amyl acetate, butyl acetate, methanol, ethanol, isopropanol, and higher molecular weight alcohols such as amyl alcohol, tetrahydrofurfuryl alcohol, hexanol, octanol, etc., ethylene glycol, propylene glycol, glycerine and N-methyl-2-pyrrolidinone. Water is generally the carrier of choice for the dilution of concentrates.

Suitable solid carriers include, for example, talc, titanium dioxide, pyrophyllite clay, silica, attapulgite clay, kieselguhr, chalk, diatomaceous earth, lime, calcium carbonate, bentonite clay, fuller's earth, cotton seed hulls, wheat flour, soybean flour, pumice, wood flour, walnut shell flour and lignin.

A broad range of surface-active agents are advantageously employed in both said liquid and solid compositions, especially those designed to be diluted with carrier before application. These agents, when used, normally comprise from 0.1% to 15% by weight of the formulation. They can be

anionic, cationic, non-ionic or polymeric in character and can be employed as emulsifying agents, wetting agents, suspending agents or for other purposes. Typical surface active agents include salts of alkyl sulfates, such as diethanolammonium lauryl sulphate; alkylarylsulfonate salts, such as calcium dodecylbenzenesulfonate; alkylphenol-alkylene oxide addition products, such as nonylphenol-C.sub.
5 18 ethoxylate; alcohol-alkylene oxide addition products, such as tridecyl alcohol-C.sub. 16 ethoxylate; soaps, such as sodium stearate; alkylnaphthalenesulfonate salts, such as sodium dibutylnaphthalenesulfonate; dialkyl esters of sulfosuccinate salts, such as sodium di(2-ethylhexyl) sulfosuccinate; sorbitol esters, such as sorbitol oleate; quaternary amines, such as lauryl trimethylammonium chloride; polyethylene glycol esters of fatty acids, such as polyethylene glycol
10 stearate; block copolymers of ethylene oxide and propylene oxide; and salts of mono and dialkyl phosphate esters.

Other adjuvants commonly utilized in agricultural compositions include crystallisation inhibitors, viscosity modifiers, suspending agents, spray droplet modifiers, pigments, antioxidants, foaming agents, anti-foaming agents, light-blocking agents, compatibilizing agents, antifoam agents,
15 sequestering agents, neutralising agents and buffers, corrosion inhibitors, dyes, odorants, spreading agents, penetration aids, micronutrients, emollients, lubricants and sticking agents.

In addition, further, other biocidally active ingredients or compositions may be combined with the compositions of the invention and used in the methods of the invention and applied simultaneously or sequentially with the compositions of the invention. When applied simultaneously, these further
20 active ingredients may be formulated together with the compositions of the invention or mixed in, for example, the spray tank. These further biocidally active ingredients may be fungicides, herbicides, insecticides, bactericides, acaricides, nematocides and/or plant growth regulators.

Pesticidal agents are referred to herein using their common name are known, for example, from "The Pesticide Manual", 15th Ed., British Crop Protection Council 2009.
25

In addition, the compositions of the invention may also be applied with one or more systemically acquired resistance inducers ("SAR" inducer). SAR inducers are known and described in, for example, United States Patent No. US 6,919,298 and include, for example, salicylates and the commercial SAR inducer acibenzolar-S-methyl.

The compounds of Formula (I) are normally used in the form of agrochemical compositions and can be applied to the crop area or plant to be treated, simultaneously or in succession with further compounds. These further compounds can be e.g. fertilizers or micronutrient donors or other preparations, which influence the growth of plants. They can also be selective herbicides or non-selective herbicides as well as insecticides, fungicides, bactericides, nematocides, molluscicides or
35 mixtures of several of these preparations, if desired together with further carriers, surfactants or application promoting adjuvants customarily employed in the art of formulation.

The compounds of Formula (I) may be used in the form of (fungicidal) compositions for controlling or protecting against phytopathogenic microorganisms, comprising as active ingredient at least one compound of Formula (I) or of at least one preferred individual compound as defined herein,
40 in free form or in agrochemically usable salt form, and at least one of the above-mentioned adjuvants.

The invention therefore provides a composition, preferably a fungicidal composition, comprising at least one compound Formula (I) an agriculturally acceptable carrier and optionally an adjuvant. An agricultural acceptable carrier is for example a carrier that is suitable for agricultural use. Agricultural carriers are well known in the art. Preferably said composition may comprise at least one or more
 5 pesticidally-active compounds, for example an additional fungicidal active ingredient in addition to the compound of Formula (I).

The compound of Formula (I) may be the sole active ingredient of a composition or it may be admixed with one or more additional active ingredients such as a pesticide, fungicide, synergist,
 10 herbicide or plant growth regulator where appropriate. An additional active ingredient may, in some cases, result in unexpected synergistic activities.

Examples of suitable additional active ingredients include the following: acycloamino acid fungicides, aliphatic nitrogen fungicides, amide fungicides, anilide fungicides, antibiotic fungicides, aromatic fungicides, arsenical fungicides, aryl phenyl ketone fungicides, benzamide fungicides,
 15 benzanilide fungicides, benzimidazole fungicides, benzothiazole fungicides, botanical fungicides, bridged diphenyl fungicides, carbamate fungicides, carbanilate fungicides, conazole fungicides, copper fungicides, dicarboximide fungicides, dinitrophenol fungicides, dithiocarbamate fungicides, dithiolane fungicides, furamide fungicides, furanilide fungicides, hydrazide fungicides, imidazole fungicides, mercury fungicides, morpholine fungicides, organophosphorous fungicides, organotin fungicides,
 20 oxathiin fungicides, oxazole fungicides, phenylsulfamide fungicides, polysulfide fungicides, pyrazole fungicides, pyridine fungicides, pyrimidine fungicides, pyrrole fungicides, quaternary ammonium fungicides, quinoline fungicides, quinone fungicides, quinoxaline fungicides, strobilurin fungicides, sulfonanilide fungicides, thiadiazole fungicides, thiazole fungicides, thiazolidine fungicides, thiocarbamate fungicides, thiophene fungicides, triazine fungicides, triazole fungicides,
 25 triazolopyrimidine fungicides, urea fungicides, valinamide fungicides, and zinc fungicides.

Examples of suitable additional active ingredients also include the following: 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylene-1,2,3,4-tetrahydro-1,4-methano-naphthalen-5-yl)-amide , 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid methoxy-[1-methyl-2-(2,4,6-trichlorophenyl)-ethyl]-amide , 1-methyl-3-difluoromethyl-1H-pyrazole-4-carboxylic acid (2-dichloromethylene-3-ethyl-1-methyl-indan-4-yl)-amide (1072957-71-1), 1-methyl-3-difluoromethyl-1H-pyrazole-4-carboxylic acid (4'-methylsulfanyl-biphenyl-2-yl)-amide, 1-methyl-3-difluoromethyl-4H-pyrazole-4-carboxylic acid [2-(2,4-dichloro-phenyl)-2-methoxy-1-methyl-ethyl]-amide, (5-Chloro-2,4-dimethyl-pyridin-3-yl)-(2,3,4-trimethoxy-6-methyl-phenyl)-methanone, (5-Bromo-4-chloro-2-methoxy-pyridin-3-yl)-(2,3,4-trimethoxy-6-methyl-phenyl)-methanone, 2-{2-[(E)-3-(2,6-Dichloro-phenyl)-1-methyl-prop-2-en-(E)-ylideneaminoxymethyl]-phenyl}-2-[(Z)-methoxyimino]-N-methyl-acetamide, 3-[5-(4-Chloro-phenyl)-2,3-dimethyl-isoxazolidin-3-yl]-pyridine, (E)-N-methyl-2- [2- (2, 5-dimethylphenoxy-methyl) phenyl]-2-methoxy-iminoacetamide, 4-bromo-2-cyano-N, N-dimethyl-6-trifluoromethylbenzimidazole-1-sulphonamide, α -[N-(3-chloro-2,6-xyllyl)-2-methoxyacetamido]-y-butyrolactone, 4-chloro-2-cyano-N,N - dimethyl-5-p-tolylimidazole-1-sulfonamide, N-allyl-4, 5,-dimethyl-2-trimethylsilylthiophene-3-carboxamide, N- (l-cyano-1, 2-dimethylpropyl)-2- (2, 4-dichlorophenoxy)

propionamide, N- (2-methoxy-5-pyridyl)-cyclopropane carboxamide, (.+.-)-cis-1-(4-chlorophenyl)-2-(1H-1,2,4-triazol-1-yl)-cycloheptanol, 2-(1-*tert*-butyl)-1-(2-chlorophenyl)-3-(1,2,4-triazol-1-yl)-propan-2-ol, 2',6'-dibromo-2-methyl-4-trifluoromethoxy-4'-trifluoromethyl-1,3-thiazole-5-carboxanilide, 1-imidazolyl-1-(4'-chlorophenoxy)-3,3-dimethylbutan-2-one, methyl (E)-2-[2-[6-(2-cyanophenoxy)pyrimidin-4-yloxy]phenyl]-3-methoxyacrylate, methyl (E)-2-[2-[6-(2-thioamidophenoxy)pyrimidin-4-yloxy]phenyl]-3-methoxyacrylate, methyl (E)-2-[2-[6-(2-fluorophenoxy)pyrimidin-4-yloxy]phenyl]-3-methoxyacrylate, methyl (E)-2-[2-[6-(2,6-difluorophenoxy)pyrimidin-4-yloxy]phenyl]-3-methoxyacrylate, methyl (E)-2-[2-[3-(pyrimidin-2-yloxy)phenoxy]phenyl]-3-methoxyacrylate, methyl (E)-2-[2-[3-(5-methylpyrimidin-2-yloxy)phenoxy]phenyl]-3-methoxyacrylate, methyl (E)-2-[2-[3-(phenyl-sulphonyloxy)phenoxy]phenyl]-3-methoxyacrylate, methyl (E)-2-[2-[3-(4-nitrophenoxy)phenoxy]phenyl]-3-methoxyacrylate, methyl (E)-2-[2-[2-phenoxyphenyl]-3-methoxyacrylate, methyl (E)-2-[2-(3,5-dimethyl-benzoyl)pyrrol-1-yl]-3-methoxyacrylate, methyl (E)-2-[2-(3-methoxyphenoxy)phenyl]-3-methoxyacrylate, methyl (E)-2-[2-(2-phenylethen-1-yl)-phenyl]-3-methoxyacrylate, methyl (E)-2-[2-(3,5-dichlorophenoxy)pyridin-3-yl]-3-methoxyacrylate, methyl (E)-2-(2-(3-(1,1,2,2-tetrafluoroethoxy)phenoxy)phenyl)-3-methoxyacrylate, methyl (E)-2-(2-[3-(alpha-hydroxybenzyl)phenoxy]phenyl)-3-methoxyacrylate, methyl (E)-2-(2-(4-phenoxy)pyridin-2-yloxy)phenyl)-3-methoxyacrylate, methyl (E)-2-[2-(3-n-propyloxy-phenoxy)phenyl]-3-methoxyacrylate, methyl (E)-2-[2-(3-isopropyloxyphenoxy)phenyl]-3-methoxyacrylate, methyl (E)-2-[2-[3-(2-fluorophenoxy)phenoxy]phenyl]-3-methoxyacrylate, methyl (E)-2-[2-(3-ethoxyphenoxy)phenyl]-3-methoxyacrylate, methyl (E)-2-[2-(4-*tert*-butyl-pyridin-2-yloxy)phenyl]-3-methoxyacrylate, methyl (E)-2-[2-[3-(3-cyanophenoxy)phenoxy]phenyl]-3-methoxyacrylate, methyl (E)-2-[2-[(3-methyl-pyridin-2-yloxymethyl)phenyl]-3-methoxyacrylate, methyl (E)-2-[2-[6-(2-methyl-phenoxy)pyrimidin-4-yloxy]phenyl]-3-methoxyacrylate, methyl (E)-2-[2-(5-bromo-pyridin-2-yloxymethyl)phenyl]-3-methoxyacrylate, methyl (E)-2-[2-(3-(3-iodopyridin-2-yloxy)phenoxy)phenyl]-3-methoxyacrylate, methyl (E),(E)-2-[2-[6-(2-chloropyridin-3-yloxy)pyrimidin-4-yloxy]phenyl]-3-methoxyacrylate, methyl (E),(E)-2-[2-(5,6-dimethylpyrazin-2-ylmethyloximinomethyl)phenyl]-3-methoxyacrylate, methyl (E),(E)-2-[2-[6-(6-methylpyridin-2-yloxy)pyrimidin-4-yloxy]phenyl]-3-methoxyacrylate, methyl (E),(E)-2-[2-(3-methoxyphenyl)methyloximinomethyl]-phenyl]-3-methoxyacrylate, methyl (E)-2-[2-(6-(2-azidophenoxy)-pyrimidin-4-yloxy]phenyl]-3-methoxyacrylate, methyl (E),(E)-2-[2-[6-phenylpyrimidin-4-yl)-methyloximinomethyl]phenyl]-3-methoxyacrylate, methyl (E),(E)-2-[2-[(4-chlorophenyl)-methyloximinomethyl]-phenyl]-3-methoxyacrylate, methyl (E)-2-[2-[6-(2-n-propylphenoxy)-1,3,5-triazin-4-yloxy]phenyl]-3-methoxyacrylate, methyl (E),(E)-2-[2-[(3-nitrophenyl)methyloximinomethyl]phenyl]-3-methoxyacrylate, 3-chloro-7-(2-aza-2,7,7-trimethyl-oct-3-en-5-ine), 2,6-dichloro-N-(4-trifluoromethylbenzyl)-benzamide, 3-iodo-2-propinyl alcohol, 4-chlorophenyl-3-iodopropargyl formal, 3-bromo-2,3-diiodo-2-propenyl ethylcarbamate, 2,3,3-triiodoallyl alcohol, 3-bromo-2,3-diiodo-2-propenyl alcohol, 3-iodo-2-propinyl n-butylcarbamate, 3-iodo-2-propinyl n-hexylcarbamate, 3-iodo-2-propinyl cyclohexyl-carbamate, 3-iodo-2-propinyl phenylcarbamate; phenol derivatives, such as tribromophenol, tetrachlorophenol, 3-methyl-4-chlorophenol, 3,5-dimethyl-4-chlorophenol, phenoxyethanol, dichlorophene, o-phenylphenol, m-phenylphenol, p-phenylphenol, 2-benzyl-4-chlorophenol, 5-hydroxy-2(5H)-furanone; 4,5-dichlorodithiazolinone, 4,5-benzodithiazolinone,

4,5-trimethylenedithiazolinone, 4,5-dichloro-(3H)-1,2-dithiol-3-one, 3,5-dimethyl-tetrahydro-1,3,5-thiadiazine-2-thione, N-(2-p-chlorobenzoyl)ethyl-hexaminium chloride, acibenzolar, acypetacs, alanycarb, albendazole, aldimorph, allicin, allyl alcohol, ametoctradin, amisulbrom, amobam, ampropylfos, anilazine, asomate, aureofungin, azaconazole, azafendin, azithiram, azoxystrobin, barium polysulfide, benalaxyl, benalaxyl-M, benodanil, benomyl, benquinox, bentalurone, benthiavalicarb, benthiazole, benzalkonium chloride, benzamacril, benzamorf, benzohydroxamic acid, benzovindiflupyr, berberine, bethoxazin, biloxazol, binapacryl, biphenyl, bitertanol, bithionol, bixafen, blasticidin-S, boscalid, bromothalonil, bromuconazole, bupirimate, buthiobate, butylamine calcium polysulfide, captafol, captan, carbamorph, carbendazim, carbendazim chlorhydrate, carboxin, carpropamid, 5 carvone, CGA41396, CGA41397, chinomethionate, chitosan, chlobenthiazole, chloraniformethan, chloranil, chlorfenazole, chloroneb, chloropicrin, chlorothalonil, chlorozolate, chlozolate, climbazole, clotrimazole, clozylacon, copper containing compounds such as copper acetate, copper carbonate, copper hydroxide, copper naphthenate, copper oleate, copper oxychloride, copper oxyquinolate, copper silicate, copper sulphate, copper tallate, copper zinc chromate and Bordeaux mixture, cresol, cufraneb, 10 cuprobam, cuprous oxide, cyazofamid, cyclafuramid, cycloheximide, cyflufenamid, cymoxanil, cypendazole, cyproconazole, cyprodinil, dazomet, debacarb, decafentin, dehydroacetic acid, di-2-pyridyl disulphide 1,1'-dioxide, dichlofluanid, diclomezine, dichlone, dicloran, dichlorophen, dichlozoline, diclobutrazol, diclocymet, diethofencarb, difenoconazole, difenzoquat, diflumetorim, O, O-di-iso-propyl-S-benzyl thiophosphate, dimefluzole, dimetachlone, dimetconazole, dimethomorph, dimethirimol, 15 diniconazole, diniconazole-M, dinobuton, dinocap, dinocton, dinopenton, dinosulfon, dinoterbon, diphenylamine, dipyrithione, disulfiram, ditalimfos, dithianon, dithioether, dodecyl dimethyl ammonium chloride, dodemorph, dodicin, dodine, doguadine, drazoxolon, edifenphos, enestroburin, epoxiconazole, etaconazole, etem, ethaboxam, ethirimol, ethoxyquin, ethilicin, ethyl (Z)-N-benzyl-N ([methyl (methyl-thioethylideneamino-oxycarbonyl) amino] thio)- β -alaninate, etridiazole, famoxadone, 20 fenamidone, fenaminosulf, fenapanil, fenarimol, fenbuconazole, fenfuram, fenhexamid, fenitropan, fenoxanil, fempiclonil, fempicoxamid, fenpropidin, fenpropimorph, fenpyrazamine, fentin acetate, fentin hydroxide, ferbam, ferimzone, fluazinam, fludioxonil, flumetover, flumorph, flupicolide, fluopyram, fluoroimide, fluotrimazole, fluoxastrobin, fluquinconazole, flusilazole, flusulfamide, flutanil, flutolanil, flutriafol, fluxapyroxad, folpet, formaldehyde, fosetyl, fuberidazole, furalaxyl, furametpyr, furcarbanil, 30 furconazole, furfural, furmecyclox, furophanate, glyodin, griseofulvin, guazatine, halacrinat, hexachlorobenzene, hexachlorobutadiene, hexachlorophene, hexaconazole, hexylthiofos, hydrargaphen, hydroxyisoxazole, hymexazole, imazalil, imazalil sulphate, imibenconazole, iminocadine, iminocadine triacetate, inezin, iodocarb, ipconazole, ipfentrifluconazole, iprobenfos, iprodione, iprovalicarb, isopropanyl butyl carbamate, isoprothiolane, isopyrazam, isotianil, isovalidione, izopamfos, 35 kasugamycin, kresoxim-methyl, LY186054, LY211795, LY248908, mancozeb, mandipropamid, maneb, mebenil, mecarbinzid, mefenoxam, mefentrifluconazole, mepanipirim, mepronil, mercuric chloride, mercurous chloride, meptyldinocap, metalaxyl, metalaxyl-M, metam, metazoxolon, metconazole, methasulfocarb, methfuroxam, methyl bromide, methyl iodide, methyl isothiocyanate, metiram, metiram-zinc, metominostrobin, metrafenone, metsulfovax, milneb, moroxydine, myclobutanil, 40 myclozolin, nabam, natamycin, neoasozin, nickel dimethyldithiocarbamate, nitrostyrene, nitrothal-iso-

propyl, nuarimol, octhilinone, ofurace, organomercury compounds, orysastrobin, osthol, oxadixyl, oxasulfuron, oxathiapiprolin, oxine-copper, oxolinic acid, oxpoconazole, oxycarboxin, parinol, pefurazoate, penconazole, pencycuron, penflufen, pentachlorophenol, penthiopyrad, phenamacril, phenazin oxide, phosdiphen, phosetyl-Al, phosphorus acids, phthalide, picoxystrobin, piperalin, polycarbamate, polyoxin D, polyoxrim, polyram, probenazole, prochloraz, procymidone, propamidine, propamocarb, propiconazole, propineb, propionic acid, proquinazid, prothiocarb, prothioconazole, pydiflumetofen, pyracarbolid, pyraclostrobin, pyrametrostrobin, pyraoxystrobin, pyrazophos, pyribencarb, pyridinitril, pyrifenox, pyrimethanil, pyriofenone, pyroquilon, pyroxychlor, pyroxyfur, pyrrolnitrin, quaternary ammonium compounds, quinacetol, quinazamid, quinconazole, quinomethionate, quinoxifen, quintozene, rabenzazole, santonin, sedaxane, silthiofam, simeconazole, sipconazole, sodium pentachlorophenate, spiroxamine, streptomycin, sulphur, sultropen, tebuconazole, tebfloquin, tecloftalam, tecnazene, tecoram, tetraconazole, thiabendazole, thiadifluor, thicyofen, thifluzamide, 2- (thiocyanomethylthio) benzothiazole, thiophanate-methyl, thioquinox, thiram, tiadinil, timibenconazole, tioxymid, tolclofos-methyl, tolylfluanid, triadimefon, triadimenol, triamiphos, triarimol, triazbutil, triazoxide, tricyclazole, tridemorph, trifloxystrobin, triflumazole, triforine, triflumizole, triticonazole, uniconazole, urbacide, validamycin, valifenalate, vapam, vinclozolin, zarilamid, zineb, ziram, and zoxamide.

The compounds of the invention may also be used in combination with anthelmintic agents. Such anthelmintic agents include, compounds selected from the macrocyclic lactone class of compounds such as ivermectin, avermectin, abamectin, emamectin, eprinomectin, doramectin, selamectin, moxidectin, nemadectin and milbemycin derivatives as described in EP- 357460, EP- 444964 and EP-594291. Additional anthelmintic agents include semisynthetic and biosynthetic avermectin/milbemycin derivatives such as those described in US-5015630, WO-9415944 and WO- 9522552. Additional anthelmintic agents include the benzimidazoles such as albendazole, cambendazole, fenbendazole, flubendazole, mebendazole, oxfendazole, oxibendazole, parbendazole, and other members of the class. Additional anthelmintic agents include imidazothiazoles and tetrahydropyrimidines such as tetramisole, levamisole, pyrantel pamoate, oxantel or morantel. Additional anthelmintic agents include flukicides, such as triclabendazole and clorsulon and the cestocides, such as praziquantel and epsiprantel.

The compounds of the invention may be used in combination with derivatives and analogues of the paraherquamide/marcfortine class of anthelmintic agents, as well as the antiparasitic oxazolines such as those disclosed in US-5478855, US- 4639771 and DE-19520936.

The compounds of the invention may be used in combination with derivatives and analogues of the general class of dioxomorpholine antiparasitic agents as described in WO 96/15121 and also with anthelmintic active cyclic depsipeptides such as those described in WO 96/11945, WO 93/19053, WO 93/25543, EP 0 626 375, EP 0 382 173, WO 94/19334, EP 0 382 173, and EP 0 503 538.

The compounds of the invention may be used in combination with other ectoparasiticides; for example, fipronil; pyrethroids; organophosphates; insect growth regulators such as lufenuron; ecdysone agonists such as tebufenozide and the like; neonicotinoids such as imidacloprid and the like.

The compounds of the invention may be used in combination with terpene alkaloids, for example those described in International Patent Application Publication Numbers WO 95/19363 or WO 04/72086, particularly the compounds disclosed therein.

5 Other examples of such biologically active compounds that the compounds of the invention may be used in combination with include but are not restricted to the following:

Organophosphates: acephate, azamethiphos, azinphos-ethyl, azinphos- methyl, bromophos, bromophos-ethyl, cadusafos, chlorethoxyphos, chlorpyrifos, chlorfenvinphos, chlormephos, demeton, demeton-S-methyl, demeton-S-methyl sulphone, dialifos, diazinon, dichlorvos, dicrotophos, dimethoate, disulfoton, ethion, ethoprophos, etrimfos, famphur, fenamiphos, fenitrothion, fensulfothion, 10 fenthion, flupyrazofos, fonofos, formothion, fosthiazate, heptenophos, isazophos, isothioate, isoxathion, malathion, methacriphos, methamidophos, methidathion, methyl- parathion, mevinphos, monocrotophos, naled, omethoate, oxydemeton-methyl, paraoxon, parathion, parathion-methyl, phenthoate, phosalone, phosfolan, phosphocarb, phosmet, phosphamidon, phorate, phoxim, pirimiphos, pirimiphos- methyl, profenofos, propaphos, proetamphos, prothiofos, pyraclofos, 15 pyridapenthion, quinalphos, sulprophos, temephos, terbufos, tebupirimfos, tetrachlorvinphos, thimeton, triazophos, trichlorfon, vamidothion.

Carbamates: alanycarb, aldicarb, 2-sec-butylphenyl methylcarbamate, benfuracarb, carbaryl, carbofuran, carbosulfan, cloethocarb, ethiofencarb, fenoxycarb, fenthio carb, furathiocarb, HCN-801, isoprocarb, indoxacarb, methiocarb, methomyl, 5-methyl-m-cumenylbutyryl(methyl)carbamate, oxamyl, 20 pirimicarb, propoxur, thiodicarb, thiofanox, triazamate, UC-51717.

Pyrethroids: acrinathin, allethrin, alphamethrin, 5-benzyl-3-furylmethyl (E)-(1 R)-cis-2,2-dimethyl-3-(2-oxothiolan-3-ylidenemethyl)cyclopropanecarboxylate, bifenthrin, beta-cyfluthrin, cyfluthrin, a-cypermethrin, beta-cypermethrin, bioallethrin, bioallethrin((S)-cyclopentylisomer), bioresmethrin, bifenthrin, NCI-85193, cycloprothrin, cyhalothrin, cythithrin, cyphenothrin, deltamethrin, 25 empenthrin, esfenvalerate, ethofenprox, fenfluthrin, fenpropathrin, fenvalerate, flucythrinate, flumethrin, fluvalinate (D isomer), imiprothrin, cyhalothrin, lambda-cyhalothrin, permethrin, phenothrin, prallethrin, pyrethrins (natural products), resmethrin, tetramethrin, transfluthrin, theta-cypermethrin, silafluofen, t-fluvalinate, tefluthrin, tralomethrin, Zeta-cypermethrin.

Arthropod growth regulators: a) chitin synthesis inhibitors: benzoylureas: chlorfluazuron, 30 diflubenzuron, fluazuron, flucycloxuron, flufenoxuron, hexaflumuron, lufenuron, novaluron, teflubenzuron, triflumuron, buprofezin, diofenolan, hexythiazox, etoxazole, chlorfentazine; b) ecdysone antagonists: halofenozide, methoxyfenozide, tebufenozide; c) juvenoids: pyriproxyfen, methoprene (including S-methoprene), fenoxycarb; d) lipid biosynthesis inhibitors: spiroadicofen.

Other antiparasitics: acequinocyl, amitraz, AKD-1022, ANS-118, azadirachtin, Bacillus 35 thuringiensis, bensultap, bifenazate, binapacryl, bromopropylate, BTG-504, BTG-505, camphechlor, cartap, chlorobenzilate, chlordimeform, chlorfenapyr, chromafenozide, clothianidine, cyromazine, diacloden, diafenthiuron, DBI-3204, dinactin, dihydroxymethyl-dihydroxypyrrolidine, dinobuton, dinocap, endosulfan, ethiprole, ethofenprox, fenazaquin, flumite, MTI- 800, fenpyroximate, fluacrypyrim, flubenzimine, flubrocycythrinate, flufenzine, flufenprox, fluproxyfen, halofenprox, hydramethylnon, IKI- 40 220, kanemite, NC-196, neem guard, nidinorterfuran, nitenpyram, SD-35651, WL-108477, pirydaryl,

propargite, protrifenbute, pymethrozone, pyridaben, pyrimidifen, NC-1111, R-195, RH-0345, RH-2485, RYI-210, S-1283, S-1833, SI-8601, silafluofen, silomadine, spinosad, tebufenpyrad, tetradifon, tetranactin, thiocloprid, thiocyclam, thiamethoxam, tolfenpyrad, triazamate, triethoxyspinosyn, trinactin, verbutin, vertalec, YI-5301.

5 Biological agents: *Bacillus thuringiensis* ssp *aizawai*, *kurstaki*, *Bacillus thuringiensis* delta endotoxin, baculovirus, entomopathogenic bacteria, virus and fungi.

Bactericides: chlortetracycline, oxytetracycline, streptomycin.

Other biological agents: enrofloxacin, febantel, penethamate, moloxicam, cefalexin, kanamycin, pimobendan, clenbuterol, omeprazole, tiamulin, benazepril, pyriprole, cefquinome, florfenicol,
10 buserelin, cefovecin, tulathromycin, ceftiour, carprofen, metaflumizone, praziquarantel, triclabendazole.

The following mixtures of the compounds of formula (I) with active ingredients are preferred. The abbreviation "TX" means one compound selected from the group consisting of the compounds T-2.01 to T-2.08 to T-47.01 to T-47.08 shown in Tables 2 to 47 (below) and compounds A.1 to A.35 described
15 in Table A (below).

an adjuvant selected from the group of substances consisting of petroleum oils (alternative name) (628) + TX,

an acaricide selected from the group of substances consisting of 1,1-bis(4-chlorophenyl)-2-ethoxyethanol (IUPAC name) (910) + TX, 2,4-dichlorophenyl benzenesulfonate (IUPAC/Chemical
20 Abstracts name) (1059) + TX, 2-fluoro-*N*-methyl-*N*-1-naphthylacetamide (IUPAC name) (1295) + TX, 4-chlorophenyl phenyl sulfone (IUPAC name) (981) + TX, abamectin (1) + TX, acequinocyl (3) + TX, acetoprole [CCN] + TX, acrinathrin (9) + TX, aldicarb (16) + TX, aldoxycarb (863) + TX, alpha-cypermethrin (202) + TX, amidithion (870) + TX, amidoflumet [CCN] + TX, amidothioate (872) + TX,
25 amiton (875) + TX, amiton hydrogen oxalate (875) + TX, amitraz (24) + TX, aramite (881) + TX, arsenous oxide (882) + TX, AVI 382 (compound code) + TX, AZ 60541 (compound code) + TX, azinphos-ethyl (44) + TX, azinphos-methyl (45) + TX, azobenzene (IUPAC name) (888) + TX, azocyclotin (46) + TX, azothoate (889) + TX, benomyl (62) + TX, benoxafos (alternative name) [CCN] + TX, benzoximate (71) + TX, benzyl benzoate (IUPAC name) [CCN] + TX, bifenazate (74) + TX,
30 bifenthrin (76) + TX, binapacryl (907) + TX, brofenvalerate (alternative name) + TX, bromocyclen (918) + TX, bromophos (920) + TX, bromophos-ethyl (921) + TX, bromopropylate (94) + TX, buprofezin (99) + TX, butocarboxim (103) + TX, butoxycarboxim (104) + TX, butylpyridaben (alternative name) + TX, calcium polysulfide (IUPAC name) (111) + TX, camphechlor (941) + TX, carbanolate (943) + TX, carbaryl (115) + TX, carbofuran (118) + TX, carbophenothion (947) + TX, CGA 50'439 (development
35 code) (125) + TX, chinomethionat (126) + TX, chlorbenside (959) + TX, chlordimeform (964) + TX, chlordimeform hydrochloride (964) + TX, chlorfenapyr (130) + TX, chlorfenethol (968) + TX, chlorfenson (970) + TX, chlorfensulfide (971) + TX, chlorfenvinphos (131) + TX, chlorobenzilate (975) + TX, chloromebuform (977) + TX, chloromethiuron (978) + TX, chloropropylate (983) + TX, chlorpyrifos (145) + TX, chlorpyrifos-methyl (146) + TX, chlorthiophos (994) + TX, cinerin I (696) + TX, cinerin II (696) +
40 TX, cinerins (696) + TX, clofentezine (158) + TX, closantel (alternative name) [CCN] + TX, coumaphos

(174) + TX, crotamiton (alternative name) [CCN] + TX, crotoxyphos (1010) + TX, cufraneb (1013) + TX, cyanthoate (1020) + TX, cyflumetofen (CAS Reg. No.: 400882-07-7) + TX, cyhalothrin (196) + TX, cyhexatin (199) + TX, cypermethrin (201) + TX, DCPM (1032) + TX, DDT (219) + TX, demephion (1037) + TX, demephion-O (1037) + TX, demephion-S (1037) + TX, demeton (1038) + TX, demeton-methyl (224) + TX, demeton-O (1038) + TX, demeton-O-methyl (224) + TX, demeton-S (1038) + TX, demeton-S-methyl (224) + TX, demeton-S-methylsulfon (1039) + TX, diafenthuron (226) + TX, dialifos (1042) + TX, diazinon (227) + TX, dichlofluanid (230) + TX, dichlorvos (236) + TX, dicliphos (alternative name) + TX, dicofol (242) + TX, dicrotophos (243) + TX, dienochlor (1071) + TX, dimefox (1081) + TX, dimethoate (262) + TX, dinactin (alternative name) (653) + TX, dinex (1089) + TX, dinex-diclexine (1089) + TX, dinobuton (269) + TX, dinocap (270) + TX, dinocap-4 [CCN] + TX, dinocap-6 [CCN] + TX, dinocton (1090) + TX, dinopenton (1092) + TX, dinosulfon (1097) + TX, dinoterbon (1098) + TX, dioxathion (1102) + TX, diphenyl sulfone (IUPAC name) (1103) + TX, disulfiram (alternative name) [CCN] + TX, disulfoton (278) + TX, DNOC (282) + TX, dofenapyn (1113) + TX, doramectin (alternative name) [CCN] + TX, endosulfan (294) + TX, endothion (1121) + TX, EPN (297) + TX, eprinomectin (alternative name) [CCN] + TX, ethion (309) + TX, ethoate-methyl (1134) + TX, etoxazole (320) + TX, etrimfos (1142) + TX, fenazaflor (1147) + TX, fenazaquin (328) + TX, fenbutatin oxide (330) + TX, fenothiocarb (337) + TX, fenpropathrin (342) + TX, fenpyrad (alternative name) + TX, fenpyroximate (345) + TX, fenson (1157) + TX, fentrifanil (1161) + TX, fenvalerate (349) + TX, fipronil (354) + TX, fluacrypyrim (360) + TX, fluazuron (1166) + TX, flubenzimine (1167) + TX, flucycloxuron (366) + TX, flucythrinate (367) + TX, fluenetil (1169) + TX, flufenoxuron (370) + TX, flumethrin (372) + TX, fluorbenside (1174) + TX, fluvalinate (1184) + TX, FMC 1137 (development code) (1185) + TX, formetanate (405) + TX, formetanate hydrochloride (405) + TX, formothion (1192) + TX, formparanate (1193) + TX, gamma-HCH (430) + TX, glyodin (1205) + TX, halfenprox (424) + TX, heptenophos (432) + TX, hexadecyl cyclopropanecarboxylate (IUPAC/Chemical Abstracts name) (1216) + TX, hexythiazox (441) + TX, iodomethane (IUPAC name) (542) + TX, isocarbophos (alternative name) (473) + TX, isopropyl O-(methoxyaminothiophosphoryl)salicylate (IUPAC name) (473) + TX, ivermectin (alternative name) [CCN] + TX, jasmolin I (696) + TX, jasmolin II (696) + TX, jodfenphos (1248) + TX, lindane (430) + TX, lufenuron (490) + TX, malathion (492) + TX, malonoben (1254) + TX, mecarbarn (502) + TX, mephosfolan (1261) + TX, mesulfen (alternative name) [CCN] + TX, methacrifos (1266) + TX, methamidophos (527) + TX, methidathion (529) + TX, methiocarb (530) + TX, methomyl (531) + TX, methyl bromide (537) + TX, metolcarb (550) + TX, mevinphos (556) + TX, mexacarbate (1290) + TX, milbemectin (557) + TX, milbemycin oxime (alternative name) [CCN] + TX, mipafox (1293) + TX, monocrotophos (561) + TX, morphothion (1300) + TX, moxidectin (alternative name) [CCN] + TX, naled (567) + TX, NC-184 (compound code) + TX, NC-512 (compound code) + TX, nifluridide (1309) + TX, nikkomycins (alternative name) [CCN] + TX, nitrilacarb (1313) + TX, nitrilacarb 1:1 zinc chloride complex (1313) + TX, NNI-0101 (compound code) + TX, NNI-0250 (compound code) + TX, omethoate (594) + TX, oxamyl (602) + TX, oxydeprofos (1324) + TX, oxydisulfoton (1325) + TX, pp'-DDT (219) + TX, parathion (615) + TX, permethrin (626) + TX, petroleum oils (alternative name) (628) + TX, phenkapton (1330) + TX, phenthoate (631) + TX, phorate (636) + TX, phosalone (637) + TX, phosfolan (1338) + TX, phosmet (638) + TX, phosphamidon (639) + TX, phoxim (642) + TX, pirimiphos-methyl (652) + TX,

polychloroterpenes (traditional name) (1347) + TX, polynactins (alternative name) (653) + TX, proclonol (1350) + TX, profenofos (662) + TX, promacyl (1354) + TX, propargite (671) + TX, propetamphos (673) + TX, propoxur (678) + TX, prothidathion (1360) + TX, prothoate (1362) + TX, pyrethrin I (696) + TX, pyrethrin II (696) + TX, pyrethrins (696) + TX, pyridaben (699) + TX, pyridaphenthion (701) + TX, 5 pyrimidifen (706) + TX, pyrimitate (1370) + TX, quinalphos (711) + TX, quintiofos (1381) + TX, R-1492 (development code) (1382) + TX, RA-17 (development code) (1383) + TX, rotenone (722) + TX, schradan (1389) + TX, sebufos (alternative name) + TX, selamectin (alternative name) [CCN] + TX, SI-0009 (compound code) + TX, sophamide (1402) + TX, spirodiclofen (738) + TX, spiromesifen (739) + TX, SSI-121 (development code) (1404) + TX, sulfiram (alternative name) [CCN] + TX, sulfluramid (750) 10 + TX, sulfotep (753) + TX, sulfur (754) + TX, SZI-121 (development code) (757) + TX, tau-fluvalinate (398) + TX, tebufenpyrad (763) + TX, TEPP (1417) + TX, terbam (alternative name) + TX, tetrachlorvinphos (777) + TX, tetradifon (786) + TX, tetranactin (alternative name) (653) + TX, tetrasul (1425) + TX, thiafenox (alternative name) + TX, thiocarboxime (1431) + TX, thiofanox (800) + TX, thiometon (801) + TX, thioquinox (1436) + TX, thuringiensin (alternative name) [CCN] + TX, triamiphos 15 (1441) + TX, triarathene (1443) + TX, triazophos (820) + TX, triazuron (alternative name) + TX, trichlorfon (824) + TX, trifenofos (1455) + TX, trinactin (alternative name) (653) + TX, vamidothion (847) + TX, vaniliprole [CCN] and YI-5302 (compound code) + TX,

an algicide selected from the group of substances consisting of bethoxazin [CCN] + TX, copper dioctanoate (IUPAC name) (170) + TX, copper sulfate (172) + TX, cybutryne [CCN] + TX, dichlone 20 (1052) + TX, dichlorophen (232) + TX, endothal (295) + TX, fentin (347) + TX, hydrated lime [CCN] + TX, nabam (566) + TX, quinoclamine (714) + TX, quinonamid (1379) + TX, simazine (730) + TX, triphenyltin acetate (IUPAC name) (347) and triphenyltin hydroxide (IUPAC name) (347) + TX,

an anthelmintic selected from the group of substances consisting of abamectin (1) + TX, crufomate (1011) + TX, doramectin (alternative name) [CCN] + TX, emamectin (291) + TX, emamectin 25 benzoate (291) + TX, eprinomectin (alternative name) [CCN] + TX, ivermectin (alternative name) [CCN] + TX, milbemycin oxime (alternative name) [CCN] + TX, moxidectin (alternative name) [CCN] + TX, piperazine [CCN] + TX, selamectin (alternative name) [CCN] + TX, spinosad (737) and thiophanate (1435) + TX,

an avicide selected from the group of substances consisting of chloralose (127) + TX, endrin 30 (1122) + TX, fenthion (346) + TX, pyridin-4-amine (IUPAC name) (23) and strychnine (745) + TX,

a bactericide selected from the group of substances consisting of 1-hydroxy-1*H*-pyridine-2-thione (IUPAC name) (1222) + TX, 4-(quinoxalin-2-ylamino)benzenesulfonamide (IUPAC name) (748) + TX, 8-hydroxyquinoline sulfate (446) + TX, bronopol (97) + TX, copper dioctanoate (IUPAC name) (170) + TX, copper hydroxide (IUPAC name) (169) + TX, cresol [CCN] + TX, dichlorophen (232) + TX, 35 dipyrithione (1105) + TX, dodicin (1112) + TX, fenaminosulf (1144) + TX, formaldehyde (404) + TX, hydrargaphen (alternative name) [CCN] + TX, kasugamycin (483) + TX, kasugamycin hydrochloride hydrate (483) + TX, nickel bis(dimethyldithiocarbamate) (IUPAC name) (1308) + TX, nitrapyrin (580) + TX, octhilinone (590) + TX, oxolinic acid (606) + TX, oxytetracycline (611) + TX, potassium hydroxyquinoline sulfate (446) + TX, probenazole (658) + TX, streptomycin (744) + TX, streptomycin 40 sesquisulfate (744) + TX, tecloftalam (766) + TX, and thiomersal (alternative name) [CCN] + TX,

a biological agent selected from the group of substances consisting of *Adoxophyes orana* GV (alternative name) (12) + TX, *Agrobacterium radiobacter* (alternative name) (13) + TX, *Amblyseius* spp. (alternative name) (19) + TX, *Anagrapha falcifera* NPV (alternative name) (28) + TX, *Anagrus atomus* (alternative name) (29) + TX, *Aphelinus abdominalis* (alternative name) (33) + TX, *Aphidius colemani* (alternative name) (34) + TX, *Aphidoletes aphidimyza* (alternative name) (35) + TX, *Autographa californica* NPV (alternative name) (38) + TX, *Bacillus firmus* (alternative name) (48) + TX, *Bacillus sphaericus* Neide (scientific name) (49) + TX, *Bacillus thuringiensis* Berliner (scientific name) (51) + TX, *Bacillus thuringiensis* subsp. *aizawai* (scientific name) (51) + TX, *Bacillus thuringiensis* subsp. *israelensis* (scientific name) (51) + TX, *Bacillus thuringiensis* subsp. *japonensis* (scientific name) (51) + TX, *Bacillus thuringiensis* subsp. *kurstaki* (scientific name) (51) + TX, *Bacillus thuringiensis* subsp. *tenebrionis* (scientific name) (51) + TX, *Beauveria bassiana* (alternative name) (53) + TX, *Beauveria brongniartii* (alternative name) (54) + TX, *Chrysoperla carnea* (alternative name) (151) + TX, *Cryptolaemus montrouzieri* (alternative name) (178) + TX, *Cydia pomonella* GV (alternative name) (191) + TX, *Dacnusa sibirica* (alternative name) (212) + TX, *Diglyphus isaea* (alternative name) (254) + TX, *Encarsia formosa* (scientific name) (293) + TX, *Eretmocerus eremicus* (alternative name) (300) + TX, *Helicoverpa zea* NPV (alternative name) (431) + TX, *Heterorhabditis bacteriophora* and *H. megidis* (alternative name) (433) + TX, *Hippodamia convergens* (alternative name) (442) + TX, *Leptomastix dactylopii* (alternative name) (488) + TX, *Macrolophus caliginosus* (alternative name) (491) + TX, *Mamestra brassicae* NPV (alternative name) (494) + TX, *Metaphycus helvolus* (alternative name) (522) + TX, *Metarhizium anisopliae* var. *acridum* (scientific name) (523) + TX, *Metarhizium anisopliae* var. *anisopliae* (scientific name) (523) + TX, *Neodiprion sertifer* NPV and *N. lecontei* NPV (alternative name) (575) + TX, *Orius* spp. (alternative name) (596) + TX, *Paecilomyces fumosoroseus* (alternative name) (613) + TX, *Phytoseiulus persimilis* (alternative name) (644) + TX, *Spodoptera exigua* multicapsid nuclear polyhedrosis virus (scientific name) (741) + TX, *Steinernema bibionis* (alternative name) (742) + TX, *Steinernema carpocapsae* (alternative name) (742) + TX, *Steinernema feltiae* (alternative name) (742) + TX, *Steinernema glaseri* (alternative name) (742) + TX, *Steinernema riobrave* (alternative name) (742) + TX, *Steinernema riobravense* (alternative name) (742) + TX, *Steinernema scapterisci* (alternative name) (742) + TX, *Steinernema* spp. (alternative name) (742) + TX, *Trichogramma* spp. (alternative name) (826) + TX, *Typhlodromus occidentalis* (alternative name) (844) and *Verticillium lecanii* (alternative name) (848) + TX, *bacillus subtilis* var. *amyloliquefaciens* Strain FZB24 (available from Novozymes Biologicals Inc., 5400 Corporate Circle, Salem, VA 24153, U.S.A. and known under the trade name Taegro®) + TX,

a soil sterilant selected from the group of substances consisting of iodomethane (IUPAC name) (542) and methyl bromide (537) + TX,

a chemosterilant selected from the group of substances consisting of apholate [CCN] + TX, bisazir (alternative name) [CCN] + TX, busulfan (alternative name) [CCN] + TX, diflubenzuron (250) + TX, dimatif (alternative name) [CCN] + TX, hemel [CCN] + TX, hempa [CCN] + TX, metepa [CCN] + TX, methiotepa [CCN] + TX, methyl apholate [CCN] + TX, morzid [CCN] + TX, penfluron (alternative name) [CCN] + TX, tepa [CCN] + TX, thiohempa (alternative name) [CCN] + TX, thiotepa (alternative name) [CCN] + TX, tretamine (alternative name) [CCN] and uredepa (alternative name) [CCN] + TX,

an insect pheromone selected from the group of substances consisting of (*E*)-dec-5-en-1-yl acetate with (*E*)-dec-5-en-1-ol (IUPAC name) (222) + TX, (*E*)-tridec-4-en-1-yl acetate (IUPAC name) (829) + TX, (*E*)-6-methylhept-2-en-4-ol (IUPAC name) (541) + TX, (*E,Z*)-tetradeca-4,10-dien-1-yl acetate (IUPAC name) (779) + TX, (*Z*)-dodec-7-en-1-yl acetate (IUPAC name) (285) + TX, (*Z*)-hexadec-11-enal (IUPAC name) (436) + TX, (*Z*)-hexadec-11-en-1-yl acetate (IUPAC name) (437) + TX, (*Z*)-hexadec-13-en-11-yn-1-yl acetate (IUPAC name) (438) + TX, (*Z*)-icos-13-en-10-one (IUPAC name) (448) + TX, (*Z*)-tetradec-7-en-1-al (IUPAC name) (782) + TX, (*Z*)-tetradec-9-en-1-ol (IUPAC name) (783) + TX, (*Z*)-tetradec-9-en-1-yl acetate (IUPAC name) (784) + TX, (*7E,9Z*)-dodeca-7,9-dien-1-yl acetate (IUPAC name) (283) + TX, (*9Z,11E*)-tetradeca-9,11-dien-1-yl acetate (IUPAC name) (780) + TX, (*9Z,12E*)-tetradeca-9,12-dien-1-yl acetate (IUPAC name) (781) + TX, 14-methyloctadec-1-ene (IUPAC name) (545) + TX, 4-methylnonan-5-ol with 4-methylnonan-5-one (IUPAC name) (544) + TX, alpha-multistriatin (alternative name) [CCN] + TX, brevicomin (alternative name) [CCN] + TX, codlure (alternative name) [CCN] + TX, codlemone (alternative name) (167) + TX, cuelure (alternative name) (179) + TX, disparlure (277) + TX, dodec-8-en-1-yl acetate (IUPAC name) (286) + TX, dodec-9-en-1-yl acetate (IUPAC name) (287) + TX, dodeca-8 + TX, 10-dien-1-yl acetate (IUPAC name) (284) + TX, dominicalure (alternative name) [CCN] + TX, ethyl 4-methyloctanoate (IUPAC name) (317) + TX, eugenol (alternative name) [CCN] + TX, frontaline (alternative name) [CCN] + TX, gossyplure (alternative name) (420) + TX, grandlure (421) + TX, grandlure I (alternative name) (421) + TX, grandlure II (alternative name) (421) + TX, grandlure III (alternative name) (421) + TX, grandlure IV (alternative name) (421) + TX, hexalure [CCN] + TX, ipsdienol (alternative name) [CCN] + TX, ipsenol (alternative name) [CCN] + TX, japonilure (alternative name) (481) + TX, lineatin (alternative name) [CCN] + TX, litlure (alternative name) [CCN] + TX, looplure (alternative name) [CCN] + TX, medlure [CCN] + TX, megatomoic acid (alternative name) [CCN] + TX, methyl eugenol (alternative name) (540) + TX, muscalure (563) + TX, octadeca-2,13-dien-1-yl acetate (IUPAC name) (588) + TX, octadeca-3,13-dien-1-yl acetate (IUPAC name) (589) + TX, orfralure (alternative name) [CCN] + TX, oryctalure (alternative name) (317) + TX, ostramone (alternative name) [CCN] + TX, siglure [CCN] + TX, sordidin (alternative name) (736) + TX, sulcatol (alternative name) [CCN] + TX, tetradec-11-en-1-yl acetate (IUPAC name) (785) + TX, trimedlure (839) + TX, trimedlure A (alternative name) (839) + TX, trimedlure B₁ (alternative name) (839) + TX, trimedlure B₂ (alternative name) (839) + TX, trimedlure C (alternative name) (839) and trunc-call (alternative name) [CCN] + TX,

an insect repellent selected from the group of substances consisting of 2-(octylthio)ethanol (IUPAC name) (591) + TX, butopyronoxyl (933) + TX, butoxy(polypropylene glycol) (936) + TX, dibutyl adipate (IUPAC name) (1046) + TX, dibutyl phthalate (1047) + TX, dibutyl succinate (IUPAC name) (1048) + TX, diethyltoluamide [CCN] + TX, dimethyl carbate [CCN] + TX, dimethyl phthalate [CCN] + TX, ethyl hexanediol (1137) + TX, hexamide [CCN] + TX, methoquin-butyl (1276) + TX, methylneodecanamide [CCN] + TX, oxamate [CCN] and picaridin [CCN] + TX,

an insecticide selected from the group of substances consisting of 1-dichloro-1-nitroethane (IUPAC/Chemical Abstracts name) (1058) + TX, 1,1-dichloro-2,2-bis(4-ethylphenyl)ethane (IUPAC name) (1056), + TX, 1,2-dichloropropane (IUPAC/Chemical Abstracts name) (1062) + TX, 1,2-dichloropropane with 1,3-dichloropropene (IUPAC name) (1063) + TX, 1-bromo-2-chloroethane

(IUPAC/Chemical Abstracts name) (916) + TX, 2,2,2-trichloro-1-(3,4-dichlorophenyl)ethyl acetate (IUPAC name) (1451) + TX, 2,2-dichlorovinyl 2-ethylsulfinyethyl methyl phosphate (IUPAC name) (1066) + TX, 2-(1,3-dithiolan-2-yl)phenyl dimethylcarbamate (IUPAC/ Chemical Abstracts name) (1109) + TX, 2-(2-butoxyethoxy)ethyl thiocyanate (IUPAC/Chemical Abstracts name) (935) + TX, 2-(4,5-dimethyl-1,3-dioxolan-2-yl)phenyl methylcarbamate (IUPAC/ Chemical Abstracts name) (1084) + TX, 2-(4-chloro-3,5-xylyloxy)ethanol (IUPAC name) (986) + TX, 2-chlorovinyl diethyl phosphate (IUPAC name) (984) + TX, 2-imidazolidone (IUPAC name) (1225) + TX, 2-isovalerylindan-1,3-dione (IUPAC name) (1246) + TX, 2-methyl(prop-2-ynyl)aminophenyl methylcarbamate (IUPAC name) (1284) + TX, 2-thiocyanatoethyl laurate (IUPAC name) (1433) + TX, 3-bromo-1-chloroprop-1-ene (IUPAC name) (917) + TX, 3-methyl-1-phenylpyrazol-5-yl dimethylcarbamate (IUPAC name) (1283) + TX, 4-methyl(prop-2-ynyl)amino-3,5-xylyl methylcarbamate (IUPAC name) (1285) + TX, 5,5-dimethyl-3-oxocyclohex-1-enyl dimethylcarbamate (IUPAC name) (1085) + TX, abamectin (1) + TX, acephate (2) + TX, acetamiprid (4) + TX, acethion (alternative name) [CCN] + TX, acetoprole [CCN] + TX, acrinathrin (9) + TX, acrylonitrile (IUPAC name) (861) + TX, alanycarb (15) + TX, aldicarb (16) + TX, aldoxycarb (863) + TX, aldrin (864) + TX, allethrin (17) + TX, allosamidin (alternative name) [CCN] + TX, allyxycarb (866) + TX, alpha-cypermethrin (202) + TX, alpha-ecdysone (alternative name) [CCN] + TX, aluminium phosphide (640) + TX, amidithion (870) + TX, amidothioate (872) + TX, aminocarb (873) + TX, amiton (875) + TX, amiton hydrogen oxalate (875) + TX, amitraz (24) + TX, anabasine (877) + TX, athidathion (883) + TX, AVI 382 (compound code) + TX, AZ 60541 (compound code) + TX, azadirachtin (alternative name) (41) + TX, azamethiphos (42) + TX, azinphos-ethyl (44) + TX, azinphos-methyl (45) + TX, azothoate (889) + TX, *Bacillus thuringiensis* delta endotoxins (alternative name) (52) + TX, barium hexafluorosilicate (alternative name) [CCN] + TX, barium polysulfide (IUPAC/Chemical Abstracts name) (892) + TX, barthrin [CCN] + TX, Bayer 22/190 (development code) (893) + TX, Bayer 22408 (development code) (894) + TX, bendiocarb (58) + TX, benfuracarb (60) + TX, bensultap (66) + TX, beta-cyfluthrin (194) + TX, beta-cypermethrin (203) + TX, bifenthrin (76) + TX, bioallethrin (78) + TX, bioallethrin S-cyclopentenyl isomer (alternative name) (79) + TX, bioethanomethrin [CCN] + TX, biopermethrin (908) + TX, bioresmethrin (80) + TX, bis(2-chloroethyl) ether (IUPAC name) (909) + TX, bistrifluron (83) + TX, borax (86) + TX, brofenvalerate (alternative name) + TX, bromfenvinfos (914) + TX, bromocyclen (918) + TX, bromo-DDT (alternative name) [CCN] + TX, bromophos (920) + TX, bromophos-ethyl (921) + TX, bufencarb (924) + TX, buprofezin (99) + TX, butacarb (926) + TX, butathiofos (927) + TX, butocarboxim (103) + TX, butonate (932) + TX, butoxycarboxim (104) + TX, butylpyridaben (alternative name) + TX, cadusafos (109) + TX, calcium arsenate [CCN] + TX, calcium cyanide (444) + TX, calcium polysulfide (IUPAC name) (111) + TX, camphechlor (941) + TX, carbanolate (943) + TX, carbaryl (115) + TX, carbofuran (118) + TX, carbon disulfide (IUPAC/Chemical Abstracts name) (945) + TX, carbon tetrachloride (IUPAC name) (946) + TX, carbophenothion (947) + TX, carbosulfan (119) + TX, cartap (123) + TX, cartap hydrochloride (123) + TX, cevadine (alternative name) (725) + TX, chlorbicyclen (960) + TX, chlordane (128) + TX, chlordecone (963) + TX, chlordimeform (964) + TX, chlordimeform hydrochloride (964) + TX, chlorethoxyfos (129) + TX, chlorfenapyr (130) + TX, chlorfenvinphos (131) + TX, chlorfluazuron (132) + TX, chlormephos (136) + TX, chloroform [CCN] + TX, chloropicrin (141) + TX, chlorphoxim (989) + TX, chlorprazophos (990) +

TX, chlorpyrifos (145) + TX, chlorpyrifos-methyl (146) + TX, chlorthiophos (994) + TX, chromafenozide (150) + TX, cinerin I (696) + TX, cinerin II (696) + TX, cinerins (696) + TX, cis-resmethrin (alternative name) + TX, cismethrin (80) + TX, clocythrin (alternative name) + TX, cloethocarb (999) + TX, closantel (alternative name) [CCN] + TX, clothianidin (165) + TX, copper acetoarsenite [CCN] + TX, copper arsenate [CCN] + TX, copper oleate [CCN] + TX, coumaphos (174) + TX, coumithoate (1006) + TX, crotamiton (alternative name) [CCN] + TX, crotoxyphos (1010) + TX, crufomate (1011) + TX, cryolite (alternative name) (177) + TX, CS 708 (development code) (1012) + TX, cyanofenphos (1019) + TX, cyanophos (184) + TX, cyanthoate (1020) + TX, cyclethrin [CCN] + TX, cycloprothrin (188) + TX, cyfluthrin (193) + TX, cyhalothrin (196) + TX, cypermethrin (201) + TX, cyphenothrin (206) + TX, cyromazine (209) + TX, cythioate (alternative name) [CCN] + TX, *d*-limonene (alternative name) [CCN] + TX, *d*-tetramethrin (alternative name) (788) + TX, DAEP (1031) + TX, dazomet (216) + TX, DDT (219) + TX, decarbofuran (1034) + TX, deltamethrin (223) + TX, demephion (1037) + TX, demephion-O (1037) + TX, demephion-S (1037) + TX, demeton (1038) + TX, demeton-methyl (224) + TX, demeton-O (1038) + TX, demeton-O-methyl (224) + TX, demeton-S (1038) + TX, demeton-S-methyl (224) + TX, demeton-S-methylsulphon (1039) + TX, diafenthuron (226) + TX, dialifos (1042) + TX, diamidafos (1044) + TX, diazinon (227) + TX, dicapthon (1050) + TX, dichlofenthion (1051) + TX, dichlorvos (236) + TX, dicliphos (alternative name) + TX, dicresyl (alternative name) [CCN] + TX, dicrotophos (243) + TX, dicyclanil (244) + TX, dieldrin (1070) + TX, diethyl 5-methylpyrazol-3-yl phosphate (IUPAC name) (1076) + TX, diflubenzuron (250) + TX, dilor (alternative name) [CCN] + TX, dimefluthrin [CCN] + TX, dimefox (1081) + TX, dimetan (1085) + TX, dimethoate (262) + TX, dimethrin (1083) + TX, dimethylvinphos (265) + TX, dimetilan (1086) + TX, dinex (1089) + TX, dinex-diclexine (1089) + TX, dinoprop (1093) + TX, dinosam (1094) + TX, dinoseb (1095) + TX, dinotefuran (271) + TX, diofenolan (1099) + TX, dioxabenzofos (1100) + TX, dioxacarb (1101) + TX, dioxathion (1102) + TX, disulfoton (278) + TX, dithicrofos (1108) + TX, DNOC (282) + TX, doramectin (alternative name) [CCN] + TX, DSP (1115) + TX, ecdysterone (alternative name) [CCN] + TX, EI 1642 (development code) (1118) + TX, emamectin (291) + TX, emamectin benzoate (291) + TX, EMPC (1120) + TX, empenthrin (292) + TX, endosulfan (294) + TX, endothion (1121) + TX, endrin (1122) + TX, EPBP (1123) + TX, EPN (297) + TX, epofenonane (1124) + TX, eprinomectin (alternative name) [CCN] + TX, esfenvalerate (302) + TX, etaphos (alternative name) [CCN] + TX, ethiofencarb (308) + TX, ethion (309) + TX, ethiprole (310) + TX, ethoate-methyl (1134) + TX, ethoprophos (312) + TX, ethyl formate (IUPAC name) [CCN] + TX, ethyl-DDD (alternative name) (1056) + TX, ethylene dibromide (316) + TX, ethylene dichloride (chemical name) (1136) + TX, ethylene oxide [CCN] + TX, etofenprox (319) + TX, etrimfos (1142) + TX, EXD (1143) + TX, famphur (323) + TX, fenamiphos (326) + TX, fenazaflor (1147) + TX, fenchlorphos (1148) + TX, fenethacarb (1149) + TX, fenfluthrin (1150) + TX, fenitrothion (335) + TX, fenobucarb (336) + TX, fenoxacrim (1153) + TX, fenoxycarb (340) + TX, fenpirithrin (1155) + TX, fenpropathrin (342) + TX, fenpyrad (alternative name) + TX, fensulfothion (1158) + TX, fenthion (346) + TX, fenthion-ethyl [CCN] + TX, fenvalerate (349) + TX, fipronil (354) + TX, flonicamid (358) + TX, flubendiamide (CAS. Reg. No.: 272451-65-7) + TX, flucofuron (1168) + TX, flucycloxuron (366) + TX, flucythrinate (367) + TX, fluenetil (1169) + TX, flufenerim [CCN] + TX, flufenoxuron (370) + TX, flufenprox (1171) + TX, flumethrin (372) + TX, fluvalinate (1184) + TX, FMC 1137 (development code) (1185) + TX, fonofos (1191) + TX, formetanate

(405) + TX, formetanate hydrochloride (405) + TX, formothion (1192) + TX, formparanate (1193) + TX, fosmethilan (1194) + TX, fospirate (1195) + TX, fosthiazate (408) + TX, fosthietan (1196) + TX, furathiocarb (412) + TX, furethrin (1200) + TX, gamma-cyhalothrin (197) + TX, gamma-HCH (430) + TX, guazatine (422) + TX, guazatine acetates (422) + TX, GY-81 (development code) (423) + TX, halfenprox (424) + TX, halofenozide (425) + TX, HCH (430) + TX, HEOD (1070) + TX, heptachlor (1211) + TX, heptenophos (432) + TX, heterophos [CCN] + TX, hexaflumuron (439) + TX, HHDN (864) + TX, hydramethylnon (443) + TX, hydrogen cyanide (444) + TX, hydroprene (445) + TX, hyquincarb (1223) + TX, imidacloprid (458) + TX, imiprothrin (460) + TX, indoxacarb (465) + TX, iodomethane (IUPAC name) (542) + TX, IPSP (1229) + TX, isazofos (1231) + TX, isobenzan (1232) + TX, isocarbophos (alternative name) (473) + TX, isodrin (1235) + TX, isofenphos (1236) + TX, isolane (1237) + TX, isoprocarb (472) + TX, isopropyl O-(methoxyaminothiophosphoryl)salicylate (IUPAC name) (473) + TX, isoprothiolane (474) + TX, isothioate (1244) + TX, isoxathion (480) + TX, ivermectin (alternative name) [CCN] + TX, jasmolin I (696) + TX, jasmolin II (696) + TX, jodfenphos (1248) + TX, juvenile hormone I (alternative name) [CCN] + TX, juvenile hormone II (alternative name) [CCN] + TX, juvenile hormone III (alternative name) [CCN] + TX, kelevan (1249) + TX, kinoprene (484) + TX, lambda-cyhalothrin (198) + TX, lead arsenate [CCN] + TX, lepimectin (CCN) + TX, leptophos (1250) + TX, lindane (430) + TX, lirimfos (1251) + TX, lufenuron (490) + TX, lythidathion (1253) + TX, *m*-cumenyl methylcarbamate (IUPAC name) (1014) + TX, magnesium phosphide (IUPAC name) (640) + TX, malathion (492) + TX, malonoben (1254) + TX, mazidox (1255) + TX, mecarbam (502) + TX, mecarphon (1258) + TX, menazon (1260) + TX, mephosfolan (1261) + TX, mercurous chloride (513) + TX, mesulfenfos (1263) + TX, metaflumizone (CCN) + TX, metam (519) + TX, metam-potassium (alternative name) (519) + TX, metam-sodium (519) + TX, methacrifos (1266) + TX, methamidophos (527) + TX, methanesulfonyl fluoride (IUPAC/Chemical Abstracts name) (1268) + TX, methidathion (529) + TX, methiocarb (530) + TX, methocrotophos (1273) + TX, methomyl (531) + TX, methoprene (532) + TX, methoquin-butyl (1276) + TX, methothrin (alternative name) (533) + TX, methoxychlor (534) + TX, methoxyfenozide (535) + TX, methyl bromide (537) + TX, methyl isothiocyanate (543) + TX, methylchloroform (alternative name) [CCN] + TX, methylene chloride [CCN] + TX, metofluthrin [CCN] + TX, metolcarb (550) + TX, metoxadiazone (1288) + TX, mevinphos (556) + TX, mexacarbate (1290) + TX, milbemectin (557) + TX, milbemycin oxime (alternative name) [CCN] + TX, mipafox (1293) + TX, mirex (1294) + TX, monocrotophos (561) + TX, morphothion (1300) + TX, moxidectin (alternative name) [CCN] + TX, naftalofos (alternative name) [CCN] + TX, naled (567) + TX, naphthalene (IUPAC/Chemical Abstracts name) (1303) + TX, NC-170 (development code) (1306) + TX, NC-184 (compound code) + TX, nicotine (578) + TX, nicotine sulfate (578) + TX, nifluridide (1309) + TX, nitenpyram (579) + TX, nithiazine (1311) + TX, nitrilacarb (1313) + TX, nitrilacarb 1:1 zinc chloride complex (1313) + TX, NNI-0101 (compound code) + TX, NNI-0250 (compound code) + TX, norricotine (traditional name) (1319) + TX, novaluron (585) + TX, noviflumuron (586) + TX, O-5-dichloro-4-iodophenyl O-ethyl ethylphosphonothioate (IUPAC name) (1057) + TX, O,O-diethyl O-4-methyl-2-oxo-2H-chromen-7-yl phosphorothioate (IUPAC name) (1074) + TX, O,O-diethyl O-6-methyl-2-propylpyrimidin-4-yl phosphorothioate (IUPAC name) (1075) + TX, O,O,O',O'-tetrapropyl dithiopyrophosphate (IUPAC name) (1424) + TX, oleic acid (IUPAC name) (593) + TX, omethoate (594) + TX, oxamyl (602) + TX, oxydemeton-methyl (609) + TX, oxydeprofos

(1324) + TX, oxydisulfoton (1325) + TX, pp'-DDT (219) + TX, para-dichlorobenzene [CCN] + TX, parathion (615) + TX, parathion-methyl (616) + TX, penfluron (alternative name) [CCN] + TX, pentachlorophenol (623) + TX, pentachlorophenyl laurate (IUPAC name) (623) + TX, permethrin (626) + TX, petroleum oils (alternative name) (628) + TX, PH 60-38 (development code) (1328) + TX, phenkapton (1330) + TX, phenothrin (630) + TX, phenthoate (631) + TX, phorate (636) + TX, phosalone (637) + TX, phosfolan (1338) + TX, phosmet (638) + TX, phosnichlor (1339) + TX, phosphamidon (639) + TX, phosphine (IUPAC name) (640) + TX, phoxim (642) + TX, phoxim-methyl (1340) + TX, pirimetaphos (1344) + TX, pirimicarb (651) + TX, pirimiphos-ethyl (1345) + TX, pirimiphos-methyl (652) + TX, polychlorodicyclopentadiene isomers (IUPAC name) (1346) + TX, polychloroterpenes (traditional name) (1347) + TX, potassium arsenite [CCN] + TX, potassium thiocyanate [CCN] + TX, prallethrin (655) + TX, precocene I (alternative name) [CCN] + TX, precocene II (alternative name) [CCN] + TX, precocene III (alternative name) [CCN] + TX, primidophos (1349) + TX, profenofos (662) + TX, profluthrin [CCN] + TX, promacyl (1354) + TX, promecarb (1355) + TX, propaphos (1356) + TX, propetamphos (673) + TX, propoxur (678) + TX, prothidathion (1360) + TX, prothiofos (686) + TX, prothoate (1362) + TX, protrifenbute [CCN] + TX, pymetrozine (688) + TX, pyraclofos (689) + TX, pyrazophos (693) + TX, pyresmethrin (1367) + TX, pyrethrin I (696) + TX, pyrethrin II (696) + TX, pyrethrins (696) + TX, pyridaben (699) + TX, pyridalyl (700) + TX, pyridaphenthion (701) + TX, pyrimidifen (706) + TX, pyrimitate (1370) + TX, pyriproxyfen (708) + TX, quassia (alternative name) [CCN] + TX, quinalphos (711) + TX, quinalphos-methyl (1376) + TX, quinotion (1380) + TX, quintiofos (1381) + TX, R-1492 (development code) (1382) + TX, rafoxanide (alternative name) [CCN] + TX, resmethrin (719) + TX, rotenone (722) + TX, RU 15525 (development code) (723) + TX, RU 25475 (development code) (1386) + TX, ryania (alternative name) (1387) + TX, ryanodine (traditional name) (1387) + TX, sabadilla (alternative name) (725) + TX, schradan (1389) + TX, sebufos (alternative name) + TX, selamectin (alternative name) [CCN] + TX, SI-0009 (compound code) + TX, SI-0205 (compound code) + TX, SI-0404 (compound code) + TX, SI-0405 (compound code) + TX, silafluofen (728) + TX, SN 72129 (development code) (1397) + TX, sodium arsenite [CCN] + TX, sodium cyanide (444) + TX, sodium fluoride (IUPAC/Chemical Abstracts name) (1399) + TX, sodium hexafluorosilicate (1400) + TX, sodium pentachlorophenoxide (623) + TX, sodium selenate (IUPAC name) (1401) + TX, sodium thiocyanate [CCN] + TX, sophamide (1402) + TX, spinosad (737) + TX, spiromesifen (739) + TX, spirotetmat (CCN) + TX, sulcofuron (746) + TX, sulcofuron-sodium (746) + TX, sulfuramid (750) + TX, sulfotep (753) + TX, sulfuryl fluoride (756) + TX, sulprofos (1408) + TX, tar oils (alternative name) (758) + TX, tau-fluvalinate (398) + TX, tazimcarb (1412) + TX, TDE (1414) + TX, tebufenozide (762) + TX, tebufenpyrad (763) + TX, tebupirimfos (764) + TX, teflubenzuron (768) + TX, tefluthrin (769) + TX, temephos (770) + TX, TEPP (1417) + TX, terallethrin (1418) + TX, terbam (alternative name) + TX, terbufos (773) + TX, tetrachloroethane [CCN] + TX, tetrachlorvinphos (777) + TX, tetramethrin (787) + TX, theta-cypermethrin (204) + TX, thiacloprid (791) + TX, thiafenox (alternative name) + TX, thiamethoxam (792) + TX, thicrofos (1428) + TX, thiocarboxime (1431) + TX, thiocyclam (798) + TX, thiocyclam hydrogen oxalate (798) + TX, thiodicarb (799) + TX, thiofanox (800) + TX, thiometon (801) + TX, thionazin (1434) + TX, thiosultap (803) + TX, thiosultap-sodium (803) + TX, thuringiensin (alternative name) [CCN] + TX, tolfenpyrad (809) + TX, tralomethrin (812) + TX, transluthrin (813) +

TX, transpermethrin (1440) + TX, triamiphos (1441) + TX, triazamate (818) + TX, triazophos (820) + TX, triazuron (alternative name) + TX, trichlorfon (824) + TX, trichlormetaphos-3 (alternative name) [CCN] + TX, trichloronat (1452) + TX, trifenofos (1455) + TX, triflumuron (835) + TX, trimethacarb (840) + TX, triprene (1459) + TX, vamidothion (847) + TX, vaniliprole [CCN] + TX, veratridine (alternative name) (725) + TX, veratrine (alternative name) (725) + TX, XMC (853) + TX, xylylcarb (854) + TX, YI-5302 (compound code) + TX, zeta-cypermethrin (205) + TX, zetamethrin (alternative name) + TX, zinc phosphide (640) + TX, zolaprofos (1469) and ZXI 8901 (development code) (858) + TX, cyantraniliprole [736994-63-19 + TX, chlorantraniliprole [500008-45-7] + TX, cyenopyrafen [560121-52-0] + TX, cyflumetofen [400882-07-7] + TX, pyrifluquinazon [337458-27-2] + TX, spinetoram [187166-40-1 + 187166-15-0] + TX, spirotetramat [203313-25-1] + TX, sulfoxaflor [946578-00-3] + TX, flupiprole [704886-18-0] + TX, meperfluthrin [915288-13-0] + TX, tetramethylfluthrin [84937-88-2] + TX, triflumezopyrim (disclosed in WO 2012/092115) + TX,

a molluscicide selected from the group of substances consisting of bis(tributyltin) oxide (IUPAC name) (913) + TX, bromoacetamide [CCN] + TX, calcium arsenate [CCN] + TX, cloethocarb (999) + TX, copper acetoarsenite [CCN] + TX, copper sulfate (172) + TX, fentin (347) + TX, ferric phosphate (IUPAC name) (352) + TX, metaldehyde (518) + TX, methiocarb (530) + TX, niclosamide (576) + TX, niclosamide-olamine (576) + TX, pentachlorophenol (623) + TX, sodium pentachlorophenoxide (623) + TX, tazimcarb (1412) + TX, thiodicarb (799) + TX, tributyltin oxide (913) + TX, trifenmorph (1454) + TX, trimethacarb (840) + TX, triphenyltin acetate (IUPAC name) (347) and triphenyltin hydroxide (IUPAC name) (347) + TX, pyriprole [394730-71-3] + TX,

a nematicide selected from the group of substances consisting of AKD-3088 (compound code) + TX, 1,2-dibromo-3-chloropropane (IUPAC/Chemical Abstracts name) (1045) + TX, 1,2-dichloropropane (IUPAC/ Chemical Abstracts name) (1062) + TX, 1,2-dichloropropane with 1,3-dichloropropene (IUPAC name) (1063) + TX, 1,3-dichloropropene (233) + TX, 3,4-dichlorotetrahydrothiophene 1,1-dioxide (IUPAC/Chemical Abstracts name) (1065) + TX, 3-(4-chlorophenyl)-5-methylrhodanine (IUPAC name) (980) + TX, 5-methyl-6-thioxo-1,3,5-thiadiazinan-3-ylacetic acid (IUPAC name) (1286) + TX, 6-isopentenylaminopurine (alternative name) (210) + TX, abamectin (1) + TX, acetoprole [CCN] + TX, alanycarb (15) + TX, aldicarb (16) + TX, aldoxycarb (863) + TX, AZ 60541 (compound code) + TX, benclotiaz [CCN] + TX, benomyl (62) + TX, butylpyridaben (alternative name) + TX, cadusafos (109) + TX, carbofuran (118) + TX, carbon disulfide (945) + TX, carbosulfan (119) + TX, chloropicrin (141) + TX, chlorpyrifos (145) + TX, cloethocarb (999) + TX, cytokinins (alternative name) (210) + TX, dazomet (216) + TX, DBCP (1045) + TX, DCIP (218) + TX, diamidafos (1044) + TX, dichlofenthion (1051) + TX, dicliphos (alternative name) + TX, dimethoate (262) + TX, doramectin (alternative name) [CCN] + TX, emamectin (291) + TX, emamectin benzoate (291) + TX, eprinomectin (alternative name) [CCN] + TX, ethoprophos (312) + TX, ethylene dibromide (316) + TX, fenamiphos (326) + TX, fenpyrad (alternative name) + TX, fensulfthion (1158) + TX, fosthiazate (408) + TX, fosthietan (1196) + TX, furfural (alternative name) [CCN] + TX, GY-81 (development code) (423) + TX, heterophos [CCN] + TX, iodomethane (IUPAC name) (542) + TX, isamidofos (1230) + TX, isazofos (1231) + TX, ivermectin (alternative name) [CCN] + TX, kinetin (alternative name) (210) + TX, mecarphon (1258) + TX, metam (519) + TX, metam-potassium

(alternative name) (519) + TX, metam-sodium (519) + TX, methyl bromide (537) + TX, methyl isothiocyanate (543) + TX, milbemycin oxime (alternative name) [CCN] + TX, moxidectin (alternative name) [CCN] + TX, *Myrothecium verrucaria* composition (alternative name) (565) + TX, NC-184 (compound code) + TX, oxamyl (602) + TX, phorate (636) + TX, phosphamidon (639) + TX, phosphocarb [CCN] + TX, sebufos (alternative name) + TX, selamectin (alternative name) [CCN] + TX, spinosad (737) + TX, terbam (alternative name) + TX, terbufos (773) + TX, tetrachlorothiophene (IUPAC/ Chemical Abstracts name) (1422) + TX, thiafenox (alternative name) + TX, thionazin (1434) + TX, triazophos (820) + TX, triazuron (alternative name) + TX, xylenols [CCN] + TX, YI-5302 (compound code) and zeatin (alternative name) (210) + TX, fluensulfone [318290-98-1] + TX,

5 a nitrification inhibitor selected from the group of substances consisting of potassium ethylxanthate [CCN] and nitrapyrin (580) + TX,

a plant activator selected from the group of substances consisting of acibenzolar (6) + TX, acibenzolar-S-methyl (6) + TX, probenazole (658) and *Reynoutria sachalinensis* extract (alternative name) (720) + TX,

15 a rodenticide selected from the group of substances consisting of 2-isovalerylindan-1,3-dione (IUPAC name) (1246) + TX, 4-(quinoxalin-2-ylamino)benzenesulfonamide (IUPAC name) (748) + TX, alpha-chlorohydrin [CCN] + TX, aluminium phosphide (640) + TX, antu (880) + TX, arsenous oxide (882) + TX, barium carbonate (891) + TX, bisthiosemi (912) + TX, brodifacoum (89) + TX, bromadiolone (91) + TX, bromethalin (92) + TX, calcium cyanide (444) + TX, chloralose (127) + TX, chlorophacinone (140) + TX, cholecalciferol (alternative name) (850) + TX, coumachlor (1004) + TX, coumafuryl (1005) + TX, coumatetralyl (175) + TX, crimidine (1009) + TX, difenacoum (246) + TX, difethialone (249) + TX, diphacinone (273) + TX, ergocalciferol (301) + TX, flocoumafen (357) + TX, fluoroacetamide (379) + TX, flupropradine (1183) + TX, flupropradine hydrochloride (1183) + TX, gamma-HCH (430) + TX, HCH (430) + TX, hydrogen cyanide (444) + TX, iodomethane (IUPAC name) (542) + TX, lindane (430) + TX, magnesium phosphide (IUPAC name) (640) + TX, methyl bromide (537) + TX, norbormide (1318) + TX, phosacetim (1336) + TX, phosphine (IUPAC name) (640) + TX, phosphorus [CCN] + TX, pindone (1341) + TX, potassium arsenite [CCN] + TX, pyrinuron (1371) + TX, scilliroside (1390) + TX, sodium arsenite [CCN] + TX, sodium cyanide (444) + TX, sodium fluoroacetate (735) + TX, strychnine (745) + TX, thallium sulfate [CCN] + TX, warfarin (851) and zinc phosphide (640) + TX,

20 a synergist selected from the group of substances consisting of 2-(2-butoxyethoxy)ethyl piperonylate (IUPAC name) (934) + TX, 5-(1,3-benzodioxol-5-yl)-3-hexylcyclohex-2-enone (IUPAC name) (903) + TX, farnesol with nerolidol (alternative name) (324) + TX, MB-599 (development code) (498) + TX, MGK 264 (development code) (296) + TX, piperonyl butoxide (649) + TX, piprotal (1343) + TX, propyl isomer (1358) + TX, S421 (development code) (724) + TX, sesamex (1393) + TX, sesasmolin (1394) and sulfoxide (1406) + TX,

25 an animal repellent selected from the group of substances consisting of anthraquinone (32) + TX, chloralose (127) + TX, copper naphthenate [CCN] + TX, copper oxychloride (171) + TX, diazinon (227) + TX, dicyclopentadiene (chemical name) (1069) + TX, guazatine (422) + TX, guazatine acetates (422) + TX, methiocarb (530) + TX, pyridin-4-amine (IUPAC name) (23) + TX, thiram (804) + TX, trimethacarb (840) + TX, zinc naphthenate [CCN] and ziram (856) + TX,

40

a virucide selected from the group of substances consisting of imanin (alternative name) [CCN] and ribavirin (alternative name) [CCN] + TX,


a wound protectant selected from the group of substances consisting of mercuric oxide (512) + TX, octhillinone (590) and thiophanate-methyl (802) + TX,

5 and biologically active compounds selected from the group consisting of ametocetradin [865318-97-4] + TX, amisulbrom [348635-87-0] + TX, azaconazole [60207-31-0] + TX, benzovindiflupyr [1072957-71-1] + TX, bitertanol [70585-36-3] + TX, bixafen [581809-46-3] + TX, bromuconazole [116255-48-2] + TX, coumoxystrobin [850881-70-8] + TX, cyproconazole [94361-06-5] + TX, difenoconazole [119446-68-3] + TX, diniconazole [83657-24-3] + TX, enoxastrobin [238410-11-2] + TX,
10 epoxiconazole [106325-08-0] + TX, fenbuconazole [114369-43-6] + TX, fenpyrazamine [473798-59-3] + TX, fluquinconazole [136426-54-5] + TX, flusilazole [85509-19-9] + TX, flutriafol [76674-21-0] + TX, fluxapyroxad [907204-31-3] + TX, fluopyram [658066-35-4] + TX, fenaminstrobin [366815-39-6] + TX, isofetamid [875915-78-9] + TX, hexaconazole [79983-71-4] + TX, imazalil [35554-44-0] + TX, imibenconazole [86598-92-7] + TX, ipconazole [125225-28-7] + TX, ipfentrifluconazole [1417782-08-1] + TX,
15 isotianil [224049-04-1] + TX, mandestrobin [173662-97-0] (can be prepared according to the procedures described in WO 2010/093059) + TX, mefentrifluconazole [1417782-03-6] + TX, metconazole [125116-23-6] + TX, myclobutanil [88671-89-0] + TX, paclobutrazol [76738-62-0] + TX, pefurazoate [101903-30-4] + TX, penflufen [494793-67-8] + TX, penconazole [66246-88-6] + TX, prothioconazole [178928-70-6] + TX, pyrifenoxy [88283-41-4] + TX, prochloraz [67747-09-5] + TX, propiconazole [60207-90-1] + TX,
20 simeconazole [149508-90-7] + TX, tebuconazole [107534-96-3] + TX, tetraconazole [112281-77-3] + TX, triadimefon [43121-43-3] + TX, triadimenol [55219-65-3] + TX, triflumizole [99387-89-0] + TX, triticonazole [131983-72-7] + TX, ancymidol [12771-68-5] + TX, fenarimol [60168-88-9] + TX, nuarimol [63284-71-9] + TX, bupirimate [41483-43-6] + TX, dimethirimol [5221-53-4] + TX, ethirimol [23947-60-6] + TX, dodemorph [1593-77-7] + TX, fenpropidin [67306-00-7] + TX, fenpropimorph [67564-91-4] + TX,
25 TX, spiroxamine [118134-30-8] + TX, tridemorph [81412-43-3] + TX, cyprodinil [121552-61-2] + TX, mepanipyrim [110235-47-7] + TX, pyrimethanil [53112-28-0] + TX, fempiclonil [74738-17-3] + TX, fludioxonil [131341-86-1] + TX, fluindapyr [1383809-87-7] + TX, benalaxyl [71626-11-4] + TX, furalaxyl [57646-30-7] + TX, metalaxyl [57837-19-1] + TX, R-metalaxyl [70630-17-0] + TX, ofurace [58810-48-3] + TX, oxadixyl [77732-09-3] + TX, benomyl [17804-35-2] + TX, carbendazim [10605-21-7] + TX,
30 debacarb [62732-91-6] + TX, fuberidazole [3878-19-1] + TX, thiabendazole [148-79-8] + TX, chlozolinate [84332-86-5] + TX, dichlozoline [24201-58-9] + TX, iprodione [36734-19-7] + TX, myclozoline [54864-61-8] + TX, procymidone [32809-16-8] + TX, vinclozoline [50471-44-8] + TX, boscalid [188425-85-6] + TX, carboxin [5234-68-4] + TX, fenfuram [24691-80-3] + TX, flutolanil [66332-96-5] + TX, flutianil [958647-10-4] + TX, mepronil [55814-41-0] + TX, oxycarboxin [5259-88-1] + TX,
35 penthiopyrad [183675-82-3] + TX, thifluzamide [130000-40-7] + TX, guazatine [108173-90-6] + TX, dodine [2439-10-3] [112-65-2] (free base) + TX, iminoctadine [13516-27-3] + TX, azoxystrobin [131860-33-8] + TX, dimoxystrobin [149961-52-4] + TX, enestroburin {Proc. BCPC, Int. Congr., Glasgow, 2003, 1, 93} + TX, fluoxastrobin [361377-29-9] + TX, kresoxim-methyl [143390-89-0] + TX, metominostrobin [133408-50-1] + TX, trifloxystrobin [141517-21-7] + TX, orysastrobin [248593-16-0] + TX, picoxystrobin
40 [117428-22-5] + TX, pyraclostrobin [175013-18-0] + TX, pyraoxystrobin [862588-11-2] + TX, ferbam

[14484-64-1] + TX, mancozeb [8018-01-7] + TX, maneb [12427-38-2] + TX, metiram [9006-42-2] + TX, propineb [12071-83-9] + TX, thiram [137-26-8] + TX, zineb [12122-67-7] + TX, ziram [137-30-4] + TX, captafol [2425-06-1] + TX, captan [133-06-2] + TX, dichlofluanid [1085-98-9] + TX, fluoroimide [41205-21-4] + TX, folpet [133-07-3] + TX, tolylfluanid [731-27-1] + TX, bordeaux mixture [8011-63-0] + TX, copperhydroxid [20427-59-2] + TX, copperoxychlorid [1332-40-7] + TX, coppersulfat [7758-98-7] + TX, copperoxid [1317-39-1] + TX, mancopper [53988-93-5] + TX, oxine-copper [10380-28-6] + TX, dinocap [131-72-6] + TX, nitrothal-isopropyl [10552-74-6] + TX, edifenphos [17109-49-8] + TX, iprobenphos [26087-47-8] + TX, isoprothiolane [50512-35-1] + TX, phosdiphen [36519-00-3] + TX, pyrazophos [13457-18-6] + TX, tolclofos-methyl [57018-04-9] + TX, acibenzolar-S-methyl [135158-54-2] + TX, anilazine [101-05-3] + TX, benthiavalicarb [413615-35-7] + TX, blasticidin-S [2079-00-7] + TX, chinomethionat [2439-01-2] + TX, chloroneb [2675-77-6] + TX, chlorothalonil [1897-45-6] + TX, cyflufenamid [180409-60-3] + TX, cymoxanil [57966-95-7] + TX, dichlone [117-80-6] + TX, diclocymet [139920-32-4] + TX, diclomezine [62865-36-5] + TX, dicloran [99-30-9] + TX, diethofencarb [87130-20-9] + TX, dimethomorph [110488-70-5] + TX, SYP-LI90 (Flumorph) [211867-47-9] + TX, dithianon [3347-22-6] + TX, ethaboxam [162650-77-3] + TX, etridiazole [2593-15-9] + TX, famoxadone [131807-57-3] + TX, fenamidone [161326-34-7] + TX, fenoxanil [115852-48-7] + TX, fentin [668-34-8] + TX, ferimzone [89269-64-7] + TX, fluazinam [79622-59-6] + TX, fluopicolide [239110-15-7] + TX, flusulfamide [106917-52-6] + TX, fenhexamid [126833-17-8] + TX, fosetyl-aluminium [39148-24-8] + TX, hymexazol [10004-44-1] + TX, iprovalicarb [140923-17-7] + TX, IKF-916 (Cyazofamid) [120116-88-3] + TX, kasugamycin [6980-18-3] + TX, methasulfocarb [66952-49-6] + TX, metrafenone [220899-03-6] + TX, pencycuron [66063-05-6] + TX, phthalide [27355-22-2] + TX, picarbutrazox [500207-04-5] + TX, polyoxins [11113-80-7] + TX, probenazole [27605-76-1] + TX, propamocarb [25606-41-1] + TX, proquinazid [189278-12-4] + TX, pydiflumetofen [1228284-64-7] + TX, pyrametostrobin [915410-70-7] + TX, pyroquilon [57369-32-1] + TX, pyriofenone [688046-61-9] + TX, pyribencarb [799247-52-2] + TX, pyrisoxazole [847749-37-5] + TX, quinoxifen [124495-18-7] + TX, quintozene [82-68-8] + TX, sulfur [7704-34-9] + TX, Timorex Gold™ (plant extract containing tea tree oil from the Stockton Group) + TX, tebufloquin [376645-78-2] + TX, tiadinil [223580-51-6] + TX, triazoxide [72459-58-6] + TX, tolprocarb [911499-62-2] + TX, triclopyricarb [902760-40-1] + TX, tricyclazole [41814-78-2] + TX, triforine [26644-46-2] + TX, validamycin [37248-47-8] + TX, valifenalate [283159-90-0] + TX, zoxamide (RH7281) [156052-68-5] + TX, mandipropamid [374726-62-2] + TX, isopyrazam [881685-58-1] + TX, phenamacril + TX, sedaxane [874967-67-6] + TX, trinexapac-ethyl [95266-40-3] + TX, 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylene-1,2,3,4-tetrahydro-1,4-methano-naphthalen-5-yl)-amide (disclosed in WO 2007/048556) + TX, 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (3',4',5'-trifluorobiphenyl-2-yl)-amide (disclosed in WO 2006/087343) + TX, [(3S,4R,4aR,6S,6aS,12R,12aS,12bS)-3-[(cyclopropylcarbonyl)oxy]-1,3,4,4a,5,6,6a,12,12a,12b-decahydro-6,12-dihydroxy-4,6a,12b-trimethyl-11-oxo-9-(3-pyridinyl)-2H,11Hnaphtho[2,1-b]pyrano[3,4-e]pyran-4-yl]methyl-cyclopropanecarboxylate [915972-17-7] + TX and 1,3,5-trimethyl-N-(2-methyl-1-oxopropyl)-N-[3-(2-methylpropyl)-4-[2,2,2-trifluoro-1-methoxy-1-(trifluoromethyl)ethyl]phenyl]-1H-pyrazole-4-carboxamide [926914-55-8] + TX, or a biologically active compound selected from the group consisting of N-[(5-chloro-2-isopropyl-phenyl)methyl]-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-pyrazole-4-carboxamide

(can be prepared according to the procedures described in WO 2010/130767) + TX, 2,6-Dimethyl-1H,5H-[1,4]dithiino[2,3-c:5,6-c']dipyrrole-1,3,5,7(2H,6H)-tetrone (can be prepared according to the procedures described in WO 2011/138281) + TX, 6-ethyl-5,7-dioxo-pyrrolo[4,5][1,4]dithiino[1,2-c]isothiazole-3-carbonitrile + TX, 4-(2-bromo-4-fluoro-phenyl)-N-(2-chloro-6-fluoro-phenyl)-2,5-dimethyl-pyrazol-3-amine (can be prepared according to the procedures described in WO 2012/031061) + TX, 3-(difluoromethyl)-N-(7-fluoro-1,1,3-trimethyl-indan-4-yl)-1-methyl-pyrazole-4-carboxamide (can be prepared according to the procedures described in WO 2012/084812) + TX, CAS 850881-30-0 + TX, 3-(3,4-dichloro-1,2-thiazol-5-ylmethoxy)-1,2-benzothiazole 1,1-dioxide (can be prepared according to the procedures described in WO 2007/129454) + TX, 2-[2-[(2,5-dimethylphenoxy)methyl]phenyl]-2-methoxy-N-methyl-acetamide + TX, 3-(4,4-difluoro-3,4-dihydro-3,3-dimethylisoquinolin-1-yl)quinolone (can be prepared according to the procedures described in WO 2005/070917) + TX, 2-[2-fluoro-6-[(8-fluoro-2-methyl-3-quinolyl)oxy]phenyl]propan-2-ol (can be prepared according to the procedures described in WO 2011/081174) + TX, 2-[2-[(7,8-difluoro-2-methyl-3-quinolyl)oxy]-6-fluoro-phenyl]propan-2-ol (can be prepared according to the procedures described in WO 2011/081174) + TX, oxathiapiprolin + TX [1003318-67-9], tert-butyl N-[6-[[[(1-methyltetrazol-5-yl)-phenyl-methylene]amino]oxymethyl]-2-pyridyl]carbamate + TX, N-[2-(3,4-difluorophenyl)phenyl]-3-(trifluoromethyl)pyrazine-2-carboxamide (can be prepared according to the procedures described in WO 2007/ 072999) + TX, 3-(difluoromethyl)-1-methyl-N-[(3R)-1,1,3-trimethylindan-4-yl]pyrazole-4-carboxamide (can be prepared according to the procedures described in WO 2014/013842) + TX, 2,2,2-trifluoroethyl N-[2-methyl-1-[[[4-methylbenzoyl]amino]methyl]propyl]carbamate + TX, (2RS)-2-[4-(4-chlorophenoxy)- α,α,α -trifluoro-*o*-tolyl]-1-(1H-1,2,4-triazol-1-yl)propan-2-ol + TX, (2RS)-2-[4-(4-chlorophenoxy)- α,α,α -trifluoro-*o*-tolyl]-3-methyl-1-(1H-1,2,4-triazol-1-yl)butan-2-ol + TX, 2-(difluoromethyl)-N-[(3R)-3-ethyl-1,1-dimethyl-indan-4-yl]pyridine-3-carboxamide + TX, 2-(difluoromethyl)-N-[3-ethyl-1,1-dimethyl-indan-4-yl]pyridine-3-carboxamide + TX, N'-(2,5-dimethyl-4-phenoxy-phenyl)-N-ethyl-N-methyl-formamidine + TX, N'-[4-(4,5-dichlorothiazol-2-yl)oxy-2,5-dimethyl-phenyl]-N-ethyl-N-methyl-formamidine (can be prepared according to the procedures described in WO 2007/031513) + TX, [2-[3-[2-[1-[2-[3,5-bis(difluoromethyl)pyrazol-1-yl]acetyl]-4-piperidyl]thiazol-4-yl]-4,5-dihydroisoxazol-5-yl]-3-chloro-phenyl] methanesulfonate (can be prepared according to the procedures described in WO 2012/025557) + TX, but-3-ynyl N-[6-[[[Z)-[(1-methyltetrazol-5-yl)-phenyl-methylene]amino]oxymethyl]-2-pyridyl]carbamate (can be prepared according to the procedures described in WO 2010/000841) + TX, 2-[[3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl]-4H-1,2,4-triazole-3-thione (can be prepared according to the procedures described in WO 2010/146031) + TX, methyl N-[[[5-[4-(2,4-dimethylphenyl)triazol-2-yl]-2-methyl-phenyl]methyl]carbamate + TX, 3-chloro-6-methyl-5-phenyl-4-(2,4,6-trifluorophenyl)pyridazine (can be prepared according to the procedures described in WO 2005/121104) + TX, 2-[2-chloro-4-(4-chlorophenoxy)phenyl]-1-(1,2,4-triazol-1-yl)propan-2-ol (can be prepared according to the procedures described in WO 2013/024082) + TX, 3-chloro-4-(2,6-difluorophenyl)-6-methyl-5-phenyl-pyridazine (can be prepared according to the procedures described in WO 2012/020774) + TX, 4-(2,6-difluorophenyl)-6-methyl-5-phenyl-pyridazine-3-carbonitrile (can be prepared according to the procedures described in WO 2012/020774) + TX, (*R*)-3-(difluoromethyl)-1-

methyl-N-[1,1,3-trimethylindan-4-yl]pyrazole-4-carboxamide (can be prepared according to the procedures described in WO 2011/162397) + TX, 3-(difluoromethyl)-N-(7-fluoro-1,1,3-trimethyl-indan-4-yl)-1-methyl-pyrazole-4-carboxamide (can be prepared according to the procedures described in WO 2012/084812) + TX, 1-[2-[[1-(4-chlorophenyl)pyrazol-3-yl]oxymethyl]-3-methyl-phenyl]-4-methyl-tetrazol-5-one (can be prepared according to the procedures described in WO 2013/162072) + TX, 1-methyl-4-[3-methyl-2-[[2-methyl-4-(3,4,5-trimethylpyrazol-1-yl)phenoxy]methyl]phenyl]tetrazol-5-one (can be prepared according to the procedures described in WO 2014/051165) + TX, (Z,2E)-5-[1-(4-chlorophenyl)pyrazol-3-yl]oxy-2-methoxyimino-N,3-dimethyl-pent-3-enamide + TX, (4-phenoxyphenyl)methyl 2-amino-6-methyl-pyridine-3-carboxylate + TX, N-(5-chloro-2-isopropylbenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methylpyrazole-4-carboxamide [1255734-28-1] (can be prepared according to the procedures described in WO 2010/130767) + TX, 3-(difluoromethyl)-N-[(R)-2,3-dihydro-1,1,3-trimethyl-1H-inden-4-yl]-1-methylpyrazole-4-carboxamide [1352994-67-2] + TX, N'-(2,5-dimethyl-4-phenoxy-phenyl)-N-ethyl-N-methyl-formamidine + TX, N'-[4-(4,5-dichloro-thiazol-2-yloxy)-2,5-dimethyl-phenyl]-N-ethyl-N-methyl-formamidine + TX, N'-(2,5-dimethyl-4-phenoxy-phenyl)-N-ethyl-N-methyl-formamidine + TX, N'-[4-(4,5-dichloro-thiazol-2-yloxy)-2,5-dimethyl-phenyl]-N-ethyl-N-methyl-formamidine + TX,



(fenpicoxamid [517875-34-2]) + TX (as described in WO

2003/035617), 2-(difluoromethyl)-N-(1,1,3-trimethylindan-4-yl)pyridine-3-carboxamide + TX, 2-(difluoromethyl)-N-(3-ethyl-1,1-dimethyl-indan-4-yl)pyridine-3-carboxamide + TX, 2-(difluoromethyl)-N-(1,1-dimethyl-3-propyl-indan-4-yl)pyridine-3-carboxamide + TX, 2-(difluoromethyl)-N-(3-isobutyl-1,1-dimethyl-indan-4-yl)pyridine-3-carboxamide + TX, 2-(difluoromethyl)-N-[(3R)-1,1,3-trimethylindan-4-yl]pyridine-3-carboxamide + TX, 2-(difluoromethyl)-N-[(3R)-3-ethyl-1,1-dimethyl-indan-4-yl]pyridine-3-carboxamide + TX, and 2-(difluoromethyl)-N-[(3R)-1,1-dimethyl-3-propyl-indan-4-yl]pyridine-3-carboxamide + TX, wherein each of these carboxamide compounds can be prepared according to the procedures described in WO 2014/095675 and/or WO 2016/139189.

The references in brackets behind the active ingredients, e.g. [3878-19-1] refer to the Chemical Abstracts Registry number. The above described mixing partners are known. Where the active ingredients are included in "The Pesticide Manual" [The Pesticide Manual - A World Compendium; Thirteenth Edition; Editor: C. D. S. Tomlin; The British Crop Protection Council], they are described therein under the entry number given in round brackets hereinabove for the particular compound; for example, the compound "abamectin" is described under entry number (1). Where "[CCN]" is added hereinabove to the particular compound, the compound in question is included in the "Compendium of Pesticide Common Names", which is accessible on the internet [A. Wood; Compendium of Pesticide

Common Names, Copyright © 1995-2004]; for example, the compound "acetoprole" is described under the internet address <http://www.alanwood.net/pesticides/acetoprole.html>.

Most of the active ingredients described above are referred to hereinabove by a so-called "common name", the relevant "ISO common name" or another "common name" being used in individual cases. If the designation is not a "common name", the nature of the designation used instead is given in round brackets for the particular compound; in that case, the IUPAC name, the IUPAC/Chemical Abstracts name, a "chemical name", a "traditional name", a "compound name" or a "development code" is used or, if neither one of those designations nor a "common name" is used, an "alternative name" is employed. "CAS Reg. No" means the Chemical Abstracts Registry Number.

The active ingredient mixture of the compounds of formula (I) selected from one compound selected from compounds T-2.01 to T-2.08 to T-47.01 to T-47.08 shown in Tables 2 to 47 (below) and compounds A.1 to A.35 described in Table A (below), preferably in a mixing ratio of from 100:1 to 1:6000, especially from 50:1 to 1:50, more especially in a ratio of from 20:1 to 1:20, even more especially from 10:1 to 1:10, very especially from 5:1 and 1:5, special preference being given to a ratio of from 2:1 to 1:2, and a ratio of from 4:1 to 2:1 being likewise preferred, above all in a ratio of 1:1, or 5:1, or 5:2, or 5:3, or 5:4, or 4:1, or 4:2, or 4:3, or 3:1, or 3:2, or 2:1, or 1:5, or 2:5, or 3:5, or 4:5, or 1:4, or 2:4, or 3:4, or 1:3, or 2:3, or 1:2, or 1:600, or 1:300, or 1:150, or 1:35, or 2:35, or 4:35, or 1:75, or 2:75, or 4:75, or 1:6000, or 1:3000, or 1:1500, or 1:350, or 2:350, or 4:350, or 1:750, or 2:750, or 4:750. Those mixing ratios are by weight.

The mixtures as described above can be used in a method for controlling pests, which comprises applying a composition comprising a mixture as described above to the pests or their environment, with the exception of a method for treatment of the human or animal body by surgery or therapy and diagnostic methods practised on the human or animal body.

The mixtures comprising a compound selected from compounds T-2.01 to T-2.08 to T-47.01 to T-47.08 shown in Tables 2 to 47 (below) and compounds A.1 to A.35 described in Table A (below), and one or more active ingredients as described above can be applied, for example, in a single "ready-mix" form, in a combined spray mixture composed from separate formulations of the single active ingredient components, such as a "tank-mix", and in a combined use of the single active ingredients when applied in a sequential manner, i.e. one after the other with a reasonably short period, such as a few hours or days. The order of applying a compound selected from compounds T-2.01 to T-2.08 to T-47.01 to T-47.08 shown in Tables 2 to 47 (below) and compounds A.1 to A.35 described in Table A (below), and the active ingredient(s) as described above, is not essential for working the present invention.

The compositions according to the invention can also comprise further solid or liquid auxiliaries, such as stabilizers, for example unepoxidized or epoxidized vegetable oils (for example epoxidized coconut oil, rapeseed oil or soya oil), antifoams, for example silicone oil, preservatives, viscosity regulators, binders and/or tackifiers, fertilizers or other active ingredients for achieving specific effects, for example bactericides, fungicides, nematocides, plant activators, molluscicides or herbicides.

The compositions according to the invention are prepared in a manner known per se, in the absence of auxiliaries for example by grinding, screening and/or compressing a solid active ingredient

and in the presence of at least one auxiliary for example by intimately mixing and/or grinding the active ingredient with the auxiliary (auxiliaries). These processes for the preparation of the compositions and the use of the compounds (I) for the preparation of these compositions are also a subject of the invention.

5

Another aspect of the invention is related to the use of a compound of Formula (I) or of a preferred individual compound as defined herein, of a composition comprising at least one compound of Formula (I) or at least one preferred individual compound as above-defined, or of a fungicidal or insecticidal mixture comprising at least one compound of Formula (I) or at least one preferred individual compound as above-defined, in admixture with other fungicides or insecticides as described above, for controlling or preventing infestation of plants, e.g. useful plants such as crop plants, propagation material thereof, e.g. seeds, harvested crops, e.g. harvested food crops, or non-living materials by insects or by phytopathogenic microorganisms, preferably fungal organisms.

10

A further aspect of the invention is related to a method of controlling or preventing an infestation of plants, e.g., useful plants such as crop plants, propagation material thereof, e.g. seeds, harvested crops, e.g., harvested food crops, or of non-living materials by insects or by phytopathogenic or spoilage microorganisms or organisms potentially harmful to man, especially fungal organisms, which comprises the application of a compound of Formula (I) or of a preferred individual compound as above-defined as active ingredient to the plants, to parts of the plants or to the locus thereof, to the propagation material thereof, or to any part of the non-living materials.

15

20

Controlling or preventing means reducing infestation by phytopathogenic or spoilage microorganisms or organisms potentially harmful to man, especially fungal organisms, to such a level that an improvement is demonstrated.

25

30

A preferred method of controlling or preventing an infestation of crop plants by phytopathogenic microorganisms, especially fungal organisms, or insects which comprises the application of a compound of Formula (I), or an agrochemical composition which contains at least one of said compounds, is foliar application. The frequency of application and the rate of application will depend on the risk of infestation by the corresponding pathogen or insect. However, the compounds of Formula (I) can also penetrate the plant through the roots *via* the soil (systemic action) by drenching the locus of the plant with a liquid Formulation, or by applying the compounds in solid form to the soil, e.g. in granular form (soil application). In crops of water rice such granulates can be applied to the flooded rice field. The compounds of Formula (I) may also be applied to seeds (coating) by impregnating the seeds or tubers either with a liquid formulation of the fungicide or coating them with a solid formulation.

35

A formulation, e.g. a composition containing the compound of Formula (I), and, if desired, a solid or liquid adjuvant or monomers for encapsulating the compound of Formula (I), may be prepared in a known manner, typically by intimately mixing and/or grinding the compound with extenders, for example solvents, solid carriers and, optionally, surface active compounds (surfactants).

40

Advantageous rates of application are normally from 5g to 2kg of active ingredient (a.i.) per hectare (ha), preferably from 10g to 1kg a.i./ha, most preferably from 20g to 600g a.i./ha. When used as seed drenching agent, convenient dosages are from 10mg to 1g of active substance per kg of seeds.

When the combinations of the present invention are used for treating seed, rates of 0.001 to 50 g of a compound of Formula (I) per kg of seed, preferably from 0.01 to 10g per kg of seed are generally sufficient.

5 Suitably, a composition comprising a compound of Formula (I) according to the present invention is applied either preventative, meaning prior to disease development or curative, meaning after disease development.

The compositions of the invention may be employed in any conventional form, for example in the form of a twin pack, a powder for dry seed treatment (DS), an emulsion for seed treatment (ES), a flowable concentrate for seed treatment (FS), a solution for seed treatment (LS), a water dispersible powder for seed treatment (WS), a capsule suspension for seed treatment (CF), a gel for seed treatment (GF), an emulsion concentrate (EC), a suspension concentrate (SC), a suspo-emulsion (SE), a capsule suspension (CS), a water dispersible granule (WG), an emulsifiable granule (EG), an emulsion, water in oil (EO), an emulsion, oil in water (EW), a micro-emulsion (ME), an oil dispersion (OD), an oil miscible flowable (OF), an oil miscible liquid (OL), a soluble concentrate (SL), an ultra-low volume suspension (SU), an ultra-low volume liquid (UL), a technical concentrate (TK), a dispersible concentrate (DC), a wettable powder (WP) or any technically feasible formulation in combination with agriculturally acceptable adjuvants.

Such compositions may be produced in conventional manner, e.g. by mixing the active ingredients with appropriate formulation inerts (diluents, solvents, fillers and optionally other formulating ingredients such as surfactants, biocides, anti-freeze, stickers, thickeners and compounds that provide adjuvancy effects). Also conventional slow release formulations may be employed where long lasting efficacy is intended. Particularly Formulations to be applied in spraying forms, such as water dispersible concentrates (e.g. EC, SC, DC, OD, SE, EW, EO and the like), wettable powders and granules, may contain surfactants such as wetting and dispersing agents and other compounds that provide adjuvancy effects, e.g. the condensation product of formaldehyde with naphthalene sulphonate, an alkylarylsulphonate, a lignin sulphonate, a fatty alkyl sulphate, and ethoxylated alkylphenol and an ethoxylated fatty alcohol.

A seed dressing formulation is applied in a manner known per se to the seeds employing the combination of the invention and a diluent in suitable seed dressing formulation form, e.g. as an aqueous suspension or in a dry powder form having good adherence to the seeds. Such seed dressing formulations are known in the art. Seed dressing formulations may contain the single active ingredients or the combination of active ingredients in encapsulated form, e.g. as slow release capsules or microcapsules.


In general, the formulations include from 0.01 to 90% by weight of active agent, from 0 to 20% agriculturally acceptable surfactant and 10 to 99.99% solid or liquid formulation inerts and adjuvant(s), the active agent consisting of at least the compound of Formula (I) optionally together with other active agents, particularly microbiocides or conservatives or the like. Concentrated forms of compositions generally contain in between about 2 and 80%, preferably between about 5 and 70% by weight of active agent. Application forms of formulation may for example contain from 0.01 to 20% by weight, preferably

from 0.01 to 5% by weight of active agent. Whereas commercial products will preferably be formulated as concentrates, the end user will normally employ diluted formulations.

Whereas it is preferred to formulate commercial products as concentrates, the end user will normally use dilute formulations.

5

Table 1 (below) discloses 8 combinations (compounds 1.01 to 1.08) of substituents R¹, R², R³, R⁴, R⁵ and R⁶ in accordance with compounds as defined for Formula (T-1). Formula (T-1) corresponds to formula (I) as defined for the present invention.




10

Each of Tables 2 to 47 (which follow Table 1) make available 8 additional individual compounds of the formula (T-1) in which Z is as specifically defined in Tables 2 to 47 (Formula T-2 to T-47), which refer to Table 1 wherein R¹, R², R³, R⁴, R⁵ and R⁶ are specifically defined.

15 Table 1:

Compound no.	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶
1.01	H	H	H	H	H	H
1.02	F	H	H	H	H	H
1.03	H	H	F	H	H	H
1.04	F	F	H	H	H	H
1.05	F	H	F	H	H	H
1.06	F	H	H	F	H	H
1.07	H	H	F	F	H	H
1.08	H	H	H	H	CH ₃	H


Table 2: This table discloses compounds T-2.01 to T-2.08 of the formula (T-2), which is a compound of formula (I) wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the specific meanings given in the Table 1.



(T-2)

Table 3: This table discloses compounds T-3.01 to T-3.08 of the formula (T-3), which is a compound of formula (I) wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the specific meanings given in the


5 Table 1.



(T-3)

Table 4: This table discloses compounds T-4.01 to T-4.08 of the formula (T-4), which is a compound of formula (I) wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the specific meanings given in the


10 Table 1.



(T-4)


Table 5: This table discloses compounds T-5.01 to T-5.08 of the formula (T-5), which is a compound of formula (I) wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the specific meanings given in the

15 Table 1.




(T-5)

Table 6: This table discloses compounds T-6.01 to T-6.08 of the formula (T-6), which is a compound of formula (I) wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the specific meanings given in the Table 1.




5

Table 7: This table discloses compounds T-7.01 to T-7.08 of the formula (T-7), which is a compound of formula (I) wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the specific meanings given in the Table 1.



10

Table 8: This table discloses compounds T-8.01 to T-8.08 of the formula (T-8), which is a compound of formula (I) wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the specific meanings given in the Table 1.



15

Table 9: This table discloses compounds T-9.01 to T-9.08 of the formula (T-9), which is a compound of formula (I) wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the specific meanings given in the Table 1.




Table 10: This table discloses compounds T-10.01 to T-10.08 of the formula (T-9), which is a compound of formula (I) wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the specific meanings given in the

5 Table 1.




Table 11: This table discloses compounds T-11.01 to T-11.08 of the formula (T-11), which is a compound of formula (I) wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the specific meanings given in the

10 Table 1.




Table 12: This table discloses compounds T-12.01 to T-12.08 of the formula (T-12), which is a compound of formula (I) wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the specific meanings given in the

15 Table 1.






Table 13: This table discloses compounds T-13.01 to T-13.08 of the formula (T-13), which is a compound of formula (I) wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the specific meanings given in the Table 1.



(T-13)

5


Table 14: This table discloses compounds T-14.01 to T-14.08 of the formula (T-14), which is a compound of formula (I) wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the specific meanings given in the Table 1.



(T-14)

10


Table 15: This table discloses compounds T-15.01 to T-15.08 of the formula (T-15), which is a compound of formula (I) wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the specific meanings given in the Table 1.



(T-15)

15


Table 16: This table discloses compounds T-16.01 to T-16.08 of the formula (T-16), which is a compound of formula (I) wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the specific meanings given in the Table 1.



(T-16)

Table 17: This table discloses compounds T-17.01 to T-17.08 of the formula (T-17), which is a compound of formula (I) wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the specific meanings given in the


5 Table 1.



(T-17)

Table 18: This table discloses compounds T-18.01 to T-18.08 of the formula (T-18), which is a compound of formula (I) wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the specific meanings given in the


10 Table 1.



(T-18)


Table 19: This table discloses compounds T-19.01 to T-19.08 of the formula (T-19), which is a compound of formula (I) wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the specific meanings given in the

15 Table 1.




(T-19)

Table 20: This table discloses compounds T-20.01 to T-20.08 of the formula (T-20), which is a compound of formula (I) wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the specific meanings given in the Table 1.




5

Table 21: This table discloses compounds T-21.01 to T-21.08 of the formula (T-21), which is a compound of formula (I) wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the specific meanings given in the Table 1.



10

Table 22: This table discloses compounds T-22.01 to T-22.08 of the formula (T-22), which is a compound of formula (I) wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the specific meanings given in the Table 1.



15

Table 23: This table discloses compounds T-23.01 to T-23.08 of the formula (T-23), which is a compound of formula (I) wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the specific meanings given in the Table 1.




Table 24: This table discloses compounds T-24.01 to T-24.08 of the formula (T-24), which is a compound of formula (I) wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the specific meanings given in the

5 Table 1.




Table 25: This table discloses compounds T-25.01 to T-25.08 of the formula (T-25), which is a compound of formula (I) wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the specific meanings given in the

10 Table 1.




Table 26: This table discloses compounds T-26.01 to T-26.08 of the formula (T-26), which is a compound of formula (I) wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the specific meanings given in the

15 Table 1.






Table 27: This table discloses compounds T-27.01 to T-27.08 of the formula (T-27), which is a compound of formula (I) wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the specific meanings given in the Table 1.




5

Table 28: This table discloses compounds T-28.01 to T-28.08 of the formula (T-28), which is a compound of formula (I) wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the specific meanings given in the Table 1.



10

Table 29: This table discloses compounds T-29.01 to T-29.08 of the formula (T-29), which is a compound of formula (I) wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the specific meanings given in the Table 1.



15

Table 30: This table discloses compounds T-30.01 to T-30.08 of the formula (T-30), which is a compound of formula (I) wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the specific meanings given in the Table 1.




Table 31: This table discloses compounds T-31.01 to T-31.08 of the formula (T-31), which is a compound of formula (I) wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the specific meanings given in the

5 Table 1.




Table 32: This table discloses compounds T-32.01 to T-32.08 of the formula (T-32), which is a compound of formula (I) wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the specific meanings given in the

10 Table 1.




Table 33: This table discloses compounds T-33.01 to T-33.08 of the formula (T-33), which is a compound of formula (I) wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the specific meanings given in the

15 Table 1.






Table 34: This table discloses compounds T-34.01 to T-34.08 of the formula (T-34), which is a compound of formula (I) wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the specific meanings given in the Table 1.




5

Table 35: This table discloses compounds T-35.01 to T-35.08 of the formula (T-35), which is a compound of formula (I) wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the specific meanings given in the Table 1.




10

Table 36: This table discloses compounds T-36.01 to T-36.08 of the formula (T-36), which is a compound of formula (I) wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the specific meanings given in the Table 1.



15


Table 37: This table discloses compounds T-37.01 to T-37.08 of the formula (T-37), which is a compound of formula (I) wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the specific meanings given in the Table 1.



(T-37)

Table 38: This table discloses compounds T-38.01 to T-38.08 of the formula (T-38), which is a compound of formula (I) wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the specific meanings given in the


5 Table 1.



(T-38)

Table 39: This table discloses compounds T-39.01 to T-39.08 of the formula (T-39), which is a compound of formula (I) wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the specific meanings given in the


10 Table 1.



(T-39)


Table 40: This table discloses compounds T-40.01 to T-40.08 of the formula (T-40), which is a compound of formula (I) wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the specific meanings given in the

15 Table 1.




(T-40)

Table 41: This table discloses compounds T-41.01 to T-41.08 of the formula (T-41), which is a compound of formula (I) wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the specific meanings given in the Table 1.



5

Table 42: This table discloses compounds T-42.01 to T-42.08 of the formula (T-42), which is a compound of formula (I) wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the specific meanings given in the Table 1.



10

Table 43: This table discloses compounds T-43.01 to T-43.08 of the formula (T-43), which is a compound of formula (I) wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the specific meanings given in the Table 1.



15

Table 44: This table discloses compounds T-44.01 to T-44.08 of the formula (T-44), which is a compound of formula (I) wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the specific meanings given in the Table 1.




Table 45: This table discloses compounds T-45.01 to T-45.08 of the formula (T-45), which is a compound of formula (I) wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the specific meanings given in the

5 Table 1.




Table 46: This table discloses compounds T-46.01 to T-46.08 of the formula (T-46), which is a compound of formula (I) wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the specific meanings given in the

10 Table 1.





Table 47: This table discloses compounds T-47.01 to T-47.08 of the formula (T-47), which is a compound of formula (I) wherein R¹, R², R³, R⁴, R⁵ and R⁶ have the specific meanings given in the

15 Table 1.



EXAMPLES

The Examples which follow serve to illustrate the invention.

5 The compounds of the invention can be distinguished from known compounds by virtue of greater efficacy at low application rates, which can be verified by the person skilled in the art using the experimental procedures outlined in the Examples, using lower application rates if necessary, for example 50 ppm, 12.5 ppm, 6 ppm, 3 ppm, 1.5 ppm, 0.8 ppm or 0.2 ppm.

10 Compounds of Formula (I) may possess any number of benefits including, *inter alia*, advantageous levels of biological activity for protecting plants against diseases that are caused by fungi or superior properties for use as agrochemical active ingredients (for example, greater biological activity, an advantageous spectrum of activity, an increased safety profile (including improved crop tolerance), improved physico-chemical properties, or increased biodegradability).

15 Throughout this description, temperatures are given in degrees Celsius (°C) and "mp." means melting point. LC/MS means Liquid Chromatography Mass Spectrometry and the description of the apparatus and the method (Method A) is as follows:

The description of the LC/MS apparatus and the method A is:

SQ Detector 2 from Waters

20 Ionisation method: Electrospray

Polarity: positive and negative ions

Capillary (kV) 3.0, Cone (V) 30.00, Extractor (V) 2.00, Source Temperature (°C) 150, Desolvation Temperature (°C) 350, Cone Gas Flow (L/Hr) 0, Desolvation Gas Flow (L/Hr) 650

Mass range: 100 to 900 Da

25 DAD Wavelength range (nm): 210 to 500

Method Waters ACQUITY UPLC with the following HPLC gradient conditions:

(Solvent A: Water/Methanol 20:1 + 0.05% formic acid and Solvent B: Acetonitrile+ 0.05% formic acid)

30

Time (minutes)	A (%)	B (%)	Flow rate (ml/min)
0	100	0	0.85
1.2	0	100	0.85
1.5	0	100	0.85

35

Type of column: Waters ACQUITY UPLC HSS T3; Column length: 30 mm; Internal diameter of column: 2.1 mm; Particle Size: 1.8 micron; Temperature: 60°C.

Where necessary, enantiomerically pure final compounds may be obtained from racemic materials as appropriate via standard physical separation techniques, such as reverse phase chiral chromatography, or through stereoselective synthetic techniques, eg, by using chiral starting materials.

5 Formulation Examples

<u>Wettable powders</u>	a)	b)	c)
Active ingredient [compound of Formula (I)]	25 %	50 %	75 %
sodium lignosulfonate	5 %	5 %	-
sodium lauryl sulfate	3 %	-	5 %
sodium diisobutylphthalenesulfonate	-	6 %	10 %
phenol polyethylene glycol ether (7-8 mol of ethylene oxide)	-	2 %	-
highly dispersed silicic acid	5 %	10 %	10 %
Kaolin	62 %	27 %	-

The active ingredient is thoroughly mixed with the adjuvants and the mixture is thoroughly ground in a suitable mill, affording wettable powders that can be diluted with water to give suspensions of the desired concentration.

10

<u>Powders for dry seed treatment</u>	a)	b)	c)
Active ingredient [compound of Formula (I)]	25 %	50 %	75 %
light mineral oil	5 %	5 %	5 %
highly dispersed silicic acid	5 %	5 %	-
Kaolin	65 %	40 %	-
Talcum	-	-	20 %

The active ingredient is thoroughly mixed with the adjuvants and the mixture is thoroughly ground in a suitable mill, affording powders that can be used directly for seed treatment.

15

Emulsifiable concentrate

active ingredient [compound of Formula (I)]	10 %
octylphenol polyethylene glycol ether (4-5 mol of ethylene oxide)	3 %
calcium dodecylbenzenesulfonate	3 %
castor oil polyglycol ether (35 mol of ethylene oxide)	4 %
Cyclohexanone	30 %
xylene mixture	50 %

Emulsions of any required dilution, which can be used in plant protection, can be obtained from this concentrate by dilution with water.

<u>Dusts</u>	a)	b)	c)
Active ingredient [compound of Formula (I)]	5 %	6 %	4 %
Talcum	95 %	-	-
Kaolin	-	94 %	-
mineral filler	-	-	96 %

- 5 Ready-for-use dusts are obtained by mixing the active ingredient with the carrier and grinding the mixture in a suitable mill. Such powders can also be used for dry dressings for seed.

Extruder granules

Active ingredient [compound of Formula (I)]	15 %
sodium lignosulfonate	2 %
Carboxymethylcellulose	1 %
Kaolin	82 %

- 10 The active ingredient is mixed and ground with the adjuvants, and the mixture is moistened with water. The mixture is extruded and then dried in a stream of air.

Coated granules

Active ingredient [compound of Formula (I)]	8 %
polyethylene glycol (mol. wt. 200)	3 %
Kaolin	89 %

- 15 The finely ground active ingredient is uniformly applied, in a mixer, to the kaolin moistened with polyethylene glycol. Non-dusty coated granules are obtained in this manner.

Suspension concentrate

Active ingredient [compound of Formula (I)]	40 %
propylene glycol	10 %
nonylphenol polyethylene glycol ether (15 mol of ethylene oxide)	6 %
Sodium lignosulfonate	10 %
Carboxymethylcellulose	1 %
Silicone oil (in the form of a 75 % emulsion in water)	1 %
Water	32 %

The finely ground active ingredient is intimately mixed with the adjuvants, giving a suspension concentrate from which suspensions of any desired dilution can be obtained by dilution with water.

Using such dilutions, living plants as well as plant propagation material can be treated and protected against infestation by microorganisms, by spraying, pouring or immersion.

Flowable concentrate for seed treatment

Active ingredient [compound of Formula (I)]	40 %
propylene glycol	5 %
copolymer butanol PO/EO	2 %
tristyrenephenole with 10-20 moles EO	2 %
1,2-benzisothiazolin-3-one (in the form of a 20% solution in water)	0.5 %
monoazo-pigment calcium salt	5 %
Silicone oil (in the form of a 75 % emulsion in water)	0.2 %
Water	45.3 %

5

The finely ground active ingredient is intimately mixed with the adjuvants, giving a suspension concentrate from which suspensions of any desired dilution can be obtained by dilution with water. Using such dilutions, living plants as well as plant propagation material can be treated and protected against infestation by microorganisms, by spraying, pouring or immersion.

10

Slow-Release Capsule Suspension

28 parts of a combination of the compound of Formula I are mixed with 2 parts of an aromatic solvent and 7 parts of toluene diisocyanate/polymethylene-polyphenylisocyanate-mixture (8:1). This mixture is emulsified in a mixture of 1.2 parts of polyvinylalcohol, 0.05 parts of a defoamer and 51.6 parts of water until the desired particle size is achieved. To this emulsion a mixture of 2.8 parts 1,6-diaminohexane in 5.3 parts of water is added. The mixture is agitated until the polymerization reaction is completed.

15

The obtained capsule suspension is stabilized by adding 0.25 parts of a thickener and 3 parts of a dispersing agent. The capsule suspension Formulation contains 28% of the active ingredients. The medium capsule diameter is 8-15 microns.

20

The resulting formulation is applied to seeds as an aqueous suspension in an apparatus suitable for that purpose.

25

List of Abbreviations:


brs	= broad singlet
DMF	= dimethylformamide
DIPEA	= N,N-di-isopropylethylamine
EtOAc	= ethyl acetate
HCl	= hydrochloric acid

30


mp	= melting point
°C	= degrees Celsius
MeOH	= methyl alcohol
NaOH	= sodium hydroxide
5 min	= minutes
RT	= room temperature
h	= hour(s)
TFAA	= trifluoroacetic acid anhydride

10 Preparation Examples

Example 1: This example illustrates the preparation of N,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrimidine-5-carboxamide (Compound A.1 of Table A)



15 Step 1: Preparation of 2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetonitrile.




Under argon, to a solution of 3-[4-(bromomethyl)phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole (CAS 2093101-98-3; 1.0 g) in acetonitrile (10.0 mL) was added trimethylsilylformonitrile (420 mg). Then the mixture was cooled to 0 °C and tetrabutylammonium hydrofluoride (1M in THF, 4.2 mL) was added dropwise to the mixture. The yellow solution was then stirred at ambient temperature for 3 h. Ice and water was added to the mixture which reacted slightly exothermic. Then the phases were separated and the aqueous layer was extracted twice with ethyl acetate, the organic layers were washed with water and then with brine. The total combined organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. The residue was purified by chromatography using a cyclohexane/ethyl acetate gradient to afford the title compound (0.82 g, 99% yield) as a white solid. LC/MS (Method A) retention time = 1.01 minutes, 252 (M-H).

¹H NMR (400 MHz, CDCl₃) δ ppm: 8.18 (d, 2H), 7.54 (d, 2H), 3.88 (s, 2H).

¹⁹F NMR (400 MHz, CDCl₃) δ ppm: -65.35 (s).


Step 2: Preparation of [1-ethoxy-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]ethylidene]ammonium chloride.



5 Under nitrogen, to ethanol (8 mL) cooled to at 5-10°C was added dropwise over 0.5 h acetyl chloride (5.8 g). Within 0.25 h 2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetonitrile (2.30 g) was added portionwise. The clear solution was allowed to stir at ambient temperature for 17 h. The white suspension was vacuum filtered and the solid rinsed with ethanol (1 mL) then dried under reduced pressure to afford the title compound (2.05 g, 60% yield) as a white solid, m.p. = 209-210°C. LC/MS
10 (Method A) retention time = 0.80 minutes, 300 (M+H).

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 12.1 (brs, 1H), 8.08 (d, 2H), 7.65 (d, 2H), 4.56 (q, 2H), 4.21 (s, 2H), 1.29 (t, 3H).


15 Step 3: Preparation of [1-amino-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]ethylidene]ammonium chloride.



To a white suspension of [1-ethoxy-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]ethylidene]ammonium chloride (1.98 g) in methanol (5.0 mL) was added dropwise ammonia
20 in methanol (1.3 mL, 7 mol/L). The colourless solution was stirred at ambient temperature for 48 h. Then solvent was removed under reduced pressure and the residue was dried to afford the title compound as a white solid (1.76 g, 97% yield), mp = 250-255°C. LC/MS (Method A) retention time = 0.67 minutes, 271 (M+H).

25 ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 9.5 (s, 2H), 8.98 (s, 1H), 8.07 (d, 2H), 7.65 (d, 2H), 3.91 (s, 2H).


Step 4: Preparation of ethyl 4-methyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrimidine-5-carboxylate.



Under nitrogen, to a solution of [1-amino-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]ethylidene]ammonium chloride (100 mg) in ethanol (4.0 mL) was added ethyl 2-acetyl-3-(dimethylamino)acrylate (70 mg), followed by addition of potassium carbonate (89 mg). The mixture was stirred at reflux temperature for 0.5 h. Then water was added and the mixture was extracted three times with ethylacetate. The total combined organic phase was washed with water, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by flash chromatography over silica gel with a cyclohexane/ethyl acetate 3:1 to 1:4 as eluent gradient to afford the title compound as a solid (67 mg, 52 % yield), m.p. = 90-91°C. LC/MS (Method A) retention time = 1.29 minutes, 393 (M+H).

$^1\text{H NMR}$ (400 MHz, CDCl_3) δ ppm: 9.11 (s, 1H), 8.08 (d, 2H), 7.55 (d, 2H), 4.43 (q, 2H), 4.39 (s, 2H), 2.84 (s, 3H), 1.42 (t, 3H).


Step 5: Preparation of N,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrimidine-5-carboxamide.



Ethyl 4-methyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrimidine-5-carboxylate (85 mg) was added to methylamine in methanol (2.2 mL, 2 mol/L). The mixture was stirred at ambient temperature for 17 h. Then the solvent was removed under reduced pressure and the resultant residue was purified by chromatography using a ethanol/ethyl acetate 5:95 eluent gradient to afford the title compound (44 mg, 38% yield) as a white solid, m.p. = 166-167°C. LC/MS (Method A) retention time = 0.95 minutes, 376 (M+H).

$^1\text{H NMR}$ (400 MHz, CDCl_3) δ ppm: 8.63 (s, 1H), 8.09 (d, 2H), 7.53 (d, 2H), 5.85 (sbroad, 1H), 4.37 (s, 2H), 3.05 (d, 3H), 2.69 (s, 3H).

Example 2: This example illustrates the preparation of 3-[4-[[4-methyl-6-(trifluoromethyl)pyrimidin-2-yl]methyl]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole (Compound A.4 of Table A).




5 To a solution of [1-amino-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]ethylidene]ammonium chloride (80 mg) in ethanol (3.0 mL) was added potassium carbonate (72 mg) followed by addition of 1,1,1-trifluoro-2,4-pentanedione (45 mg). The mixture was stirred at 45°C for 21 h. Then isolate (1.5 g) was added, the solvent was removed under reduced pressure, and the crude residue was purified by chromatography on silica gel using a cyclohexane/ethyl acetate 3:1
10 to 2:1 eluent gradient to afford the title compound as a solid (14 mg, 14 % yield), m.p. = 83-84°C. LC/MS (Method A) retention time = 1.22 minutes, 389 (M+H).


¹H NMR (400 MHz, CDCl₃) δ ppm: 8.09 (d, 2H), 7.56 (d, 2H), 7.38 (s, 1H), 4.42 (s, 2H), 2.64 (s, 3H).

15

Example 3: This example illustrates the preparation of 3-[4-[(2-methoxy-4,6-dimethyl-pyrimidin-5-yl)methyl]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole (Compound A.10 of Table A)



Step 1: Preparation of 3-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pentane-2,4-dione




20

To a stirred solution of pentane-2,4-dione (245 mg) in acetonitrile (16 ml) was added potassium carbonate (341 mg) in portions at ambient temperature. The white suspension was stirred for 15 min. Then a solution of 3-[4-(bromomethyl)phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole (CAS 2093101-98-3; 500mg) in acetonitrile (2 ml) was added. The resulting mixture was heated at reflux temperature over

night, then allowed to cool to ambient temperature, filtered to remove solids, and the filtrate was concentrated under reduced pressure to yield a brown oil. This residue was purified by chromatography on silica gel, using a gradient of cyclohexane/ethyl acetate as eluent. Thus, the title compound was obtained as a yellow oil (243 mg, 46% yield). Tautomeric forms (keto- and enol) are visible in LC/MS and NMR. LC/MS (Method A) retention time = 1.07 and 1.17 minutes, both 325 (M-H in the negative mode).


Step 2: Preparation of 4,6-dimethyl-5-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrimidin-2-ol (Compound A.8 of Table A)



To a stirred solution of 3-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pentane-2,4-dione (500 mg) and urea (149 mg) in ethanol (15 ml) was added 37% aqueous HCl (0.18 mL). The resulting mixture was heated at reflux temperature over night, allowed to cool to ambient temperature, then water and sodium bicarbonate were added until pH 7 was reached. The mixture was extracted three times with ethylacetate. The total combined organic phase was washed with water, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The resultant residue (265 mg) was purified by flash chromatography on silica gel, using cyclohexane/tert-butylmethylether (2:1) as eluent. Thus, the title compound was obtained as a yellow solid (148 mg, 28% yield), m.p. = 198-200°C. LC/MS (Method A) retention time = 0.84 minutes, 351 (M+H).

$^1\text{H NMR}$ (400 MHz, CDCl_3) δ ppm: 8.09 (d, 2H), 7.23 (d, 2H), 3.96 (s, 2H), 2.42 (s, 6H).

Step 3: Preparation of 3-[4-[(2-chloro-4,6-dimethyl-pyrimidin-5-yl)methyl]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole (Compound A.9 of Table A)




A mixture of 4,6-dimethyl-5-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrimidin-2-ol (95 mg) and phosphoryl chloride (2 mL) was heated to 110°C and stirred for 2 h. The mixture was allowed to cool to ambient temperature and poured dropwise onto water at 35°C. The mixture was

extracted three times with ethylacetate. The total combined organic phase was washed with water, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel, using cyclohexane/ethylacetate (3:1) as eluent. Thus, the title compound was obtained as a yellow solid (69 mg, 69% yield), m.p. = 113-114°C. LC/MS (Method A) retention time = 1.16 minutes, 369 (M+H).

$^1\text{H NMR}$ (400 MHz, CDCl_3) δ ppm: 8.08 (d, 2H), 7.19 (d, 2H), 4.14 (s, 2H), 2.48 (s, 6H).


Step 4: Preparation of 3-[4-[(2-methoxy-4,6-dimethyl-pyrimidin-5-yl)methyl]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole (Compound A.10 of Table A)



To a stirred solution of 3-[4-[(2-chloro-4,6-dimethyl-pyrimidin-5-yl)methyl]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole (46 mg) in methanol (1 mL) was added 25% sodium methanolate in methanol (44 μL). The resulting mixture was stirred at ambient temperature over night then poured into water and extracted three times with ethylacetate. The total combined organic phase was washed with water, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The resultant residue (52 mg) was purified by flash chromatography on silica gel, using cyclohexane/ethylacetate (2:1) as eluent. Thus, the title compound was obtained as a colourless oil (19 mg, 42% yield). LC/MS (Method A) retention time = 1.15 minutes, 365 (M+H).

$^1\text{H NMR}$ (400 MHz, CDCl_3) δ ppm: 8.07 (d, 2H), 7.19 (d, 2H), 4.09 (s, 2H), 4.01 (s, 3H), 2.41 (s, 6H).


Example 4: This example illustrates the preparation of 1,4,6-trimethyl-5-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrimidin-2-one (Compound A.11 of Table A)




To a stirred suspension of 4,6-dimethyl-5-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrimidin-2-ol (35 mg) in acetonitrile (2 mL) was added potassium carbonate (16.7 mg) followed by addition of methyl iodide (7 μ L). After 2.5 h additional methyl iodide (7 μ L) was added. The resulting mixture stirred at ambient temperature over night, then poured on water and extracted with ethylacetate. The total combined organic phase was washed with water, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue (40 mg) was purified by flash chromatography on silica gel, using ethylacetate/ ethanol (4:1) as eluent. Thus, the title compound was obtained as a colourless oil (11 mg, 24% yield). LC/MS (Method A) retention time = 0.86 minutes, 365 (M+H).

$^1\text{H NMR}$ (400 MHz, CDCl_3) δ ppm: 8.08 (d, 2H), 7.23 (d, 2H), 3.98 (s, 2H), 3.64 (s, 3H), 2.39 (s, 3H), 2.32 (s, 3H).

Example 5: This example illustrates the preparation of tert-butyl 4-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]piperidine-1-carboxylate (Compound A.17 of Table A)



Step 1: Preparation of 4-[[4-[(Z)-N'-hydroxycarbamimidoyl]phenyl]methyl]piperidine-1-carboxylate



In a flask equipped with a reflux condenser was dissolved tert-butyl 4-[[4-(4-cyanophenyl)methyl]piperidine-1-carboxylate (CAS 1021363-43-8; 2.4 g) in ethanol (40 ml), then hydroxylamine hydrochloride (1.12g) was added, followed by N,N-diethylethanamine (2.26 ml). The mixture was stirred and heated to reflux for 16 hours. Then the heating was stopped and the reaction was allowed to cool to ambient temperature. The solvent was evaporated under reduced pressure to obtain a yellowish gum (5.19 g). The crude product was used as such for the next step without further purification.

LC/MS (Method A) retention time = 0.76 minutes, 333 (M-H in the negative mode).

Step 2 Preparation of tert-butyl 4-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]piperidine-1-carboxylate (Compound A.17 of Table A).

5

Under argon, to a solution of crude tert-butyl 4-[[4-[(Z)-N'-hydroxycarbamimidoyl]phenyl]methyl]piperidine-1-carboxylate (5.19 g) in tetrahydrofuran (17 mL) was added dropwise TFAA (3.38 mL). The mixture was stirred at ambient temperature for one day. Then solvent was evaporated and the residue was purified by chromatography using a cyclohexane/ethyl acetate gradient to afford the title compound (2.60 g, 78% yield) as a colorless oil.

10

LC/MS (Method A) retention time = 1.33 minutes, 397.4 (M-H in the negative mode).

¹H NMR (400 MHz, CDCl₃) δ ppm: 8.04 (d, 2H), 7.32 (d, 2H), 4.11 (m, 2H), 2.66 (m, 4H), 1.72 (m, 1H), 1.63 (d, 2H), 1.45 (s, 9H), 1.20 (m, 2H).

15

Table A: Melting point (mp) and/or LC/MS data (retention time (t_R)) for compounds of Formula (I):

Entry	Compound name	Structure	t _R (min)	Mass charge [M+H] ⁺	LCMS Method	mp (°C)
A.1	N,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrimidine-5-carboxamide		0.95	378	A	166 - 167
A.2	4-methyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrimidine-5-carboxylic acid		1.00	363	A	220 - 220
A.3	3-[4-[[4-(methoxymethyl)-6-methyl-pyrimidin-2-yl]methyl]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole		1.11	385	A	-

Entry	Compound name	Structure	t _R (min)	Mass charge [M+H] ⁺	LCMS Method	mp (°C)
A.4	3-[4-[[4-methyl-6-(trifluoromethyl)pyrimidin-2-yl]methyl]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole		1.22	389	A	83 - 84
A.5	3-[4-[(4,6-dimethylpyrimidin-2-yl)methyl]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole		1.09	335	A	75 - 76
A.6	ethyl 4-methyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrimidine-5-carboxylate		1.29	393	A	90 - 91
A.7	4-methyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1H-pyrimidin-6-one		0.89	337	A	182 - 183
A.8	4,6-dimethyl-5-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrimidin-2-ol		0.84	351	A	198 - 200
A.9	3-[4-[(2-chloro-4,6-dimethyl-pyrimidin-5-yl)methyl]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole		1.16	369	A	113 - 114

Entry	Compound name	Structure	t _R (min)	Mass charge [M+H] ⁺	LCMS Method	mp (°C)
A.10	3-[4-[(2-methoxy-4,6-dimethyl-pyrimidin-5-yl)methyl]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole		1.15	365	A	-
A.11	1,4,6-trimethyl-5-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrimidin-2-one		0.86	365	A	-
A.12	methyl 4-methyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrimidine-5-carboxylate		1.13	379.3	A	93 - 94
A.13	4-methyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrimidine-5-carboxamide		0.89	364	A	193 - 194
A.14	N-cyclopropyl-4-methyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrimidine-5-carboxamide		0.98	404.3	A	169 - 170
A.15	N-isopropyl-4-methyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrimidine-5-carboxamide		1.02	406.4	A	169 - 170

Entry	Compound name	Structure	t _R (min)	Mass charge [M+H] ⁺	LCMS Method	mp (°C)
A.16	3-[4-[[4-methyl-5-(3-methylisoxazol-5-yl)pyrimidin-2-yl]methyl]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole		1.13	402.4	A	112 - 113
A.17	tert-butyl 4-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]piperidine-1-carboxylate		1.33	397	A	
A.18	3-[4-[[4,6-dimethyl-2-methylsulfanyl-pyrimidin-5-yl]methyl]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole		1.23	381.7	A	89 - 90
A.19	3-[4-[[4-methylpyrimidin-2-yl]methyl]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole		1.04	321.4	A	
A.20	methyl 4-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]piperidine-1-carboxylate		1.19	370.3	A	
A.21	N-methyl-4-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]piperidine-1-carboxamide		1.04	369.3	A	131.9 - 133.8

Entry	Compound name	Structure	t _R (min)	Mass charge [M+H] ⁺	LCMS Method	mp (°C)
A.22	cyclopropyl-[4-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1-piperidyl]methanone		1.15	380.4	A	
A.23	1-[4-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1-piperidyl]ethanone		1.07	354.4	A	
A.24	phenyl-[4-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1-piperidyl]methanone		1.20	416.5	A	
A.25	1-[4-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1-piperidyl]propan-1-one		1.14	368.5	A	
A.26	2-methoxy-1-[4-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1-piperidyl]ethanone		1.09	384	A	

Entry	Compound name	Structure	t _R (min)	Mass charge [M+H] ⁺	LCMS Method	mp (°C)
A.27	3-[4-[(1-methylsulfonyl-4-piperidyl)methyl]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole		1.12	390.3	A	157.9 - 159.9
A.28	2,2-dimethyl-1-[4-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1-piperidyl]propan-1-one		1.24	396.4	A	
A.29	(1-methylpyrrol-2-yl)-[4-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1-piperidyl]methanone		1.20	419.7	A	
A.30	2-methyl-1-[4-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]-1-piperidyl]propan-1-one		1.18	382.5	A	
A.31	3-[4-[(5-methyl-2-pyridyl)methyl]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole		0.88	319.9	A	
A.32	3-[4-[(5,6-dimethyl-2-pyridyl)methyl]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole		0.83	334	A	

Entry	Compound name	Structure	t _R (min)	Mass charge [M+H] ⁺	LCMS Method	mp (°C)
A.33	3-[4-(pyrimidin-2-ylmethyl)phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole					77 - 83
A.34	3-[4-[fluoro-(5-methyl-2-pyridyl)methyl]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole					60 - 62
A.35	3-[4-[difluoro-(5-methyl-2-pyridyl)methyl]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole					55 - 57

BIOLOGICAL EXAMPLES

5 *General examples of leaf disk tests in well plates:*

Leaf disks or leaf segments of various plant species are cut from plants grown in a greenhouse. The cut leaf disks or segments are placed in multiwell plates (24-well format) onto water agar. The leaf disks are sprayed with a test solution before (preventative) or after (curative) inoculation. Compounds to be tested are prepared as DMSO solutions (max. 10 mg/ml) which are diluted to the appropriate concentration with 0.025% Tween20 just before spraying. The inoculated leaf disks or segments are incubated under defined conditions (temperature, relative humidity, light, etc.) according to the respective test system. A single evaluation of disease level is carried out 3 to 14 days after inoculation, depending on the pathosystem. Percent disease control relative to the untreated check leaf disks or segments is then calculated.

General examples of liquid culture tests in well plates:

Mycelia fragments or conidia suspensions of a fungus prepared either freshly from liquid cultures of the fungus or from cryogenic storage, are directly mixed into nutrient broth. DMSO solutions of the test compound (max. 10 mg/ml) are diluted with 0.025% Tween20 by a factor of 50 and 10 µl of this solution is pipetted into a microtiter plate (96-well format). The nutrient broth containing the fungal spores/mycelia fragments is then added to give an end concentration of the

tested compound. The test plates are incubated in the dark at 24°C and 96% relative humidity. The inhibition of fungal growth is determined photometrically after 2 to 7 days, depending on the pathosystem, and percent antifungal activity relative to the untreated check is calculated.

5 Example 1: Fungicidal activity against *Puccinia recondita* f. sp. *tritici* / wheat / leaf disc preventative (Brown rust)

Wheat leaf segments cv. Kanzler were placed on agar in multiwell plates (24-well format) and sprayed with the formulated test compound diluted in water. The leaf disks were inoculated with a spore suspension of the fungus 1 day after application. The inoculated leaf segments were incubated at 19°C and 75% relative humidity (rh) under a light regime of 12 hours light / 12 hours darkness in a climate cabinet and the activity of a compound was assessed as percent disease control compared to untreated when an appropriate level of disease damage appears in untreated check leaf segments (7 to 9 days after application).

15 The following compounds at 200 ppm in the applied formulation give at least 80% disease control in this test when compared to untreated control leaf disks under the same conditions, which show extensive disease development.

20 Compounds (from Table A) A.1, A.2, A.3, A.5, A.6, A.7, A.8, A.9, A.10, A.11, A.13, A.15, A.16, A.19, A.21, A.23, A.26, A.30, A.31, A.33, A.34, and A.35.

Example 2: Fungicidal activity against *Puccinia recondita* f. sp. *tritici* / wheat / leaf disc curative (Brown rust)

25 Wheat leaf segments cv. Kanzler are placed on agar in multiwell plates (24-well format). The leaf segments are then inoculated with a spore suspension of the fungus. Plates were stored in darkness at 19°C and 75% relative humidity. The formulated test compound diluted in water was applied 1 day after inoculation. The leaf segments were incubated at 19°C and 75% relative humidity under a light regime of 12 hours light / 12 hours darkness in a climate cabinet and the activity of a compound was assessed as percent disease control compared to untreated when an appropriate level of disease damage appears in untreated check leaf segments (6 to 8 days after application).

30 The following compounds at 200 ppm in the applied formulation give at least 80% disease control in this test when compared to untreated control leaf disks under the same conditions, which show extensive disease development.

35 Compounds (from Table A) A.1, A.2, A.3, A.5, A.7, A.10, A.13, A.14, A.15, A.19, A.21, A.23, A.25, A.26, A.31, A.33, A.34, and A.35.

40 Example 3: Fungicidal activity against *Phakopsora pachyrhizi* / soybean / leaf disc preventative (Asian soybean rust)

Soybean leaf disks are placed on water agar in multiwell plates (24-well format) and sprayed with the formulated test compound diluted in water. One day after application leaf discs are inoculated by spraying a spore suspension on the lower leaf surface. After an incubation period in a climate cabinet of 24-36 hours in darkness at 20°C and 75% rh leaf disc are kept at 20°C with 12 h light/day and 75% rh. The activity of a compound is assessed as percent disease control compared to untreated when an appropriate level of disease damage appears in untreated check leaf disks (12 to 14 days after application).

The following compounds at 200 ppm in the applied formulation give at least 80% disease control in this test when compared to untreated control leaf disks under the same conditions, which show extensive disease development.

Compounds (from Table A) A.1, A.5, A.7, A.13, A.19, A.31, and A.33.

Example 4: Fungicidal activity against *Glomerella lagenarium* (*Colletotrichum lagenarium*) liquid culture / cucumber / preventative (Anthracnose)


Conidia of the fungus from cryogenic storage are directly mixed into nutrient broth (PDB - potato dextrose broth). After placing a (DMSO) solution of test compound into a microtiter plate (96-well format), the nutrient broth containing the fungal spores is added. The test plates are incubated at 24°C and the inhibition of growth is measured photometrically 3 to 4 days after application.

The following compounds at 20 ppm in the applied formulation give at least 80% disease control in this test when compared to untreated control under the same conditions, which show extensive disease development.

Compounds (from Table A) A.1, A.2, A.3, A.4, A.5, A.6, A.7, A.9, A.10, A.11, A.18, A.19, A.20, A.21, A.22, A.23, A.24, A.25, A.26, A.27, A.29, A.30, A.31, A.33, A.34, and A.35.

CLAIMS:

1. A compound of formula (I):



5

wherein R^1, R^2, R^3, R^4 are independently selected from hydrogen or fluoro and wherein 0, 1 or 2 of R^1, R^2, R^3 and R^4 are fluoro;

R^5 and R^6 are independently selected from hydrogen, methyl or fluoro;

10

Z is selected from Z^1 or Z^2 ; wherein

Z^1 represents a heterocycyl linked to $C(R^5)(R^6)$ via a C-C bond, wherein the heterocycyl moiety is a 6-membered non-aromatic ring which contains 1 or 2 groups independently selected from N or NR^7 , wherein Z^1 is optionally substituted by 1, 2 or 3 substituents, which may be the same or different, selected from R^8 ;

15

R^7 is hydrogen, C_{1-4} alkyl, C_{1-4} alkoxy, formyl, C_{1-4} alkylcarbonyl, C_{1-4} alkoxycarbonyl, N- C_{1-4} alkylaminocarbonyl, N,N-di- C_{1-4} alkylaminocarbonyl, C_{1-4} alkylsulfonyl, N- C_{1-2} alkylaminosulfonyl, N,N-di- C_{1-2} alkylaminosulfonyl, C_{1-2} alkoxy- C_{1-2} alkylcarbonyl, cyclopropylcarbonyl, phenylcarbonyl;

20

R^8 is methyl, C_{2-4} alkyl, methoxy, C_{2-4} alkoxy, formyl, C_{1-4} alkylcarbonyl, C_{1-4} alkoxycarbonyl, N- C_{1-4} alkylaminocarbonyl, N,N-di- C_{1-4} alkylaminocarbonyl, C_{1-4} alkylsulfonyl, N- C_{1-2} alkylaminosulfonyl, N,N-di- C_{1-2} alkylaminosulfonyl, oxo (=O) or thio (=S);

25

Z^2 represents a heteroaryl linked to $C(R^5)(R^6)$ via a C-C bond, wherein the heteroaryl moiety is a 6-membered aromatic ring which contains 1, 2 or 3 nitrogen atoms in the ring system, wherein Z^2 is optionally substituted by 1, 2 or 3 substituents, which may be the same or different, selected from R^9 ;

30

R^9 represents cyano, amino, hydroxyl, hydrosulfido (-SH), halogen, methyl, C_{2-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} haloalkyl, C_{2-4} haloalkenyl, methoxy, C_{2-4} alkoxy, C_{1-2} fluoroalkoxy, C_{3-4} alkenyloxy, C_{3-4} alkynyloxy, C_{1-2} alkoxy- C_{1-2} alkyl, C_{1-2} alkylthio, C_{1-2} haloalkylthio, C_{3-4} alkenylthio, C_{3-4} alkynylthio, N- C_{1-2} alkylamino, N,N-di- C_{1-2} alkylamino, C_{1-2} alkylcarbonyl, hydroxycarbonyl (-C(O)OH), C_{1-2} alkoxycarbonyl, C_{1-2} alkylcarbonylamino, N- C_{1-2} alkylaminocarbonyl, N-(cyclopropyl)aminocarbonyl,

N,N-diC₁₋₂alkylaminocarbonyl, C₁₋₂alkoxycarbonylamino, N-C₁₋₂alkoxyaminocarbonyl or N-C₁₋₂alkyl(N-C₁₋₂alkoxy)aminocarbonyl;

or

5

a salt or an N-oxide thereof,

with the proviso that the compound of Formula (I) is not 3-[4-[1-(6-methoxy-3-pyridyl)ethyl]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole or 3-[4-[(6-methoxy-3-pyridyl)methyl]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole.

10


2. A compound according to claim 1, wherein R¹ to R⁴ are hydrogen.

3. A compound according to claim 1 or claim 2, wherein R⁵ and R⁶ are hydrogen.

15

4. A compound according to any one of claims 1 to 3, wherein Z is Z¹.

5. A compound according to claim 4, wherein Z¹ is selected from:




20

optionally substituted by a single R⁸ selected from methyl, C₂₋₄alkyl, methoxy, C₂₋₄alkoxy, formyl, C₁₋₄alkylcarbonyl, C₁₋₄alkoxycarbonyl, N-C₁₋₄alkylaminocarbonyl, N,N-diC₁₋₄alkylaminocarbonyl, C₁₋₄alkylsulfonyl, N-C₁₋₂alkylaminosulfonyl, N,N-diC₁₋₂alkylaminosulfonyl, oxo (=O) or thio (=S).

6. A compound according to any one of claims 1 to 3, wherein Z is Z².

25


7. A compound according to claim 6, wherein Z² is selected from:



optionally substituted by 1 or 2 substituents selected from R⁹, wherein R⁹ is hydroxyl, hydrosulfido (-SH), halogen, methyl, C₂₋₄alkyl, C₁₋₂fluoroalkyl, methoxy, C₂₋₄alkoxy, C₁₋₂alkoxyC₁₋₂alkyl, C₁₋₂alkylcarbonyl, hydroxycarbonyl, C₁₋₂alkoxycarbonyl, C₁₋₂alkylcarbonylamino or N-C₁₋₂alkylaminocarbonyl.

30

8. A compound according to any one of claims 1 to 3, wherein Z is:



wherein R⁷ is selected from hydrogen, C₁₋₄alkyl, C₁₋₄alkoxy, formyl, C₁₋₄alkylcarbonyl, C₁₋₄alkoxycarbonyl.

5

9. A compound according to claim 5 or claim 8, wherein R⁷ is selected from hydrogen, methyl, methoxy, formyl, methylcarbonyl or methoxycarbonyl.

10. An agrochemical composition comprising a fungicidally effective amount of a compound of Formula (I) according to any one of claims 1 to 9.

11. The composition according to claim 10, further comprising at least one additional active ingredient and/or an agrochemically-acceptable diluent or carrier.

12. A method of controlling or preventing infestation of useful plants by phytopathogenic microorganisms, wherein a fungicidally effective amount of a compound of Formula (I) according to any one of claims 1 to 9, or a composition comprising this compound as active ingredient, is applied to the plants, to parts thereof or the locus thereof.

13. Use of a compound of Formula (I) according to any one of claims 1 to 9 as a fungicide.

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2018/068822

A. CLASSIFICATION OF SUBJECT MATTER
INV. C07D413/14 A01N43/82 C07D413/10
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07D A01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 2017/093348 A1 (SYNGENTA PARTICIPATIONS AG [CH]) 8 June 2017 (2017-06-08) page 1, line 3 - page 3, line 28; page 8, line 15 - page 9, line 23; page 13, lines 24-28; page 19, lines 10-34; page 35, Table 1a; pages 38-39, formulas T-1a.7-T-1a.10 and T-1a.12; page 43, formula T-1b.2; page 45, formula T-1c.2; Preparation Examples, e.g. Example 2, Example 9, Example 10; pages 70-84, Table A, , Entry A-2, A-10, A-11, A-14, A-16 to A-19, A-26, A-29, A-31 to A-35, A-40 to A-44, A-48, A-49, A-52 to A-60, A-62; Biological Examples, e.g. Examples 1-5; claims</p> <p style="text-align: center;">----- -/--</p>	1-5,8-13

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
23 October 2018	15/11/2018

Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Sen, Alina
--	--------------------------------------

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2018/068822

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2017/085100 A1 (BASF SE [DE]) 26 May 2017 (2017-05-26) page 1, lines 3-12; page 1, line 26 - page 2, line 28; page 7, lines 15-18; page 15, line 9; page 75, Examples 33 and 34; pages 75-77, Biological examples for fungicidal activity -----	1-5,8-13
Y	WO 2015/185485 A1 (BASF SE [DE]) 10 December 2015 (2015-12-10) page 1, line 25 - page 3, line 19; page 56, Table A; pages 64-67, "Biological Examples for fungicidal activity"; claims -----	1-3,6-13
Y	WO 97/30047 A1 (AGREVO UK LTD [GB]; MOLONEY BRIAN ANTHONY [GB]; RIORDAN PETER DOMINIC) 21 August 1997 (1997-08-21) page 2, lines 10-13; page 5, line 19 - page 6, line 14; pages 12-13, Example 4, e.g. compounds 1, 2, 11, 12; claims -----	1-3,6-13
Y	WO 2017/076742 A1 (BASF SE [DE]) 11 May 2017 (2017-05-11) pages 96-98, Table 1, Example No. 5; pages 98-100, "Biological examples for fungicidal activity" -----	1-3,6-13

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2018/068822

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.

3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 4, 5, 8, 9(completely); 1-3, 10-13(partially)

A compound of formula (I) wherein Z is selected to be Z1 and wherein Z1 represents a heterocycyl moiety, said heterocycyl moiety being a 6-membered non-aromatic ring which contains 1 or 2 groups independently selected from N or NR7, wherein Z1 is optionally substituted by 1, 2 or 3 substituents selected from R8.

2. claims: 6, 7(completely); 1-3, 10-13(partially)

A compound of formula (I) wherein Z is selected to be Z2 and wherein Z2 represents a heteroaryl moiety, said heterocycyl moiety being a 6-membered aromatic ring which contains 1, 2 or 3 nitrogen atoms in the ring system, wherein Z2 is optionally substituted by 1, 2 or 3 substituents selected from R9.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No PCT/EP2018/068822

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2017093348	A1	08-06-2017	CN 108289448 A
			CO 2018005793 A2
			UY 36999 A
			WO 2017093348 A1

WO 2017085100	A1	26-05-2017	AR 106763 A1
			AU 2016354902 A1
			CA 3003949 A1
			CN 108289449 A
			CO 2018005384 A2
			EP 3376868 A1
			KR 20180083419 A
			WO 2017085100 A1

WO 2015185485	A1	10-12-2015	AR 100770 A1
			AU 2015270651 A1
			CA 2950084 A1
			CN 106455572 A
			EP 3151669 A1
			US 2017144980 A1
			WO 2015185485 A1

WO 9730047	A1	21-08-1997	AU 1730497 A
			WO 9730047 A1

WO 2017076742	A1	11-05-2017	AR 106605 A1
			AU 2016349662 A1
			CA 3002299 A1
			CN 108347935 A
			CO 2018005043 A2
			EP 3370524 A1
			KR 20180080286 A
			WO 2017076742 A1
